<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Biomark Insights</journal-id>
<journal-id journal-id-type="iso-abbrev">Biomark Insights</journal-id>
<journal-id journal-id-type="publisher-id">BMI</journal-id>
<journal-id journal-id-type="hwp">spbmi</journal-id>
<journal-title-group>
<journal-title>Biomarker Insights</journal-title>
</journal-title-group>
<issn pub-type="epub">1177-2719</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32913390</article-id>
<article-id pub-id-type="pmc">7444114</article-id>
<article-id pub-id-type="doi">10.1177/1177271920950319</article-id>
<article-id pub-id-type="publisher-id">10.1177_1177271920950319</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Novel Biomarkers of Neurodegenerative Disorders: Updates and Challenges</subject>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Fluid Biomarkers for Synaptic Dysfunction and Loss</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0003-1044-0192</contrib-id>
<name>
<surname>Camporesi</surname>
<given-names>Elena</given-names>
</name>
<xref ref-type="aff" rid="aff1-1177271920950319">1</xref>
<xref ref-type="corresp" rid="corresp1-1177271920950319"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nilsson</surname>
<given-names>Johanna</given-names>
</name>
<xref ref-type="aff" rid="aff1-1177271920950319">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brinkmalm</surname>
<given-names>Ann</given-names>
</name>
<xref ref-type="aff" rid="aff1-1177271920950319">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Becker</surname>
<given-names>Bruno</given-names>
</name>
<xref ref-type="aff" rid="aff1-1177271920950319">1</xref>
<xref ref-type="aff" rid="aff2-1177271920950319">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ashton</surname>
<given-names>Nicholas J</given-names>
</name>
<xref ref-type="aff" rid="aff1-1177271920950319">1</xref>
<xref ref-type="aff" rid="aff3-1177271920950319">3</xref>
<xref ref-type="aff" rid="aff4-1177271920950319">4</xref>
<xref ref-type="aff" rid="aff5-1177271920950319">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Blennow</surname>
<given-names>Kaj</given-names>
</name>
<xref ref-type="aff" rid="aff1-1177271920950319">1</xref>
<xref ref-type="aff" rid="aff2-1177271920950319">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zetterberg</surname>
<given-names>Henrik</given-names>
</name>
<xref ref-type="aff" rid="aff1-1177271920950319">1</xref>
<xref ref-type="aff" rid="aff2-1177271920950319">2</xref>
<xref ref-type="aff" rid="aff6-1177271920950319">6</xref>
<xref ref-type="aff" rid="aff7-1177271920950319">7</xref>
</contrib>
</contrib-group>
<aff id="aff1-1177271920950319"><label>1</label>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden</aff>
<aff id="aff2-1177271920950319"><label>2</label>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden</aff>
<aff id="aff3-1177271920950319"><label>3</label>King’s College London, Institute of Psychiatry, Psychology &amp; Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, London, UK</aff>
<aff id="aff4-1177271920950319"><label>4</label>NIHR Biomedical Research Centre for Mental Health &amp; Biomedical Research Unit for Dementia at South London &amp; Maudsley NHS Foundation, London, UK</aff>
<aff id="aff5-1177271920950319"><label>5</label>Wallenberg Centre for Molecular and Translational Medicine, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden</aff>
<aff id="aff6-1177271920950319"><label>6</label>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK</aff>
<aff id="aff7-1177271920950319"><label>7</label>UK Dementia Research Institute at UCL, London, UK</aff>
<author-notes>
<corresp id="corresp1-1177271920950319">Elena Camporesi, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, SE 43180 Gothenburg, Sweden. Email: <email>elena.camporesi@gu.se</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>21</day>
<month>8</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>15</volume>
<elocation-id>1177271920950319</elocation-id>
<history>
<date date-type="received">
<day>5</day>
<month>6</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>7</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2020</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</copyright-holder>
<license license-type="creative-commons" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">
<license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Synapses are the site for brain communication where information is transmitted between neurons and stored for memory formation. Synaptic degeneration is a global and early pathogenic event in neurodegenerative disorders with reduced levels of pre- and postsynaptic proteins being recognized as a core feature of Alzheimer’s disease (AD) pathophysiology. Together with AD, other neurodegenerative and neurodevelopmental disorders show altered synaptic homeostasis as an important pathogenic event, and due to that, they are commonly referred to as synaptopathies. The exact mechanisms of synapse dysfunction in the different diseases are not well understood and their study would help understanding the pathogenic role of synaptic degeneration, as well as differences and commonalities among them and highlight candidate synaptic biomarkers for specific disorders. The assessment of synaptic proteins in cerebrospinal fluid (CSF), which can reflect synaptic dysfunction in patients with cognitive disorders, is a keen area of interest. Substantial research efforts are now directed toward the investigation of CSF synaptic pathology to improve the diagnosis of neurodegenerative disorders at an early stage as well as to monitor clinical progression. In this review, we will first summarize the pathological events that lead to synapse loss and then discuss the available data on established (eg, neurogranin, SNAP-25, synaptotagmin-1, GAP-43, and α-syn) and emerging (eg, synaptic vesicle glycoprotein 2A and neuronal pentraxins) CSF biomarkers for synapse dysfunction, while highlighting possible utilities, disease specificity, and technical challenges for their detection.</p>
</abstract>
<kwd-group>
<kwd>Synaptic biomarkers</kwd>
<kwd>cerebrospinal fluid</kwd>
<kwd>synaptopathies</kwd>
<kwd>Alzheimer’s disease</kwd>
<kwd>proteomics</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>January-December 2020</meta-value>
</custom-meta>
<custom-meta>
<meta-name>typesetter</meta-name>
<meta-value>ts1</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="section1-1177271920950319" sec-type="intro">
<title>Introduction</title>
<p>The central nervous system (CNS) can be subject to numerous pathological conditions, which can affect its development, functionality, or cause premature cell death, resulting in neurodevelopmental, neuropsychiatric, and neurodegenerative disorders. Although these disorders have different etiologies and pathophysiological mechanisms, many of them have some degree of dysfunction and alteration of the synapses and can thus be categorized as synaptopathies.<sup><xref ref-type="bibr" rid="bibr1-1177271920950319">1</xref>,<xref ref-type="bibr" rid="bibr2-1177271920950319">2</xref></sup> In this review, we will discuss how synapses are affected in the most common diseases affecting the CNS, and how advances in synaptic biomarker discovery provide new tools for the study of those diseases. We will mainly focus on neurodegenerative conditions, and in particular on Alzheimer’s disease (AD), which is the predominant cause of dementia affecting approximately 50 million people worldwide.<sup><xref ref-type="bibr" rid="bibr3-1177271920950319">3</xref></sup> Although the exact mechanisms of synaptic loss and dysfunction in the different diseases are still poorly understood, there is evidence that a reduction in synaptic activity and density is one of the earliest events in many of the diseases of the CNS and may even appear before neuronal loss.<sup><xref ref-type="bibr" rid="bibr4-1177271920950319">4</xref>,<xref ref-type="bibr" rid="bibr5-1177271920950319">5</xref></sup> The significant role of synapse dysfunction in the disease pathology and progression of synaptopathies has therefore prompted a keen interest in detecting and quantifying synaptic proteins. Molecular brain imaging<sup><xref ref-type="bibr" rid="bibr6-1177271920950319">6</xref></sup> and analysis of cerebrospinal fluid (CSF)<sup><xref ref-type="bibr" rid="bibr7-1177271920950319">7</xref></sup> are used in conjunction to study synaptic proteins, with the aim of using them as biomarkers for prognosis, to follow disease progression and to evaluate effects of drug testing.</p>
</sec>
<sec id="section2-1177271920950319">
<title>Pathophysiology of Synaptic Dysfunction and Loss</title>
<sec id="section3-1177271920950319">
<title>Synaptic functions</title>
<p>The neuronal synapses are the functional units of neurotransmission in the brain, with an estimated 100 trillion interconnecting synapses<sup><xref ref-type="bibr" rid="bibr8-1177271920950319">8</xref></sup> in an elaborate and complex network. Synapses are formed during development and the early postnatal period. After reaching the maximum density at 2 to 4 years of age,<sup><xref ref-type="bibr" rid="bibr9-1177271920950319">9</xref>,<xref ref-type="bibr" rid="bibr10-1177271920950319">10</xref></sup> in the following years synapses are physiologically eliminated in a process known as pruning.<sup><xref ref-type="bibr" rid="bibr11-1177271920950319">11</xref></sup> Synapses that survive to adulthood are the ones stably maintained, although we have a certain degree of synapse formation and elimination throughout life.<sup><xref ref-type="bibr" rid="bibr12-1177271920950319">12</xref></sup></p>
<p>Neuronal signal transmission in the CNS requires the presence of functional synapses, with properly arranged pre- and postsynaptic compartments. The presynaptic compartment contains all the structures for formation, storage, and release of neurotransmitter-containing vesicles. Following an action potential, the increase of Ca<sup>2+</sup> in the presynaptic terminal triggers synaptic vesicles to fuse with the presynaptic membrane upon which neurotransmitters are released into the synaptic cleft.<sup><xref ref-type="bibr" rid="bibr13-1177271920950319">13</xref></sup> Subsequently, neurotransmitters interact with receptors on the postsynaptic compartment (the dendritic spine), and through the activation of different signaling pathways<sup><xref ref-type="bibr" rid="bibr14-1177271920950319">14</xref></sup> the neuronal signal is transmitted further. Synapses can be excitatory or inhibitory, using glutamate and GABA, as neurotransmitters, respectively.<sup><xref ref-type="bibr" rid="bibr15-1177271920950319">15</xref></sup> The dendritic spines are the primary location of excitatory synapses.</p>
<p>Synapse formation, maturation, and elimination is a dynamic series of events that can be defined as synaptic plasticity. Processes representing synaptic plasticity are phenomena termed long-term potentiation (LTP) and long-term depression (LTD), through which, during memory formation, signaling via preferred synapses is enhanced or reduced. Selection of synapses seems to be activity-dependent, LTP is usually considered as a protective mechanism and LTD as inductive of elimination.<sup><xref ref-type="bibr" rid="bibr16-1177271920950319">16</xref></sup> These 2 processes are considered the basis for memory formation and storage.<sup><xref ref-type="bibr" rid="bibr17-1177271920950319">17</xref>,<xref ref-type="bibr" rid="bibr18-1177271920950319">18</xref></sup> LTP is identified by the addition of new receptors at the postsynaptic density (PSD) and the consequent enlargement of the spine head resulting in transmission of a stronger signal.<sup><xref ref-type="bibr" rid="bibr19-1177271920950319">19</xref></sup> On the contrary, during LTD a series of events lead to spine shrinkage and elimination.<sup><xref ref-type="bibr" rid="bibr18-1177271920950319">18</xref></sup> Many different mechanisms for synaptic elimination have been suggested (for extensive review, see Cardozo et al<sup><xref ref-type="bibr" rid="bibr20-1177271920950319">20</xref></sup> and Maiti et al<sup><xref ref-type="bibr" rid="bibr21-1177271920950319">21</xref></sup>) Elimination of weaker and unnecessary synapses and maintenance of the stronger ones are processes that balance each other, to ensure proper connectivity between brain regions and signal refinement.<sup><xref ref-type="bibr" rid="bibr22-1177271920950319">22</xref>,<xref ref-type="bibr" rid="bibr23-1177271920950319">23</xref></sup> For proper synaptic activity, a balance is needed, and alterations between synapse formation and elimination can cause synaptic dysfunction and impaired brain network activities.<sup><xref ref-type="bibr" rid="bibr21-1177271920950319">21</xref></sup> To understand pathological mechanisms and at which stage synapses are affected is of utmost importance to define targets and intervention strategies.</p>
</sec>
<sec id="section4-1177271920950319">
<title>Synapse and neuronal loss in brain disorders</title>
<p>As mentioned, a balance in synapse formation and pruning is essential for proper connectivity and brain functionality. For instance, excessive synaptic pruning during adolescence is one of the hypothesized mechanisms for schizophrenia, which most commonly manifests with an onset in late adolescence or early-adulthood.<sup><xref ref-type="bibr" rid="bibr24-1177271920950319">24</xref><xref ref-type="bibr" rid="bibr25-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr26-1177271920950319">26</xref></sup> The term “synaptopathy” is applied to refer to all diseases that are characterized by a progressive synaptic dysfunction and loss.<sup><xref ref-type="bibr" rid="bibr20-1177271920950319">20</xref></sup> AD, the most common neurodegenerative disease, can be therefore considered both a synaptopathy and a proteinopathy.</p>
<p>AD pathology is identified by the presence of extracellular deposits of amyloid-β (Aβ) plaques, formed by the aggregation of Aβ peptides, and neurofibrillary tangles (NFTs) that are intraneuronal accumulations of hyperphosphorylated and truncated tau protein, respectively.<sup><xref ref-type="bibr" rid="bibr27-1177271920950319">27</xref>,<xref ref-type="bibr" rid="bibr28-1177271920950319">28</xref></sup> Along with these main hallmarks, gliosis, neuroinflammation,<sup><xref ref-type="bibr" rid="bibr29-1177271920950319">29</xref><xref ref-type="bibr" rid="bibr30-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr31-1177271920950319">31</xref></sup> and vascular dysfunction<sup><xref ref-type="bibr" rid="bibr32-1177271920950319">32</xref>,<xref ref-type="bibr" rid="bibr33-1177271920950319">33</xref></sup> are also present, which reflects the complexity of AD. However, it is synaptic loss which best correlates with cognitive symptoms<sup><xref ref-type="bibr" rid="bibr34-1177271920950319">34</xref><xref ref-type="bibr" rid="bibr35-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr36-1177271920950319">36</xref></sup> and it is also apparent in the early stages of the disease pathophysiology.<sup><xref ref-type="bibr" rid="bibr37-1177271920950319">37</xref>,<xref ref-type="bibr" rid="bibr38-1177271920950319">38</xref></sup> The number of synapses in the brain decreases during normal aging but this decrease is exacerbated in AD and, consequently, the synapse-to-neuron ratio is lower in AD brains compared with age-matched non-demented individuals.<sup><xref ref-type="bibr" rid="bibr39-1177271920950319">39</xref></sup> In AD, brain biopsies show synaptic loss in neocortical regions and the hippocampus,<sup><xref ref-type="bibr" rid="bibr40-1177271920950319">40</xref>,<xref ref-type="bibr" rid="bibr41-1177271920950319">41</xref></sup> the latter showing the greatest reduction by approximately 50%.<sup><xref ref-type="bibr" rid="bibr42-1177271920950319">42</xref><xref ref-type="bibr" rid="bibr43-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr44-1177271920950319">44</xref></sup></p>
<p>How the major AD hallmarks, tau and Aβ, pathologically interact with synapses needs more investigation. However, most studies identified the oligomeric forms of Aβ and tau, rather than larger aggregates, to be the synaptotoxic species.<sup><xref ref-type="bibr" rid="bibr45-1177271920950319">45</xref><xref ref-type="bibr" rid="bibr46-1177271920950319"></xref><xref ref-type="bibr" rid="bibr47-1177271920950319"></xref><xref ref-type="bibr" rid="bibr48-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr49-1177271920950319">49</xref></sup> Both in vivo<sup><xref ref-type="bibr" rid="bibr50-1177271920950319">50</xref></sup> and ex vivo<sup><xref ref-type="bibr" rid="bibr51-1177271920950319">51</xref></sup> Aβ oligomers (Aβo) disrupt LTP, probably interfering with NMDAR (<italic>N</italic>-methyl-<sc>d</sc>-aspartate receptor) activity and downstream pathways,<sup><xref ref-type="bibr" rid="bibr52-1177271920950319">52</xref></sup> in addition to causing oxidative stress, impairing axonal transport, and causing nerve cell death (reviewed in Cline et al<sup><xref ref-type="bibr" rid="bibr53-1177271920950319">53</xref></sup>). In AD, Aβ and tau act in concert and studies have identified their simultaneous presence in the postsynaptic compartment.<sup><xref ref-type="bibr" rid="bibr54-1177271920950319">54</xref>,<xref ref-type="bibr" rid="bibr55-1177271920950319">55</xref></sup> Aβo have been suggested to bind to a variety of targets,<sup><xref ref-type="bibr" rid="bibr56-1177271920950319">56</xref></sup> including cellular prion protein (PrP<sup>c</sup>),<sup><xref ref-type="bibr" rid="bibr57-1177271920950319">57</xref></sup> neuroligin 1, neurexin-2α,<sup><xref ref-type="bibr" rid="bibr58-1177271920950319">58</xref></sup> PirB, EphB2,<sup><xref ref-type="bibr" rid="bibr59-1177271920950319">59</xref></sup> shank, synGap, Na/K-ATPase,<sup><xref ref-type="bibr" rid="bibr60-1177271920950319">60</xref></sup> ultimately leading to impairment of LTP and synapse loss.<sup><xref ref-type="bibr" rid="bibr45-1177271920950319">45</xref>,<xref ref-type="bibr" rid="bibr50-1177271920950319">50</xref>,<xref ref-type="bibr" rid="bibr61-1177271920950319">61</xref></sup> Phosphorylated tau oligomers can relocate from axons to dendrites, interfering with NMDAR and AMPAR (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor) and impairing glutamatergic transmission.<sup><xref ref-type="bibr" rid="bibr62-1177271920950319">62</xref>,<xref ref-type="bibr" rid="bibr63-1177271920950319">63</xref></sup></p>
<p>Moreover, as points of transmission of signals between neurons, synapses seem also to help the spreading of the pathology via prion-like mechanisms, and some studies show the possibility of Aβo and tau oligomers to be transferred from neuron to neuron.<sup><xref ref-type="bibr" rid="bibr64-1177271920950319">64</xref><xref ref-type="bibr" rid="bibr65-1177271920950319"></xref><xref ref-type="bibr" rid="bibr66-1177271920950319"></xref><xref ref-type="bibr" rid="bibr67-1177271920950319"></xref><xref ref-type="bibr" rid="bibr68-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr69-1177271920950319">69</xref></sup></p>
<p>Tau aggregation, without Aβ pathology, is also a pathological hallmark of other neurodegenerative diseases, the so-called tauopathies.<sup><xref ref-type="bibr" rid="bibr70-1177271920950319">70</xref></sup> Tauopathies include, among others, some forms of frontotemporal lobar degeneration (FTLD), namely FTLD-tau, progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). Although all tauopathies have in common the presence of tau aggregates in the CNS, the characteristics of these aggregates differ among them and are different from the NFTs of AD. PSP shows filamentous aggregates in astrocytes and oligodendrocytes, while in CBD tau accumulation in neurons is less fibrillar and in astrocytes it accumulates in the form of astrocytic plaques.<sup><xref ref-type="bibr" rid="bibr71-1177271920950319">71</xref></sup> As introduced above, oligomeric tau has been connected to synaptic damage through different pathways,<sup><xref ref-type="bibr" rid="bibr63-1177271920950319">63</xref></sup> also involving activation of microglia and astrocytes through inflammatory processes,<sup><xref ref-type="bibr" rid="bibr72-1177271920950319">72</xref></sup> and animal models of tau pathology show early synaptic loss prior to neuronal death.<sup><xref ref-type="bibr" rid="bibr73-1177271920950319">73</xref>,<xref ref-type="bibr" rid="bibr74-1177271920950319">74</xref></sup></p>
<p>As the combination of Aβ and tau pathology define AD, accumulation of aggregated α-synuclein (α-syn) is the pathological feature of several diseases, which are commonly collectively referred to as α-synucleinopathies.<sup><xref ref-type="bibr" rid="bibr75-1177271920950319">75</xref></sup> Among the most common synucleopathies are Parkinson’s disease (PD), Parkinson’s disease dementia (PDD), dementia with Lewy body (DLB), and multiple system atrophy (MSA). PD, PDD, and DLB show accumulation of the so-called Lewy neurites (LN) and Lewy bodies (LB), where α-syn is the principal component.<sup><xref ref-type="bibr" rid="bibr76-1177271920950319">76</xref></sup> The physiological role of α-syn at the synapse is not precisely understood yet<sup><xref ref-type="bibr" rid="bibr77-1177271920950319">77</xref></sup>; however, it is commonly accepted that its dyshomeostasis and accumulation leads to cell damage and it is responsible for synaptic impairment and neuronal damage.<sup><xref ref-type="bibr" rid="bibr78-1177271920950319">78</xref>,<xref ref-type="bibr" rid="bibr79-1177271920950319">79</xref></sup> Alpha-syn, localized mainly presynaptically, is involved in synaptic vesicle regulation and trafficking,<sup><xref ref-type="bibr" rid="bibr80-1177271920950319">80</xref>,<xref ref-type="bibr" rid="bibr81-1177271920950319">81</xref></sup> and in the SNARE complex formation.<sup><xref ref-type="bibr" rid="bibr82-1177271920950319">82</xref>,<xref ref-type="bibr" rid="bibr83-1177271920950319">83</xref></sup> It also interacts with membrane lipids and can associate with mitochondria,<sup><xref ref-type="bibr" rid="bibr84-1177271920950319">84</xref></sup> the Golgi-endoplasmic reticulum system,<sup><xref ref-type="bibr" rid="bibr85-1177271920950319">85</xref></sup> and the endolysosomal system. Pathologic α-syn can interfere with all these organelles, consequently impairing-related pathways.<sup><xref ref-type="bibr" rid="bibr86-1177271920950319">86</xref>,<xref ref-type="bibr" rid="bibr87-1177271920950319">87</xref></sup> The protein can change its conformation and aggregate, giving rise to oligomers, fibrils, and larger aggregates.<sup><xref ref-type="bibr" rid="bibr88-1177271920950319">88</xref></sup> Which form is responsible for toxicity is still a matter of debate. However, as discussed for AD, the oligomeric form of α-syn has been suggested to be the responsible for the synaptic damage in dopaminergic neurons,<sup><xref ref-type="bibr" rid="bibr89-1177271920950319">89</xref>,<xref ref-type="bibr" rid="bibr90-1177271920950319">90</xref></sup> and the possibility for oligomeric α-syn of spreading in a prion-like manner has been proposed.<sup><xref ref-type="bibr" rid="bibr91-1177271920950319">91</xref>,<xref ref-type="bibr" rid="bibr92-1177271920950319">92</xref></sup> At a cellular level, typically PD and DLB are distinguished from MSA, inasmuch the accumulations of LN and LB are mainly present in neurons, while in MSA, α-syn accumulation appears in oligodendrocytes.<sup><xref ref-type="bibr" rid="bibr93-1177271920950319">93</xref></sup> Moreover, MSA inclusions seem to be more compact and aggressive,<sup><xref ref-type="bibr" rid="bibr94-1177271920950319">94</xref></sup> in line with the increased severity of the disease.<sup><xref ref-type="bibr" rid="bibr95-1177271920950319">95</xref></sup> However, it was most recently reported that also neurons in MSA show α-syn oligomers depositions.<sup><xref ref-type="bibr" rid="bibr96-1177271920950319">96</xref></sup> A recent study showed that α-syn filaments differ in DLB and MSA.<sup><xref ref-type="bibr" rid="bibr97-1177271920950319">97</xref></sup> PD and DLB are usually distinguished based on the symptoms, with DLB being the second most common type of dementia.<sup><xref ref-type="bibr" rid="bibr98-1177271920950319">98</xref></sup> PD, similar to AD, starts many years before symptoms become overt and at that point, patients had already lost up to 60% motor neurons in the substantia nigra.<sup><xref ref-type="bibr" rid="bibr99-1177271920950319">99</xref></sup></p>
<p>Nonetheless, α-syn was first identified and characterized in relation to AD when it was found to be a major non-amyloid beta component of Aβ plaques.<sup><xref ref-type="bibr" rid="bibr100-1177271920950319">100</xref></sup> In fact, Lewy pathology can be also found in over half of all patients with AD.<sup><xref ref-type="bibr" rid="bibr101-1177271920950319">101</xref><xref ref-type="bibr" rid="bibr102-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr103-1177271920950319">103</xref></sup> To further complicate the clinical picture, α-syn depositions are found in tauopathies like PSP and CBD, and NFTs have been found in PD brains.<sup><xref ref-type="bibr" rid="bibr104-1177271920950319">104</xref>,<xref ref-type="bibr" rid="bibr105-1177271920950319">105</xref></sup></p>
<p>Comorbidities and co-occurrence of different pathologies make diagnosis of these diseases challenging. Synapse damage is a common and early first change in the disease development and prolonged synaptic damage can lead to synaptic loss. Neuronal damage and death seem to be a follow-up event seen only at later stages. For these reasons, the investigation of synaptic biomarkers has the potential to find a way to diagnose the disease in its early stages and also to give us information on the main pathological mechanisms involved.</p>
</sec>
</sec>
<sec id="section5-1177271920950319">
<title>Current Climate of Fluid Biomarkers in Dementia</title>
<sec id="section6-1177271920950319">
<title>Imaging and CSF biomarkers</title>
<p>The core CSF biomarkers for AD (Aβ42/Aβ40, total-tau, and phospho-tau), reflecting the defining Aβ and tau neuropathologies, consistently demonstrate diagnostically significant changes across studies<sup><xref ref-type="bibr" rid="bibr106-1177271920950319">106</xref></sup> and now have prominent positions in biological and diagnostic criteria for AD.<sup><xref ref-type="bibr" rid="bibr28-1177271920950319">28</xref>,<xref ref-type="bibr" rid="bibr107-1177271920950319">107</xref></sup> The concentrations of these core AD biomarkers, however, are no different from healthy controls in the majority of dementias outside of the AD continuum<sup><xref ref-type="bibr" rid="bibr108-1177271920950319">108</xref>,<xref ref-type="bibr" rid="bibr109-1177271920950319">109</xref></sup> which can be of great utility in the differential diagnosis of patients with cognitive symptoms. An exception can be made for Creutzfeldt–Jakob disease (CJD), which presents vastly increased levels of t-tau, whereas the concentrations of p-tau181 remain normal or only marginally changed in CJD.<sup><xref ref-type="bibr" rid="bibr110-1177271920950319">110</xref>,<xref ref-type="bibr" rid="bibr111-1177271920950319">111</xref></sup></p>
<p>Together with CSF biomarkers, positron emission tomography (PET) and magnetic resonance imaging (MRI) are used to provide a clearer view of pathology and atrophy patterns in the brains of living humans. MRI allows for the measurement of brain atrophy and provides information on regional, structural, and functional integrity of the brain.<sup><xref ref-type="bibr" rid="bibr112-1177271920950319">112</xref></sup> In the research of neurodegenerative disorders, PET tracers for protein aggregation such as Aβ<sup><xref ref-type="bibr" rid="bibr113-1177271920950319">113</xref>,<xref ref-type="bibr" rid="bibr114-1177271920950319">114</xref></sup> and tau,<sup><xref ref-type="bibr" rid="bibr115-1177271920950319">115</xref></sup> as well as glucose metabolism as a measure for neuronal activity<sup><xref ref-type="bibr" rid="bibr116-1177271920950319">116</xref>,<xref ref-type="bibr" rid="bibr117-1177271920950319">117</xref></sup> and synaptic density,<sup><xref ref-type="bibr" rid="bibr118-1177271920950319">118</xref></sup> have been developed. Together with CSF biomarkers, MRI and PET are nowadays included in the research diagnostic criteria for AD.<sup><xref ref-type="bibr" rid="bibr28-1177271920950319">28</xref>,<xref ref-type="bibr" rid="bibr119-1177271920950319">119</xref></sup> However, the availability of PET scans is limited and when possible expensive, thus it is not always applicable.</p>
</sec>
<sec id="section7-1177271920950319">
<title>Blood biomarkers</title>
<p>In certain instances, the biomarkers field is rapidly evolving from CSF into blood, which is a more easily accessible biological fluid. Despite the latest advancement in developing CSF biomarkers for synaptic integrity and large high-resolution mass spectrometry proteomic studies demonstrating the presence of synaptic proteins in blood,<sup><xref ref-type="bibr" rid="bibr120-1177271920950319">120</xref>,<xref ref-type="bibr" rid="bibr121-1177271920950319">121</xref></sup> to date no studies have shown positive results for any pre- or postsynaptic biomarkers in blood correlating to any neurodegenerative disease phenotype.</p>
<p>The advancement of ultrasensitive methodologies has enabled, however, the detection of the CSF core biomarkers and neuronal injury, like neurofilaments, in blood. New evidence from high-resolution mass spectrometry,<sup><xref ref-type="bibr" rid="bibr122-1177271920950319">122</xref>,<xref ref-type="bibr" rid="bibr123-1177271920950319">123</xref></sup> single molecule array (Simoa),<sup><xref ref-type="bibr" rid="bibr124-1177271920950319">124</xref></sup> and fully automated immunoassays,<sup><xref ref-type="bibr" rid="bibr125-1177271920950319">125</xref></sup> which are highly sensitive and alleviate confounding matrix effects in blood, suggests that Aβ peptide ratios are specific markers of individuals with Aβ- positive brain scans. In addition, recent evidence has shown that plasma p-tau181 concentrations are higher in individuals with AD dementia than in healthy controls.<sup><xref ref-type="bibr" rid="bibr126-1177271920950319">126</xref></sup> Plasma p-tau181 correlates with tau PET in Aβ-positive AD individuals and, encouragingly, can accurately identify elderly controls and mild cognitive impairment (MCI) individuals with a positive Aβ-PET scan (area under the curve [AUC] &gt; 0.85).<sup><xref ref-type="bibr" rid="bibr127-1177271920950319">127</xref><xref ref-type="bibr" rid="bibr128-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr129-1177271920950319">129</xref></sup> Conversely, although significant increase of plasma t-tau has been vastly observed in individuals with AD, the plasma t-tau levels between control, MCI, and AD groups substantially overlapped.<sup><xref ref-type="bibr" rid="bibr130-1177271920950319">130</xref></sup></p>
<p>The neurofilaments are cytoskeletal protein abundantly expressed in neuronal axons, among which neurofilament light polypeptide (NfL) is the smallest of the neurofilament proteins (for a detailed review on neurofilament structure and function, please see Khalil et al<sup><xref ref-type="bibr" rid="bibr131-1177271920950319">131</xref></sup>). A moderate-to-good correlation between NfL concentration in blood and CSF has been observed in several studies and many CSF findings of increased NfL in neurodegenerative diseases have subsequently been replicated in blood.<sup><xref ref-type="bibr" rid="bibr132-1177271920950319">132</xref></sup> Although not a specific marker for AD, blood NfL has the potential to track or predict many aspects of neurodegeneration, including cognitive performance,<sup><xref ref-type="bibr" rid="bibr133-1177271920950319">133</xref></sup> the degree of postmortem pathology,<sup><xref ref-type="bibr" rid="bibr134-1177271920950319">134</xref></sup> structural imaging,<sup><xref ref-type="bibr" rid="bibr135-1177271920950319">135</xref></sup> and glucose metabolism.<sup><xref ref-type="bibr" rid="bibr136-1177271920950319">136</xref>,<xref ref-type="bibr" rid="bibr137-1177271920950319">137</xref></sup></p>
</sec>
</sec>
<sec id="section8-1177271920950319">
<title>Fluid Biomarkers for Synapse Pathology</title>
<p>The pathophysiology of synaptopathies and the significance of synapses in cognition make a convincing argument for the need and use of biomarkers of synapse pathology as representation of cognitive and synaptic function. Clinically, synaptic biomarkers may link synaptic degeneration with the cognitive status and decline of the patient, and they could be implemented together with cognitive tests to have a more precise description of the patient’s symptoms, especially at early stages. Moreover, synaptic biomarkers can help to understand the underlying pathological processes ongoing during cognitive diseases, as different proteins could reflect different mechanisms, thus helping the diagnosis. In addition, synaptic biomarkers can also be used during drug development, to monitor the efficacy of treatments on synaptic functioning in drug trials.</p>
<sec id="section9-1177271920950319">
<title>Pre- and postsynaptic biomarkers</title>
<p>Biomarkers for synaptic dysfunction can be divided into pre- and postsynaptic biomarkers depending on the localization of the protein. The presence of synaptic proteins in CSF was first demonstrated in the late 1990s,<sup><xref ref-type="bibr" rid="bibr138-1177271920950319">138</xref>,<xref ref-type="bibr" rid="bibr139-1177271920950319">139</xref></sup> but for a long time, most studies still involved postmortem brain tissue. However, in the last decade, advances in mass spectrometry and immunoassays have allowed the accurate quantification of synaptic proteins in biofluids. As of today, there are 4 main presynaptic biomarkers, growth-associated protein 43 (GAP-43), synaptosomal-associated protein 25 (SNAP-25), synaptotagmin-1, and α-syn, and 1 postsynaptic marker, neurogranin.</p>
<sec id="section10-1177271920950319">
<title>GAP-43</title>
<p>GAP-43 is a presynaptic protein which plays an important role in memory and information storage.<sup><xref ref-type="bibr" rid="bibr140-1177271920950319">140</xref></sup> It is anchored on the cytoplasmic side of the presynaptic plasma membrane and is mainly expressed in the hippocampus, entorhinal cortex, and neocortex of the adult brain. At the synapse, upon intracellular Ca<sup>2+</sup> increase, GAP-43 is phosphorylated by protein kinase C. This leads GAP-43 to interact, among others, with synaptophysin and SNAP-25, facilitating synaptic vesicle recycling.<sup><xref ref-type="bibr" rid="bibr141-1177271920950319">141</xref></sup> Studies have found GAP-43 CSF levels to be significantly increased in patients with AD compared with controls<sup><xref ref-type="bibr" rid="bibr142-1177271920950319">142</xref></sup> and also other neurodegenerative disorders.<sup><xref ref-type="bibr" rid="bibr143-1177271920950319">143</xref></sup> CSF GAP-43 levels were also increased in preclinical and clinical patients with AD compared with controls. However, in an antibody-based explorative study, no significant changes in patients with PD or DLB were found in comparison with controls.<sup><xref ref-type="bibr" rid="bibr144-1177271920950319">144</xref></sup> Altered CSF GAP-43 levels have also been reported in progressive multiple sclerosis (MS),<sup><xref ref-type="bibr" rid="bibr143-1177271920950319">143</xref>,<xref ref-type="bibr" rid="bibr145-1177271920950319">145</xref></sup> inflammation,<sup><xref ref-type="bibr" rid="bibr146-1177271920950319">146</xref></sup> stroke,<sup><xref ref-type="bibr" rid="bibr147-1177271920950319">147</xref></sup> and PD,<sup><xref ref-type="bibr" rid="bibr109-1177271920950319">109</xref></sup> but not in frontotemporal dementia (FTD).<sup><xref ref-type="bibr" rid="bibr109-1177271920950319">109</xref></sup></p>
</sec>
<sec id="section11-1177271920950319">
<title>SNAP-25</title>
<p>SNAP-25 is a presynaptic protein with a key role in neuronal survival and cognitive function due to its essential part in vesicular exocytosis, neurite outgrowth, and LTP.<sup><xref ref-type="bibr" rid="bibr148-1177271920950319">148</xref></sup> SNAP-25, together with vesicle-associated membrane proteins (VAMPs) and syntaxins, forms SNARE complexes, which mediate synaptic vesicle apposition to the presynaptic membrane thus allowing for the Ca<sup>2+</sup>-triggered vesicle fusion during exocytosis.<sup><xref ref-type="bibr" rid="bibr149-1177271920950319">149</xref></sup> SNAP-25 has, in various studies using both enzyme-linked immunosorbent assay (ELISA) and mass spectrometry-based assays, shown to have significantly higher CSF levels in AD, even at a very early stages.<sup><xref ref-type="bibr" rid="bibr7-1177271920950319">7</xref>,<xref ref-type="bibr" rid="bibr150-1177271920950319">150</xref><xref ref-type="bibr" rid="bibr151-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr152-1177271920950319">152</xref></sup> Increased CSF levels of SNAP-25 have also been found in patients with PD<sup><xref ref-type="bibr" rid="bibr153-1177271920950319">153</xref></sup> and patients with sporadic CJD.<sup><xref ref-type="bibr" rid="bibr154-1177271920950319">154</xref></sup> In addition, SNAP-25 has been associated with several psychiatric diseases such as attention deficiency hyperactivity disorder (ADHD), schizophrenia, and bipolar disorder.<sup><xref ref-type="bibr" rid="bibr149-1177271920950319">149</xref></sup> Furthermore, there are 2 splicing variants of SNAP-25: SNAP-25A and SNAP-25B. Mass spectrometry–based methods to quantify both total SNAP-25 and the 2 isoforms have therefore been developed to study potential differences in the roles of the isoforms of SNAP-25 in disease. Nine amino acids differentiate the 2 protein isoforms, which also differ in their effects on neurotransmission.<sup><xref ref-type="bibr" rid="bibr155-1177271920950319">155</xref></sup> To our knowledge, no studies have investigated the different isoforms in CSF. However, a postmortem brain tissue study by Barakauskas et al<sup><xref ref-type="bibr" rid="bibr155-1177271920950319">155</xref></sup> found significantly decreased levels of total SNAP-25 and SNAP-25A but not of SNAP-25B, indicating a specific differential expression of SNAP-25A in schizophrenia.</p>
</sec>
<sec id="section12-1177271920950319">
<title>Synaptotagmin-1</title>
<p>Synaptotagmin-1 is a calcium sensor vesicle protein vital for fast synchronous neurotransmitter release in hippocampal neurons.<sup><xref ref-type="bibr" rid="bibr156-1177271920950319">156</xref></sup> It is a transmembrane protein anchored in the vesicle membranes containing 2 Ca<sup>2+</sup>-binding domains. In response to Ca<sup>2+</sup>-binding at elevated concentrations, synaptotagmin-1 triggers the vesicle fusion, but the exact molecular mechanisms remain to be elucidated (for review see Park and Ryu<sup><xref ref-type="bibr" rid="bibr157-1177271920950319">157</xref></sup>). Initial CSF studies of synaptotagmin-1 found it to be decreased in a CSF pool from patients with early-onset AD compared with a CSF pool from healthy controls.<sup><xref ref-type="bibr" rid="bibr138-1177271920950319">138</xref></sup> Two decades later, Öhrfelt et al<sup><xref ref-type="bibr" rid="bibr158-1177271920950319">158</xref></sup> quantified synaptotagmin-1 in individual CSF samples from patients with AD, MCI, and controls, demonstrating significantly increased concentrations of synaptotagmin-1 in patients with AD and MCI, the highest being MCI due to AD. These findings have been corroborated in a recent study where synaptotagmin-1 was quantified in patients in the AD continuum and cognitive decline from other dementias.<sup><xref ref-type="bibr" rid="bibr159-1177271920950319">159</xref>,<xref ref-type="bibr" rid="bibr160-1177271920950319">160</xref></sup></p>
<p>In the same study by Tible et al, in addition to synaptotagmin-1, the concentrations of GAP-43 and SNAP-25 were quantified. All 3 presynaptic proteins were significantly increased in AD and MCI-AD compared with the other disorders. However, only SNAP-25 and GAP-43 levels were also significantly higher in AD versus MCI-AD. Only synaptotagmin-1 concentrations were significantly lower in other neurodegenerative disorders compared with controls. Recently, Clarke et al<sup><xref ref-type="bibr" rid="bibr161-1177271920950319">161</xref></sup> compared synaptotagmin-1 and SNAP-25 concentrations in patients with FTD and demonstrated increased levels in patients with AD biomarker profile compared with those patients with an FTD profile.</p>
</sec>
<sec id="section13-1177271920950319">
<title>Alpha-synuclein and its forms</title>
<p>Alpha-syn is a key player in the etiology of different neurodegenerative conditions and as such, it has been studied as a possible biomarker for their detection. However, besides being a possible cause for diseases, it is also a presynaptic protein, taking part in many synaptic processes as previously described, which is why it is important to include it in this review. The synucleins family comprises α-, β-, and γ-synuclein, which are soluble proteins encoded by 3 different genes. Among them, α-syn is the most studied.<sup><xref ref-type="bibr" rid="bibr162-1177271920950319">162</xref></sup></p>
<sec id="section14-1177271920950319">
<title>Total α-syn</title>
<p>Studies of α-syn in CSF have mainly been focused on α-synucleinopathies and were based on immunological assays measuring total α-syn (t-α-syn); however, they have been largely inconsistent. For instance, in PD compared with controls, t-α-syn has been found in several studies to be slightly decreased<sup><xref ref-type="bibr" rid="bibr163-1177271920950319">163</xref><xref ref-type="bibr" rid="bibr164-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr165-1177271920950319">165</xref></sup> which is supported by several meta-analyses which concluded that there are significantly lower levels of t-α-syn in PD (10%-15%). However, in other studies no significant difference has been found,<sup><xref ref-type="bibr" rid="bibr166-1177271920950319">166</xref>,<xref ref-type="bibr" rid="bibr167-1177271920950319">167</xref></sup> and the diagnostic performance of t-α-syn is not considered sufficient for clinical utility due to significant overlap between the populations.<sup><xref ref-type="bibr" rid="bibr168-1177271920950319">168</xref><xref ref-type="bibr" rid="bibr169-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr170-1177271920950319">170</xref></sup> Other synucleinopathies, like DLB and MSA, have also shown a similar decrease compared with healthy controls, while tauopathies such as PSP and CBD seem to show no significant difference.<sup><xref ref-type="bibr" rid="bibr163-1177271920950319">163</xref>,<xref ref-type="bibr" rid="bibr165-1177271920950319">165</xref>,<xref ref-type="bibr" rid="bibr171-1177271920950319">171</xref></sup> For AD in comparison with healthy controls, t-α-syn levels seem to be elevated<sup><xref ref-type="bibr" rid="bibr171-1177271920950319">171</xref><xref ref-type="bibr" rid="bibr172-1177271920950319"></xref><xref ref-type="bibr" rid="bibr173-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr174-1177271920950319">174</xref></sup>; however, several studies showed no significant difference.<sup><xref ref-type="bibr" rid="bibr175-1177271920950319">175</xref><xref ref-type="bibr" rid="bibr176-1177271920950319"></xref><xref ref-type="bibr" rid="bibr177-1177271920950319"></xref><xref ref-type="bibr" rid="bibr178-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr179-1177271920950319">179</xref></sup> Patients with CJD, on the other hand, have a more pronounced increase in CSF t-α-syn, both compared with controls and with other neurodegenerative diseases.<sup><xref ref-type="bibr" rid="bibr178-1177271920950319">178</xref>,<xref ref-type="bibr" rid="bibr180-1177271920950319">180</xref>,<xref ref-type="bibr" rid="bibr181-1177271920950319">181</xref></sup> An explanation for the inconclusive findings of CSF α-syn is that leakage into the CSF from synapse breakdown occurs simultaneously as α-syn is retained in pathological inclusions. In addition, the extensive reduction in synapse number over time might lead to a decrease of α-syn production. Together these events might contribute to the confounding results.<sup><xref ref-type="bibr" rid="bibr166-1177271920950319">166</xref>,<xref ref-type="bibr" rid="bibr182-1177271920950319">182</xref></sup> Another contributing factor for the varying results might be due to technical variation such as handling of samples or quantification methods leading to low reproducibility.<sup><xref ref-type="bibr" rid="bibr182-1177271920950319">182</xref></sup> Moreover, α-syn is largely expressed outside of the CNS and highly abundant in blood, with red blood cells (RBCs) as its major source. Thus, blood contamination during CSF acquisition might represent another source of variation, skewing the t-α-syn concentration results in CSF.<sup><xref ref-type="bibr" rid="bibr183-1177271920950319">183</xref>,<xref ref-type="bibr" rid="bibr184-1177271920950319">184</xref></sup></p>
<p>Despite the possible problems just discussed, there have been many studies evaluating α-syn as blood biomarker for dementias. Studies for α-syn in plasma and serum in PD have all shown similar conflicting results as in CSF.<sup><xref ref-type="bibr" rid="bibr185-1177271920950319">185</xref><xref ref-type="bibr" rid="bibr186-1177271920950319"></xref><xref ref-type="bibr" rid="bibr187-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr188-1177271920950319">188</xref></sup> However, a meta-analysis indicates that plasma t-α-syn is significantly higher in PD than in controls.<sup><xref ref-type="bibr" rid="bibr189-1177271920950319">189</xref></sup> In a study by Laske et al,<sup><xref ref-type="bibr" rid="bibr190-1177271920950319">190</xref></sup> decreased serum concentrations of t-α-syn in DLB were found but with no difference for AD compared with controls. There are also a few studies on RBC t-α-syn<sup><xref ref-type="bibr" rid="bibr191-1177271920950319">191</xref><xref ref-type="bibr" rid="bibr192-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr193-1177271920950319">193</xref></sup> which showed significantly decreased levels of the protein in PD and AD compared with controls. Studies on t-α-syn in saliva have also been performed, but with limited success in differentiating PD from controls.<sup><xref ref-type="bibr" rid="bibr194-1177271920950319">194</xref><xref ref-type="bibr" rid="bibr195-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr196-1177271920950319">196</xref></sup></p>
</sec>
<sec id="section15-1177271920950319">
<title>Oligomeric, phosphorylated, and aggregated forms of α-synuclein</title>
<p>The inconclusive results of t-α-syn as a diagnostic biomarker have sparked research into pathological forms of α-syn, such as oligomeric (o-α-syn), phosphorylated (Ser129) (p-α-syn), and aggregated forms of α-synuclein. <italic>Oligomeric α-syn</italic> in CSF seems to be increased in PD compared with controls<sup><xref ref-type="bibr" rid="bibr169-1177271920950319">169</xref></sup> but not in AD and DLB.<sup><xref ref-type="bibr" rid="bibr174-1177271920950319">174</xref>,<xref ref-type="bibr" rid="bibr197-1177271920950319">197</xref></sup> Furthermore, Parnetti et al<sup><xref ref-type="bibr" rid="bibr198-1177271920950319">198</xref></sup> found that the diagnostic accuracy of PD can be improved by using the ratio of oligomeric/total α-syn in CSF. In plasma,<sup><xref ref-type="bibr" rid="bibr199-1177271920950319">199</xref></sup> serum,<sup><xref ref-type="bibr" rid="bibr200-1177271920950319">200</xref></sup> and RBC,<sup><xref ref-type="bibr" rid="bibr193-1177271920950319">193</xref>,<xref ref-type="bibr" rid="bibr201-1177271920950319">201</xref></sup> significantly elevated levels have been reported for PD, but also non-significant results exist.<sup><xref ref-type="bibr" rid="bibr202-1177271920950319">202</xref><xref ref-type="bibr" rid="bibr203-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr204-1177271920950319">204</xref></sup> In a study by Vivacqua et al,<sup><xref ref-type="bibr" rid="bibr205-1177271920950319">205</xref></sup> increased saliva levels of o-α-syn were found for PD. <italic>Phosphorylated α-syn</italic>, one of the main disease-associated posttranslational modifications (PTMs),<sup><xref ref-type="bibr" rid="bibr206-1177271920950319">206</xref></sup> is hard to quantify due to its low CSF concentration, but similar to the oligomeric and the total form, it has been found elevated in PD<sup><xref ref-type="bibr" rid="bibr169-1177271920950319">169</xref></sup> and its diagnostic accuracy increases when its ratio to other α-syn forms are used.<sup><xref ref-type="bibr" rid="bibr207-1177271920950319">207</xref></sup> Phosphorylated-α-syn has also been indicated to be elevated in CJD<sup><xref ref-type="bibr" rid="bibr181-1177271920950319">181</xref></sup> and not increased in AD.<sup><xref ref-type="bibr" rid="bibr174-1177271920950319">174</xref>,<xref ref-type="bibr" rid="bibr179-1177271920950319">179</xref></sup> Plasma p-α-syn has been found to be significantly increased in PD compared with controls.<sup><xref ref-type="bibr" rid="bibr185-1177271920950319">185</xref>,<xref ref-type="bibr" rid="bibr203-1177271920950319">203</xref></sup> For the measurement of pathogenic <italic>α-syn aggregates</italic> in CSF, aggregation assays have been developed. Assays based on real-time quaking-induced conversion (RT-QuIC) or protein misfolding cyclic amplification (PMCA) have shown very promising results (specificity &gt; 95%, sensitivity &gt; 80%) in discriminating synucleinopathies (PD, MSA, and DLB) from nonsynucleinopathies (AD and controls).<sup><xref ref-type="bibr" rid="bibr208-1177271920950319">208</xref><xref ref-type="bibr" rid="bibr209-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr210-1177271920950319">210</xref></sup></p>
</sec>
</sec>
<sec id="section16-1177271920950319">
<title>Neurogranin</title>
<p>Neurogranin is an intracellular 7.5-kDa protein, concentrated in the dendritic and postsynaptic compartment of synaptic spines of neurons.<sup><xref ref-type="bibr" rid="bibr211-1177271920950319">211</xref>,<xref ref-type="bibr" rid="bibr212-1177271920950319">212</xref></sup> There it binds via its central IQ domain<sup><xref ref-type="bibr" rid="bibr213-1177271920950319">213</xref></sup> to the Ca<sup>2+</sup>-signaling mediator calmodulin, enhancing signaling for processes important in memory formation and to phosphatidic acid at the inner plasma membrane.<sup><xref ref-type="bibr" rid="bibr214-1177271920950319">214</xref></sup> A neurogranin knockout mouse model showed deficits in spatial memory and synaptic plasticity.<sup><xref ref-type="bibr" rid="bibr215-1177271920950319">215</xref></sup> In a first study, CSF neurogranin was shown by immunoprecipitation and Western blot to be increased in AD.<sup><xref ref-type="bibr" rid="bibr216-1177271920950319">216</xref></sup> After the development of immunoassay methods using ELISA,<sup><xref ref-type="bibr" rid="bibr217-1177271920950319">217</xref></sup> Singulex,<sup><xref ref-type="bibr" rid="bibr218-1177271920950319">218</xref></sup> and Mesoscale,<sup><xref ref-type="bibr" rid="bibr219-1177271920950319">219</xref></sup> these findings have been verified in several studies and neurogranin consistently showed increased levels in CSF of AD patients as compared with controls.<sup><xref ref-type="bibr" rid="bibr121-1177271920950319">121</xref>,<xref ref-type="bibr" rid="bibr220-1177271920950319">220</xref><xref ref-type="bibr" rid="bibr221-1177271920950319"></xref><xref ref-type="bibr" rid="bibr222-1177271920950319"></xref><xref ref-type="bibr" rid="bibr223-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr224-1177271920950319">224</xref></sup> This increase appears to be specific for AD, as CSF from patients with other neurodegenerative diseases, with the exception of CJD,<sup><xref ref-type="bibr" rid="bibr225-1177271920950319">225</xref></sup> do not show such an increase.<sup><xref ref-type="bibr" rid="bibr161-1177271920950319">161</xref>,<xref ref-type="bibr" rid="bibr226-1177271920950319">226</xref>,<xref ref-type="bibr" rid="bibr227-1177271920950319">227</xref></sup> High levels of neurogranin in CSF during prodromal AD have been shown to be predictive of more rapid progression toward AD.<sup><xref ref-type="bibr" rid="bibr217-1177271920950319">217</xref>,<xref ref-type="bibr" rid="bibr219-1177271920950319">219</xref></sup></p>
<p>Besides full-length neurogranin, CSF contains mainly fragments of the C-terminal half (with a variety of different truncations at their C-terminal and N-terminal ends).<sup><xref ref-type="bibr" rid="bibr216-1177271920950319">216</xref>,<xref ref-type="bibr" rid="bibr217-1177271920950319">217</xref></sup> Two intracellular enzymes have been identified that can generate cleavages in the functionally important IQ domain and at the very C-terminal end (calpain-1 and prolyl endopeptidase, respectively).<sup><xref ref-type="bibr" rid="bibr228-1177271920950319">228</xref></sup> Whether these different fragments of neurogranin have roles in different physiological or pathophysiological functions is still unknown. In a comparison study, different ELISAs and the Singulex assay were found to have similar performance in predicting AD, in spite targeting different parts of neurogranin.<sup><xref ref-type="bibr" rid="bibr229-1177271920950319">229</xref></sup> However, this does not rule out that particular neurogranin fragments could yield more discriminatory power to detect AD. Overall, it can be said that neurogranin may be a useful biomarker in CSF to detect early degeneration of neurons and it appears to be fairly specific for AD among several tauopathies.</p>
<p>Plasma concentrations of neurogranin are detectable with conventional ELISAs but are unchanged in AD and do not correlate with CSF neurogranin, probably due to the contribution of peripherally expressed neurogranin peptides to blood neurogranin measurements.<sup><xref ref-type="bibr" rid="bibr121-1177271920950319">121</xref>,<xref ref-type="bibr" rid="bibr220-1177271920950319">220</xref></sup></p>
</sec>
</sec>
<sec id="section17-1177271920950319">
<title>Emerging synaptic biomarkers</title>
<p>Recently, other studies identified more synaptic proteins in CSF, which have been investigated without success so far or that show promise as synaptic biomarkers, thus worth to be mentioned in this section. Wesenhagen et al have recently reviewed 29 proteomic studies that investigated AD-related changes in CSF protein abundances. In total, 97 proteins, including the synaptic proteins neurofascin, NPTX1, NPTX2, and neurexin 1, were reported by 2 or more studies and associated with AD.<sup><xref ref-type="bibr" rid="bibr230-1177271920950319">230</xref></sup> One of the reviewed studies<sup><xref ref-type="bibr" rid="bibr231-1177271920950319">231</xref></sup> reported a synaptic biomarker panel where only the 3 synaptic proteins neurofascin, NPTX1, and neurexin 1 were significantly lowered in AD. Similarly, Lleó et al<sup><xref ref-type="bibr" rid="bibr232-1177271920950319">232</xref></sup> found that 6 synaptic proteins, calsyntenin-1, glutamate receptor 4 (GRIA4), neurexin-2A, neurexin-3A, syntaxin-1B, and thy-1 membrane glycoprotein, were increased in CSF in preclinical AD even before the core CSF biomarkers for neurodegeneration.</p>
<p>In explorative proteomics, high-resolution separation methods such as gel electrophoresis, isoelectric focusing, and high-performance liquid chromatography are used in conjunction with mass spectrometry and bioinformatics to study differences in protein expression due to diseases, genetic variations, or therapy. A major advantage of using an explorative approach to study protein abundances is that many hundred proteins and protein variants can be studied simultaneously without existing hypotheses or bias. Thus, the discovery of novel biomarkers could lead to new insights on disease mechanisms and eventually the formulation of novel hypotheses. However, using the explorative approach to identify biomarkers in biofluids from individual patient samples is challenging and the overlap of identified biomarker candidates among these studies has historically been relatively low. These discrepancies may be due to a low number of study participants, differences in sample handling, and other analytical parameters. Another possible approach to identify new candidate biomarkers is setting up targeted assays based on proteins of interest from studying the literature and/or public databases. Commonly shotgun proteomics, to identify possible proteins of interest, is also used in the selective process. In this way, several potential biomarker candidates can be validated in a targeted setting in larger cohorts. Among emerging synaptic biomarkers, of special note are neuronal pentraxins and the synaptic vesicle glycoprotein 2A.</p>
<sec id="section18-1177271920950319">
<title>Neuronal pentraxins</title>
<p>Neuronal pentraxin I (NPTX1, also called NP1) and II (NPTX2, also called NP2), and the neuronal pentraxin receptor (NPTXR) are widely expressed at excitatory synapses, where they bind to AMPA receptors and are suggested to be involved in synaptic plasticity.<sup><xref ref-type="bibr" rid="bibr233-1177271920950319">233</xref>,<xref ref-type="bibr" rid="bibr234-1177271920950319">234</xref></sup> All 3 neuronal pentraxins have lately received much attention and have been shown in several studies to have decreased CSF levels in AD and MCI groups compared with controls.<sup><xref ref-type="bibr" rid="bibr231-1177271920950319">231</xref>,<xref ref-type="bibr" rid="bibr235-1177271920950319">235</xref><xref ref-type="bibr" rid="bibr236-1177271920950319"></xref><xref ref-type="bibr" rid="bibr237-1177271920950319"></xref><xref ref-type="bibr" rid="bibr238-1177271920950319"></xref><xref ref-type="bibr" rid="bibr239-1177271920950319"></xref><xref ref-type="bibr" rid="bibr240-1177271920950319"></xref><xref ref-type="bibr" rid="bibr241-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr242-1177271920950319">242</xref></sup> CSF pentraxin levels also correlate with cognitive performance and hippocampal volume.<sup><xref ref-type="bibr" rid="bibr150-1177271920950319">150</xref>,<xref ref-type="bibr" rid="bibr242-1177271920950319">242</xref>,<xref ref-type="bibr" rid="bibr243-1177271920950319">243</xref></sup> Few studies have been performed on other diseases but NPTXR has also been associated with other neurological diseases such as MS<sup><xref ref-type="bibr" rid="bibr244-1177271920950319">244</xref></sup> and FTD.<sup><xref ref-type="bibr" rid="bibr245-1177271920950319">245</xref></sup> Furthermore, in a study by Magdalinou et al<sup><xref ref-type="bibr" rid="bibr246-1177271920950319">246</xref></sup> both NPTXR and NPTX1 were found to be decreased in between atypical parkinsonian disorders (PSP, MSA, CBD) and controls.</p>
</sec>
<sec id="section19-1177271920950319">
<title>SV2A</title>
<p>Recent studies using [<sup>11</sup>C]UCB-J PET have identified SV2A as the first in vivo marker of synaptic density<sup><xref ref-type="bibr" rid="bibr247-1177271920950319">247</xref></sup> which demonstrates widespread synaptic loss in AD.<sup><xref ref-type="bibr" rid="bibr118-1177271920950319">118</xref></sup> SV2A is a synaptic vesicle transmembrane protein, which in brain is widely expressed in neurons.<sup><xref ref-type="bibr" rid="bibr248-1177271920950319">248</xref></sup> SV2A has been described to be located in the dense-core vesicles<sup><xref ref-type="bibr" rid="bibr249-1177271920950319">249</xref>,<xref ref-type="bibr" rid="bibr250-1177271920950319">250</xref></sup> and in small synaptic vesicles,<sup><xref ref-type="bibr" rid="bibr251-1177271920950319">251</xref></sup> most probably in both. Although its exact mechanism needs more investigation, it is involved in regulation of neurotransmitter release<sup><xref ref-type="bibr" rid="bibr252-1177271920950319">252</xref>,<xref ref-type="bibr" rid="bibr253-1177271920950319">253</xref></sup> and expression and trafficking of synaptotagmin.<sup><xref ref-type="bibr" rid="bibr254-1177271920950319">254</xref></sup> Compared with the typical pattern of hypometabolism seen in AD using [<sup><xref ref-type="bibr" rid="bibr18-1177271920950319">18</xref></sup>F]FDG, the spatial extent of decreases in [<sup>11</sup>C]UCB-J uptake was significantly more confined. The reduction in hippocampal binding is in line with the early loss of entorhinal cortical cell projections to the hippocampus, and reductions of hippocampal SV2A seen in postmortem studies in AD brain tissue.<sup><xref ref-type="bibr" rid="bibr255-1177271920950319">255</xref>,<xref ref-type="bibr" rid="bibr256-1177271920950319">256</xref></sup> More recently, changes in [<sup>11</sup>C]UCB-J PET have been observed in PD,<sup><xref ref-type="bibr" rid="bibr257-1177271920950319">257</xref></sup> PSP,<sup><xref ref-type="bibr" rid="bibr258-1177271920950319">258</xref></sup> cortical basal syndrome, and epilepsy<sup><xref ref-type="bibr" rid="bibr247-1177271920950319">247</xref></sup> suggesting that SV2A could be a global marker for synaptic density, unlike CSF synaptotagmin-1, SNAP-25, GAP-43, and neurogranin, which are rather specific to AD or amyloidopathies. Recently, SV2A has been detected in CSF and shown to be reduced in AD<sup><xref ref-type="bibr" rid="bibr259-1177271920950319">259</xref></sup>; however it is yet to be determined whether CSF SV2A can be used as a marker for synaptic density in other dementias and whether it has a meaningful correlation with [<sup>11</sup>C]UCB-J (<xref ref-type="fig" rid="fig1-1177271920950319">Figure 1</xref>).</p>
<fig id="fig1-1177271920950319" orientation="portrait" position="float">
<label>Figure 1.</label>
<caption>
<p>Synaptic and neuronal biomarkers location. The picture is a schematic representation of the most studied synaptic biomarkers described in this review. As it can be noticed, most of the candidate biomarkers are localized presynaptically, with the exception of <italic>neurogranin</italic> and neuronal pentraxins (<italic>NPTX</italic>), which has also been described to be present presynaptically.<sup><xref ref-type="bibr" rid="bibr260-1177271920950319">260</xref></sup> Many proteins are involved in synaptic vesicle assembly and neurotransmitters release, like <italic>synaptotagmin-1 (syt 1), synaptophysin, SNAP-25</italic>, and <italic>SV2A</italic>.<sup><xref ref-type="bibr" rid="bibr248-1177271920950319">248</xref></sup> α-Synuclein (<italic>α-syn</italic>) can be found as a soluble form in the cytoplasm, but also associating with membrane lipids as, for instance, with synaptic vesicles and mitochondria.<sup><xref ref-type="bibr" rid="bibr87-1177271920950319">87</xref></sup>
<italic>GAP-43</italic> shows high density in the presynaptic terminal, where depending on its phosphorylation status, participates in neuronal growth modulating actin or in synaptic plasticity modulating synaptic vesicle trafficking.<sup><xref ref-type="bibr" rid="bibr141-1177271920950319">141</xref></sup> Together with actin filaments and microtubules, <italic>neurofilaments</italic> are cytoskeletal elements of the neurons, providing mechanical strength and stability.<sup><xref ref-type="bibr" rid="bibr131-1177271920950319">131</xref></sup>
<italic>Tau</italic> protein, mainly expressed in axons, binds to tubulin and induce its polymerization into microtubules, which support axon outgrowth and elongation.<sup><xref ref-type="bibr" rid="bibr261-1177271920950319">261</xref></sup> α-syn indicates synuclein; DCV, dense-core vesicles; GAP-43, growth-associated protein 43; LTP, long-term potentiation; NPTX, neuronal pentraxin; SNAP-25, synaptosomal-associated protein 25.</p>
<p>Figure made with <ext-link ext-link-type="uri" xlink:href="http://www.biorender.com">www.biorender.com</ext-link>.</p>
</caption>
<graphic xlink:href="10.1177_1177271920950319-fig1"></graphic>
</fig>
</sec>
</sec>
<sec id="section20-1177271920950319">
<title>Miscellaneous: other emerging synaptic biomarkers</title>
<p>The Rab family are key synaptic proteins involved in both recycling of neurotransmitter receptors and exocytosis of neurotransmitters. Of special note is the family member ras-related protein 3a (<italic>Rab3a</italic>), highly abundant in brain tissues, which has been connected with several neurodegenerative diseases (AD, PD, and DLB) due to its regulation of Aβ production and interaction with α-syn.<sup><xref ref-type="bibr" rid="bibr262-1177271920950319">262</xref></sup> The protein has been investigated by Bereczki et al,<sup><xref ref-type="bibr" rid="bibr153-1177271920950319">153</xref></sup> which however did not find any significant difference in CSF between patients with PD and control. A second important protein family for neurotransmitter exocytosis is the granin family, which is constituted of dense-core vesicle proteins involved, inter alia, in neuropeptide biogenesis and secretion. The proteins have not only been associated with neurodegenerative diseases, such as AD, but also with other synaptopathies, such as schizophrenia and depression.<sup><xref ref-type="bibr" rid="bibr263-1177271920950319">263</xref></sup> Three of the key granins: chromogranin-A, secretogranin-2, and neurosecretory protein VGF, have been found to have significantly lower CSF concentrations in AD.<sup><xref ref-type="bibr" rid="bibr231-1177271920950319">231</xref>,<xref ref-type="bibr" rid="bibr264-1177271920950319">264</xref></sup></p>
<p>Another synaptic protein involved in the pathology of AD is <italic>contactin-2</italic>, a cell-adhesion protein that interacts with APP and beta-secretase 1 (BACE1). Chatterjee et al<sup><xref ref-type="bibr" rid="bibr265-1177271920950319">265</xref></sup> found that the protein was reduced in both brain tissue and CSF in AD. The less well-studied members of the synuclein family, beta-synuclein (<italic>β-syn</italic>) and gamma-synuclein (<italic>γ-syn</italic>), are also present in proteinaceous aggregates in some α-synucleinopathies.<sup><xref ref-type="bibr" rid="bibr266-1177271920950319">266</xref></sup> Oeckl et al<sup><xref ref-type="bibr" rid="bibr167-1177271920950319">167</xref></sup> was the first to measure all 3 synucleins protein family members, α, β, γ in CSF. They found increased concentrations of all synucleins in AD and CJD; however for PD, DLB, and atypical parkinsonian syndromes the concentrations were not altered. Furthermore, a high correlation between the 3 synucleins was seen. In another study by Oeckl et al,<sup><xref ref-type="bibr" rid="bibr267-1177271920950319">267</xref></sup> β-syn was quantified in blood and found it to be increased in AD and CJD compared with controls but not in other neurodegenerative diseases, such as PDD, DLB, amyotrophic lateral sclerosis (ALS), and FTD.</p>
<sec id="section21-1177271920950319">
<title>14-3-3</title>
<p>14-3-3 proteins refer to a family of 7 isoforms which are highly expressed in the brain, accounting for 1% of its soluble protein content. They are also particularly enriched at synapses (presynaptic) and important modulators of synaptic functions, such as neurotransmission and plasticity. 14-3-3 protein detection by Western blot has since long been used to detect CJD, albeit this technique is only semi-quantitative. However, more recently, 14-3-3 have been studied in the context of other neurodegenerative pathologies. 14-3-3 isoforms have not only been found to co-localize in LB in PD and NFTs in AD, but also been found to interact with key proteins such as tau and α-syn. They have also been genetically linked to both neurodegenerative diseases (PD, AD, and CJD) and neuropsychiatric disorders (schizophrenia and bipolar disorder).<sup><xref ref-type="bibr" rid="bibr268-1177271920950319">268</xref>,<xref ref-type="bibr" rid="bibr269-1177271920950319">269</xref></sup> A recent study by Antonell et al<sup><xref ref-type="bibr" rid="bibr270-1177271920950319">270</xref></sup> found significantly increased <italic>gamma</italic> 14-3-3 concentrations in both FTD and AD compared with controls. For AD, increased concentrations were found already in a prodromal stage and the protein level was also significantly higher at later stages compared with FTD. Furthermore, when analyzing for 14-3-3, 96% of subjects were positive for neurodegeneration when applying the AT(N) system, compared with 94% for neurofilament light and 62% for neurogranin.<sup><xref ref-type="bibr" rid="bibr270-1177271920950319">270</xref></sup></p>
<p><italic>Synaptophysin</italic> is one of the most used synaptic biomarkers in immunohistochemistry since it is the most abundant integral synaptic vesicle and plasma membrane protein. In studies of AD postmortem brain tissue, it has been shown that the synaptophysin content is reduced.<sup><xref ref-type="bibr" rid="bibr271-1177271920950319">271</xref>,<xref ref-type="bibr" rid="bibr272-1177271920950319">272</xref></sup> Several studies have reported that the protein is not detectable in CSF,<sup><xref ref-type="bibr" rid="bibr139-1177271920950319">139</xref>,<xref ref-type="bibr" rid="bibr138-1177271920950319">138</xref>,<xref ref-type="bibr" rid="bibr273-1177271920950319">273</xref></sup> possibly due to its high hydrophobic profile.<sup><xref ref-type="bibr" rid="bibr139-1177271920950319">139</xref></sup> However, it has recently been reported to be detected in exosome preparations from body fluids.<sup><xref ref-type="bibr" rid="bibr274-1177271920950319">274</xref>,<xref ref-type="bibr" rid="bibr275-1177271920950319">275</xref></sup></p>
</sec>
<sec id="section22-1177271920950319">
<title>Neuronal-derived exosomes</title>
<p>A recent approach for the discovery of new synaptic biomarkers has been based on isolating neuronal exosomes from blood (plasma). As discussed previously, blood is an easily accessible peripheral fluid, preferred to CSF, which entails a more invasive extraction procedure. However, blood has the disadvantage of being further away from the brain and give peripheral contribution to the levels of the protein. Studying neuronal exosomes enriched from blood gives the advantage to use blood while hopefully better reflecting brain pathogenic processes. Explorative proteomic analysis has tried to map the protein content of the neuronal exosomes and confirmed the presence of several synaptic proteins such as Rab3a and GRIA4.<sup><xref ref-type="bibr" rid="bibr276-1177271920950319">276</xref></sup> In plasma samples, Goetzl et al<sup><xref ref-type="bibr" rid="bibr274-1177271920950319">274</xref></sup> reported significantly decreased neuronal-derived levels of synaptophysin together with synaptopodin, synaptotagmin-2, and neurogranin in patients with AD and FTD compared with controls. In the same study, GAP-43 and synapsin-1 were also detected, but were found to have significantly lower levels only in AD. Furthermore, in another study by Goetzl et al,<sup><xref ref-type="bibr" rid="bibr277-1177271920950319">277</xref></sup> plasma neuronal–derived exosome levels of NPTX2, neurexin 2, GRIA4, and neuroligin 1 were found to be significantly decreased in AD, where also GluR4 and neuroligin 1 correlated with cognitive loss. Another protein that has been quantified in neuronal exosomes is α-syn, found to have increased concentrations in PD compared with controls.<sup><xref ref-type="bibr" rid="bibr278-1177271920950319">278</xref></sup> For proteins such as neurogranin or α-syn, where peripheral expression complicates the quantification in blood, neuronally derived exosomes seem like an excellent option. However, even if this has promise, it is limited by expensive and time-consuming sample preparation, which as of today restricts its potential for high-throughput biomarker screening and its use in clinical routine. Nevertheless, exosomes are being connected to an increasing number of synaptopathies and they have even been implicated in the propagation of disease-associated proteins such as tau, Aβ, PrP<sup>C</sup>, and α-syn.<sup><xref ref-type="bibr" rid="bibr279-1177271920950319">279</xref>,<xref ref-type="bibr" rid="bibr280-1177271920950319">280</xref></sup> They are a relatively unexplored source for synaptic biomarkers, which makes them a vital part of the field (<xref ref-type="fig" rid="fig2-1177271920950319">Figure 2</xref>).</p>
<fig id="fig2-1177271920950319" orientation="portrait" position="float">
<label>Figure 2.</label>
<caption>
<p>Proteomic approaches in synaptic biomarkers discovery and validation. Proteomic studies can start with large explorative investigations in brain tissue, which might lead to the discovery of new candidate biomarkers. However, these studies can be seen as starting points, and they have no clinical utilities. Thus, investigations in CSF are needed to be able to translate the biomarker discovery into a tool of clinical use. Once the biomarker has been validated in CSF, further investigations can be carried in blood, a biofluid with higher accessibility and cheaper to use. On the other hand blood is further away from the brain and the targeted protein level might be susceptible to peripheral contribution, resulting in lower biomarker specificity and confounding results. A possible approach to overcome this problem is the use of plasma-derived neuronal exosomes. These investigations can be carried out with a targeted or non-targeted approach. In the diagram, pros and cons of both approaches are highlighted. ELISA indicates enzyme-linked immunosorbent assay; IP, immunoprecipitation; LC-MS, liquid chromatography-mass spectrometry; PRM, parallel reaction monitoring; SIMOA, single molecule array; WB, Western blot.</p>
<p>Figure made with <ext-link ext-link-type="uri" xlink:href="http://www.biorender.com">www.biorender.com</ext-link>.</p>
</caption>
<graphic xlink:href="10.1177_1177271920950319-fig2"></graphic>
</fig>
</sec>
</sec>
</sec>
<sec id="section23-1177271920950319" sec-type="conclusions">
<title>Conclusions and Future Perspective</title>
<p>Synapses are essential interconnecting points for neurons and are primarily affected in neurodegenerative and neurodevelopmental disorders.<sup><xref ref-type="bibr" rid="bibr72-1177271920950319">72</xref></sup> Accumulation of misfolded proteins seems to directly affect them,<sup><xref ref-type="bibr" rid="bibr35-1177271920950319">35</xref></sup> leading to their dysfunction and loss, which is closely related to the cognitive deficits seen in these aging disorders. This review summarizes latest studies on more established and newly investigated synaptic proteins as candidate biomarkers for synapse dysfunction and neuronal injury in different neurodegenerative diseases, in relation to both CSF and blood (<xref ref-type="table" rid="table1-1177271920950319">Table 1</xref>).</p>
<table-wrap id="table1-1177271920950319" orientation="portrait" position="float">
<label>Table 1.</label>
<caption>
<p>Synaptic biomarkers changes in CSF and blood based on current literature.</p>
</caption>
<alternatives>
<graphic xlink:href="10.1177_1177271920950319-table1"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="3">Pathology Compared with controls</th>
<th align="left" colspan="9" rowspan="1">Cerebrospinal fluid</th>
<th align="left" colspan="2" rowspan="1">Blood</th>
<th align="left" colspan="1" rowspan="1">References</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">Amyloid-β</th>
<th align="left" colspan="1" rowspan="1">Prion</th>
<th align="left" colspan="3" rowspan="1">Lewy body</th>
<th align="left" colspan="3" rowspan="1">Tauopathies</th>
<th align="left" colspan="1" rowspan="1">Inflam.</th>
<th align="left" colspan="1" rowspan="1">Amyloid</th>
<th align="left" colspan="1" rowspan="1">Lewy body</th>
<th colspan="1" rowspan="1"></th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">AD</th>
<th align="left" colspan="1" rowspan="1">CJD</th>
<th align="left" colspan="1" rowspan="1">PD</th>
<th align="left" colspan="1" rowspan="1">DLB</th>
<th align="left" colspan="1" rowspan="1">MSA</th>
<th align="left" colspan="1" rowspan="1">PSP</th>
<th align="left" colspan="1" rowspan="1">CBD</th>
<th align="left" colspan="1" rowspan="1">FTD</th>
<th align="left" colspan="1" rowspan="1">MS</th>
<th align="left" colspan="1" rowspan="1">AD</th>
<th align="left" colspan="1" rowspan="1">PD</th>
<th colspan="1" rowspan="1"></th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="13" rowspan="1">
<italic>Presynaptic</italic>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">SNAP-25</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">=</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr7-1177271920950319">7</xref>,<xref ref-type="bibr" rid="bibr150-1177271920950319">150</xref><xref ref-type="bibr" rid="bibr151-1177271920950319"></xref><xref ref-type="bibr" rid="bibr152-1177271920950319"></xref><xref ref-type="bibr" rid="bibr153-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr154-1177271920950319">154</xref>,<xref ref-type="bibr" rid="bibr161-1177271920950319">161</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAP-43</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">=</td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1">↓<sup>E</sup></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr109-1177271920950319">109</xref>,<xref ref-type="bibr" rid="bibr143-1177271920950319">143</xref>,<xref ref-type="bibr" rid="bibr144-1177271920950319">144</xref>,<xref ref-type="bibr" rid="bibr145-1177271920950319">145</xref>,<xref ref-type="bibr" rid="bibr147-1177271920950319">147</xref>,<xref ref-type="bibr" rid="bibr161-1177271920950319">161</xref></sup>, in blood<sup><xref ref-type="bibr" rid="bibr274-1177271920950319">274</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Synaptotagmin-1</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">=</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr159-1177271920950319">159</xref>,<xref ref-type="bibr" rid="bibr161-1177271920950319">161</xref>,<xref ref-type="bibr" rid="bibr158-1177271920950319">158</xref></sup></td>
</tr>
<tr>
<td colspan="13" rowspan="1">Alpha-synuclein</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Total</td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1">=</td>
<td colspan="1" rowspan="1">=</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">=<sup>S</sup></td>
<td colspan="1" rowspan="1">↑<sup>P, E</sup>↓<sup>R</sup></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr163-1177271920950319">163</xref><xref ref-type="bibr" rid="bibr164-1177271920950319"></xref><xref ref-type="bibr" rid="bibr165-1177271920950319"></xref><xref ref-type="bibr" rid="bibr166-1177271920950319"></xref><xref ref-type="bibr" rid="bibr167-1177271920950319"></xref><xref ref-type="bibr" rid="bibr168-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr169-1177271920950319">169</xref>,<xref ref-type="bibr" rid="bibr171-1177271920950319">171</xref><xref ref-type="bibr" rid="bibr172-1177271920950319"></xref><xref ref-type="bibr" rid="bibr173-1177271920950319"></xref><xref ref-type="bibr" rid="bibr174-1177271920950319"></xref><xref ref-type="bibr" rid="bibr175-1177271920950319"></xref><xref ref-type="bibr" rid="bibr176-1177271920950319"></xref><xref ref-type="bibr" rid="bibr177-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr178-1177271920950319">178</xref>,<xref ref-type="bibr" rid="bibr180-1177271920950319">180</xref>,<xref ref-type="bibr" rid="bibr207-1177271920950319">207</xref>,<xref ref-type="bibr" rid="bibr281-1177271920950319">281</xref></sup>, in blood<sup><xref ref-type="bibr" rid="bibr189-1177271920950319">189</xref>,<xref ref-type="bibr" rid="bibr190-1177271920950319">190</xref>,<xref ref-type="bibr" rid="bibr278-1177271920950319">278</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Oligomeric</td>
<td colspan="1" rowspan="1">=</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1">=</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">↑<sup>S, P,R</sup></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr169-1177271920950319">169</xref>,<xref ref-type="bibr" rid="bibr174-1177271920950319">174</xref>,<xref ref-type="bibr" rid="bibr197-1177271920950319">197</xref>,<xref ref-type="bibr" rid="bibr198-1177271920950319">198</xref>,<xref ref-type="bibr" rid="bibr207-1177271920950319">207</xref></sup>, in blood<sup><xref ref-type="bibr" rid="bibr193-1177271920950319">193</xref>,<xref ref-type="bibr" rid="bibr199-1177271920950319">199</xref><xref ref-type="bibr" rid="bibr200-1177271920950319"></xref><xref ref-type="bibr" rid="bibr201-1177271920950319"></xref><xref ref-type="bibr" rid="bibr202-1177271920950319"></xref><xref ref-type="bibr" rid="bibr203-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr204-1177271920950319">204</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Phosporylated</td>
<td colspan="1" rowspan="1">=</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">↑<sup>S</sup></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr165-1177271920950319">165</xref>,<xref ref-type="bibr" rid="bibr169-1177271920950319">169</xref>,<xref ref-type="bibr" rid="bibr174-1177271920950319">174</xref>,<xref ref-type="bibr" rid="bibr179-1177271920950319">179</xref>,<xref ref-type="bibr" rid="bibr181-1177271920950319">181</xref>,<xref ref-type="bibr" rid="bibr207-1177271920950319">207</xref></sup>, in blood<sup><xref ref-type="bibr" rid="bibr185-1177271920950319">185</xref>,<xref ref-type="bibr" rid="bibr203-1177271920950319">203</xref></sup></td>
</tr>
<tr>
<td colspan="13" rowspan="1">
<italic>Postsynaptic</italic>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Neurogranin</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1">=</td>
<td colspan="1" rowspan="1">=</td>
<td colspan="1" rowspan="1">=</td>
<td colspan="1" rowspan="1">=</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">=</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">=<sup>P</sup>↓<sup>E</sup></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr1-1177271920950319">1</xref>,<xref ref-type="bibr" rid="bibr3-1177271920950319">3</xref>,<xref ref-type="bibr" rid="bibr18-1177271920950319">18</xref>,<xref ref-type="bibr" rid="bibr121-1177271920950319">121</xref>,<xref ref-type="bibr" rid="bibr150-1177271920950319">150</xref>,<xref ref-type="bibr" rid="bibr161-1177271920950319">161</xref>,<xref ref-type="bibr" rid="bibr216-1177271920950319">216</xref>,<xref ref-type="bibr" rid="bibr217-1177271920950319">217</xref>,<xref ref-type="bibr" rid="bibr219-1177271920950319">219</xref>,<xref ref-type="bibr" rid="bibr220-1177271920950319">220</xref>,<xref ref-type="bibr" rid="bibr222-1177271920950319">222</xref>,<xref ref-type="bibr" rid="bibr224-1177271920950319">224</xref><xref ref-type="bibr" rid="bibr225-1177271920950319"></xref><xref ref-type="bibr" rid="bibr226-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr227-1177271920950319">227</xref></sup> in blood<sup><xref ref-type="bibr" rid="bibr121-1177271920950319">121</xref>,<xref ref-type="bibr" rid="bibr220-1177271920950319">220</xref>,<xref ref-type="bibr" rid="bibr274-1177271920950319">274</xref></sup></td>
</tr>
<tr>
<td colspan="13" rowspan="1">
<italic>Neuronal</italic>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Neurofilaments</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Light chain</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1">=</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">↑<sup>P, S</sup></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup>171,<xref ref-type="bibr" rid="bibr282-1177271920950319">282</xref><xref ref-type="bibr" rid="bibr283-1177271920950319"></xref><xref ref-type="bibr" rid="bibr284-1177271920950319"></xref><xref ref-type="bibr" rid="bibr285-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr286-1177271920950319">286</xref></sup>, in blood<sup><xref ref-type="bibr" rid="bibr132-1177271920950319">132</xref>,<xref ref-type="bibr" rid="bibr134-1177271920950319">134</xref>,<xref ref-type="bibr" rid="bibr135-1177271920950319">135</xref>,<xref ref-type="bibr" rid="bibr287-1177271920950319">287</xref>,<xref ref-type="bibr" rid="bibr288-1177271920950319">288</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Heavy chain</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr286-1177271920950319">286</xref></sup></td>
</tr>
<tr>
<td colspan="13" rowspan="1">
<italic>Emerging</italic>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Synaptophysin</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">↓<sup>E</sup></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In blood<sup><xref ref-type="bibr" rid="bibr274-1177271920950319">274</xref></sup></td>
</tr>
<tr>
<td colspan="13" rowspan="1">Synucleins</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Gamma</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1">=</td>
<td colspan="1" rowspan="1">=</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr167-1177271920950319">167</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Beta</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1">=</td>
<td colspan="1" rowspan="1">=</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">↑<sup>S</sup></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr167-1177271920950319">167</xref></sup>, in blood<sup><xref ref-type="bibr" rid="bibr167-1177271920950319">167</xref></sup></td>
</tr>
<tr>
<td colspan="13" rowspan="1">Neuronal pentraxins</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 1</td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr231-1177271920950319">231</xref>,<xref ref-type="bibr" rid="bibr246-1177271920950319">246</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2</td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">↓<sup>E</sup></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr44-1177271920950319">44</xref>,<xref ref-type="bibr" rid="bibr150-1177271920950319">150</xref>,<xref ref-type="bibr" rid="bibr235-1177271920950319">235</xref>,<xref ref-type="bibr" rid="bibr236-1177271920950319">236</xref>,<xref ref-type="bibr" rid="bibr242-1177271920950319">242</xref></sup>, in blood<sup><xref ref-type="bibr" rid="bibr277-1177271920950319">277</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Receptor</td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr237-1177271920950319">237</xref><xref ref-type="bibr" rid="bibr238-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr239-1177271920950319">239</xref>,<xref ref-type="bibr" rid="bibr244-1177271920950319">244</xref><xref ref-type="bibr" rid="bibr245-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr246-1177271920950319">246</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">SV2A</td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr259-1177271920950319">259</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Contactin-2</td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr265-1177271920950319">265</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Neurofascin</td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr231-1177271920950319">231</xref></sup></td>
</tr>
<tr>
<td colspan="13" rowspan="1">Neurexin</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 1</td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr231-1177271920950319">231</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">↓<sup>E</sup></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr232-1177271920950319">232</xref></sup>, in blood<sup><xref ref-type="bibr" rid="bibr277-1177271920950319">277</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 3</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr232-1177271920950319">232</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Syntaxin-1</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr232-1177271920950319">232</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Calsyntenin-1</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr232-1177271920950319">232</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Glutamate receptor 4</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">↓<sup>E</sup></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr232-1177271920950319">232</xref></sup>, in blood<sup><xref ref-type="bibr" rid="bibr277-1177271920950319">277</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Thy-1 membrane glycoprotein</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr232-1177271920950319">232</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Synaptopodin</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">↓<sup>E</sup></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In blood<sup><xref ref-type="bibr" rid="bibr274-1177271920950319">274</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Synaptotagmin-2</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">↓<sup>E</sup></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In blood<sup><xref ref-type="bibr" rid="bibr274-1177271920950319">274</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Synapsin 1</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">↓<sup>E</sup></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In blood<sup><xref ref-type="bibr" rid="bibr274-1177271920950319">274</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Rab3a</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">=</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr153-1177271920950319">153</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Neuroligin 1</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">↓<sup>E</sup></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In blood<sup><xref ref-type="bibr" rid="bibr277-1177271920950319">277</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1">14-3-3 Gamma</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">↑</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<sup><xref ref-type="bibr" rid="bibr270-1177271920950319">270</xref>,<xref ref-type="bibr" rid="bibr289-1177271920950319">289</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Granins</td>
<td colspan="1" rowspan="1">↓</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">In CSF<xref ref-type="bibr" rid="bibr231-1177271920950319">231</xref>,<xref ref-type="bibr" rid="bibr264-1177271920950319">264</xref></td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="table-fn1-1177271920950319">
<p>Abbreviations: ↑, statistical increase; ↓, statistical decrease; =, no change; AD, Alzheimer’s disease; CBD, corticobasal degeneration; CJD, Creutzfeldt–Jakob disease; CSF, cerebrospinal fluid; DLB, dementia with Lewy body; E, plasma-derived exosomes; FTD, frontotemporal dementia; GAP-43, growth-associated protein 43; MS, multiple sclerosis; MSA, multiple system atrophy; P, plasma; PD, Parkinson’s disease; PSP, progressive supranuclear palsy; R, red blood cells (RBCs); S, serum; SNAP-25, synaptosomal-associated protein 25.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Current CSF synaptic biomarkers are altered in AD but seemingly not in other neurodegenerative disorders. This can reflect a higher response of synapses and neurons to Aβ-mediated damage, probably making AD the pathology with the highest synaptic damage. However, more efforts are needed to characterize synaptic loss in non-AD dementias and other synaptopathies. Increasing evidence suggests that synaptic dysfunction is also involved in neurodevelopmental diseases<sup><xref ref-type="bibr" rid="bibr290-1177271920950319">290</xref>,<xref ref-type="bibr" rid="bibr291-1177271920950319">291</xref></sup> and neuropsychiatric disorders.<sup><xref ref-type="bibr" rid="bibr26-1177271920950319">26</xref>,<xref ref-type="bibr" rid="bibr292-1177271920950319">292</xref></sup> Thus, the study of these conditions may help understanding differences or commonalities between synaptopathies.<sup><xref ref-type="bibr" rid="bibr293-1177271920950319">293</xref></sup></p>
<p>It can be noticed that most of the synaptic biomarkers described are represented by presynaptic proteins<sup><xref ref-type="bibr" rid="bibr294-1177271920950319">294</xref></sup> and, in AD, glutamatergic synapses appear to be primarily affected.<sup><xref ref-type="bibr" rid="bibr6-1177271920950319">6</xref>,<xref ref-type="bibr" rid="bibr294-1177271920950319">294</xref><xref ref-type="bibr" rid="bibr295-1177271920950319"></xref><xref ref-type="bibr" rid="bibr296-1177271920950319"></xref>-<xref ref-type="bibr" rid="bibr297-1177271920950319">297</xref></sup> Among the reviewed synaptic proteins, neurogranin is the most extensively studied and the evidence presented thus far is seemingly specific for AD or Aβ deposition. The other synaptic proteins also show changed levels in relation to AD, with most of them showing increased CSF concentrations, but also in non-AD neurodegenerative diseases (eg, PD, tauopathies), even though in these diseases they are less investigated. NfL is a good marker for general neuronal loss and it would be suitable to represent the “N” in the ATN criteria<sup><xref ref-type="bibr" rid="bibr119-1177271920950319">119</xref>,<xref ref-type="bibr" rid="bibr298-1177271920950319">298</xref></sup> given that CSF t-tau also mainly changes in AD and CJD. Blood NfL strongly reflects CSF NfL.<sup><xref ref-type="bibr" rid="bibr299-1177271920950319">299</xref></sup> Elucidating the mechanisms of release of these proteins into biofluids would be of importance to understand their changes in concentration, thus connecting pathological mechanisms to biological responses and increase the interpretability of this biomarker category.</p>
<p>Understanding the pathological mechanisms responsible for synaptic damage is of central importance also during synaptic biomarker investigation. Brain studies could be a starting point, helping to understand the pathophysiological events and for selecting biomarker candidates. The next steps may involve the investigation of biofluids, like CSF, ideally followed by studies in blood, representing the way to bring the investigation further and possibly find synaptic biomarkers of clinical utility. The future of biomarkers ideally would be able to rely on sampling blood, which is a more accessible source than CSF. However, the possible contribution of peripheral expression of the biomarker protein, as discussed for neurogranin and α-syn, can represent a problem and, to date, we still have no blood biomarkers reflecting synaptic pathology. Neuronal-derived exosomes in blood can represent an alternative; however the complexity and variability of the exosome enrichment procedure is currently a drawback for large studies and routine use.</p>
<p>Future directions of research should consider more longitudinal studies, to compare protein time-related changes with the disease progression. The contribution of sex differences should be also considered in more detail, as developing evidence suggests that differing biomarker profiles do exist but is protein-specific.<sup><xref ref-type="bibr" rid="bibr300-1177271920950319">300</xref>,<xref ref-type="bibr" rid="bibr301-1177271920950319">301</xref></sup></p>
<p>In conclusion, the available evidence on CSF synaptic biomarkers points toward the possible use of these proteins as indicators of synaptic alteration and elimination in synaptopathies, and their use to follow cognitive deficits in neurodegenerative diseases. More efforts are needed to assess their possible use in blood. Mechanistic studies will possibly help understanding how those proteins are affected in pathological processes thus increasing their value as potential biomarkers. Moreover, developing assays for their quantification using highly sensitive and high-throughput platforms will push synaptic protein quantification toward broader investigations. This overview of the field will hopefully highlight possible gaps and guide future studies.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding:</bold>The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: KB is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), and European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), and the UK Dementia Research Institute at UCL.</p>
</fn>
<fn fn-type="COI-statement">
<p><bold>Declaration of conflicting interests:</bold>The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, and CogRx; has given lectures in symposia sponsored by Fujirebio, Alzecure, and Biogen; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.</p>
</fn>
<fn fn-type="con">
<p><bold>Author Contributions:</bold> EC, JN and NJA provided the initial idea and outline of content of the manuscript; EC created figures 1 and 2. JN created the table. All authors contributed to the content of the article and critically reviewed and edited the manuscript.</p>
</fn>
<fn fn-type="other">
<p><bold>ORCID iD:</bold> Elena Camporesi <inline-graphic xlink:href="10.1177_1177271920950319-img1.jpg"></inline-graphic>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0003-1044-0192">https://orcid.org/0000-0003-1044-0192</ext-link></p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1177271920950319">
<label>1.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taoufik</surname><given-names>E</given-names></name><name><surname>Kouroupi</surname><given-names>G</given-names></name><name><surname>Zygogianni</surname><given-names>O</given-names></name><name><surname>Matsas</surname><given-names>R.</given-names></name></person-group>
<article-title>Synaptic dysfunction in neurodegenerative and neurodevelopmental diseases: an overview of induced pluripotent stem-cell-based disease models</article-title>. <source/>Open Biol. <year>2018</year>;<volume>8</volume>:<fpage>180138</fpage>.<pub-id pub-id-type="pmid">30185603</pub-id></mixed-citation>
</ref>
<ref id="bibr2-1177271920950319">
<label>2.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lepeta</surname><given-names>K</given-names></name><name><surname>Lourenco</surname><given-names>MV</given-names></name><name><surname>Schweitzer</surname><given-names>BC</given-names></name></person-group>, <etal>et al</etal>
<article-title>Synaptopathies: synaptic dysfunction in neurological disorders —a review from students to students</article-title>. <source/>J Neurochem. <year>2016</year>;<volume>138</volume>:<fpage>785</fpage>-<lpage>805</lpage>.<pub-id pub-id-type="pmid">27333343</pub-id></mixed-citation>
</ref>
<ref id="bibr3-1177271920950319">
<label>3.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frankish</surname><given-names>H</given-names></name><name><surname>Horton</surname><given-names>R.</given-names></name></person-group>
<article-title>Prevention and management of dementia: a priority for public health</article-title>. <source/>Lancet (London, England). <year>2017</year>;<volume>390</volume>:<fpage>2614</fpage>-<lpage>2615</lpage>.</mixed-citation>
</ref>
<ref id="bibr4-1177271920950319">
<label>4.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Mallory</surname><given-names>M</given-names></name><name><surname>Alford</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease</article-title>. <source/>Neurology. <year>2001</year>;<volume>56</volume>:<fpage>127</fpage>-<lpage>129</lpage>.<pub-id pub-id-type="pmid">11148253</pub-id></mixed-citation>
</ref>
<ref id="bibr5-1177271920950319">
<label>5.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Janezic</surname><given-names>S</given-names></name><name><surname>Threlfell</surname><given-names>S</given-names></name><name><surname>Dodson</surname><given-names>PD</given-names></name></person-group>, <etal>et al</etal>
<article-title>Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model</article-title>. <source/>Proc Natl Acad Sci U S A. <year>2013</year>;<volume>110</volume>:<fpage>E4016</fpage>-<lpage>E4025</lpage>.<pub-id pub-id-type="pmid">24082145</pub-id></mixed-citation>
</ref>
<ref id="bibr6-1177271920950319">
<label>6.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heurling</surname><given-names>K</given-names></name><name><surname>Ashton</surname><given-names>NJ</given-names></name><name><surname>Leuzy</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Synaptic vesicle protein 2A as a potential biomarker in synaptopathies</article-title>. <source/>Mol Cell Neurosci. <year>2019</year>;<volume>97</volume>:<fpage>34</fpage>-<lpage>42</lpage>.<pub-id pub-id-type="pmid">30796959</pub-id></mixed-citation>
</ref>
<ref id="bibr7-1177271920950319">
<label>7.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brinkmalm</surname><given-names>A</given-names></name><name><surname>Brinkmalm</surname><given-names>G</given-names></name><name><surname>Honer</surname><given-names>WG</given-names></name></person-group>, <etal>et al</etal>
<article-title>SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease</article-title>. <source/>Mol Neurodegener. <year>2014</year>;<volume>9</volume>:<fpage>53</fpage>.<pub-id pub-id-type="pmid">25418885</pub-id></mixed-citation>
</ref>
<ref id="bibr8-1177271920950319">
<label>8.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Korade</surname><given-names>Z</given-names></name><name><surname>Mirnics</surname><given-names>K.</given-names></name></person-group>
<article-title>Programmed to be human?</article-title>
<source/>Neuron. <year>2014</year>;<volume>81</volume>:<fpage>224</fpage>-<lpage>226</lpage>.<pub-id pub-id-type="pmid">24462090</pub-id></mixed-citation>
</ref>
<ref id="bibr9-1177271920950319">
<label>9.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ming</surname><given-names>GL</given-names></name><name><surname>Song</surname><given-names>H.</given-names></name></person-group>
<article-title>Adult neurogenesis in the mammalian brain: significant answers and significant questions</article-title>. <source/>Neuron. <year>2011</year>;<volume>70</volume>:<fpage>687</fpage>-<lpage>702</lpage>.<pub-id pub-id-type="pmid">21609825</pub-id></mixed-citation>
</ref>
<ref id="bibr10-1177271920950319">
<label>10.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sudhof</surname><given-names>TC.</given-names></name></person-group>
<article-title>Towards an understanding of synapse formation</article-title>. <source/>Neuron. <year>2018</year>;<volume>100</volume>:<fpage>276</fpage>-<lpage>293</lpage>.<pub-id pub-id-type="pmid">30359597</pub-id></mixed-citation>
</ref>
<ref id="bibr11-1177271920950319">
<label>11.</label>
<mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Santos</surname><given-names>E</given-names></name><name><surname>Noggle</surname><given-names>CA</given-names></name></person-group>
<article-title>Synaptic pruning</article-title>. In: <person-group person-group-type="editor"><name><surname>Goldstein</surname><given-names>S</given-names></name><name><surname>Naglieri</surname><given-names>JA</given-names></name></person-group>, eds. <source/>Encyclopedia of Child Behavior and Development. <publisher-loc>Boston, MA</publisher-loc>: <publisher-name>Springer US</publisher-name>; <volume>2011</volume>:<fpage>1464</fpage>-<lpage>1465</lpage>.</mixed-citation>
</ref>
<ref id="bibr12-1177271920950319">
<label>12.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sando</surname><given-names>R</given-names></name><name><surname>Bushong</surname><given-names>E</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal>
<article-title>Assembly of excitatory synapses in the absence of glutamatergic neurotransmission</article-title>. <source/>Neuron. <year>2017</year>;<volume>94</volume>:312e313-312321.</mixed-citation>
</ref>
<ref id="bibr13-1177271920950319">
<label>13.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Südhof</surname><given-names>TC.</given-names></name></person-group>
<article-title>Neurotransmitter release: the last millisecond in the life of a synaptic vesicle</article-title>. <source/>Neuron. <year>2013</year>;<volume>80</volume>:<fpage>675</fpage>-<lpage>690</lpage>.<pub-id pub-id-type="pmid">24183019</pub-id></mixed-citation>
</ref>
<ref id="bibr14-1177271920950319">
<label>14.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hering</surname><given-names>H</given-names></name><name><surname>Sheng</surname><given-names>M.</given-names></name></person-group>
<article-title>Dendritic spines: structure, dynamics and regulation</article-title>. <source/>Nat Rev Neurosci. <year>2001</year>;<volume>2</volume>:<fpage>880</fpage>-<lpage>888</lpage>.<pub-id pub-id-type="pmid">11733795</pub-id></mixed-citation>
</ref>
<ref id="bibr15-1177271920950319">
<label>15.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tao</surname><given-names>CL</given-names></name><name><surname>Liu</surname><given-names>YT</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>
<article-title>Differentiation and characterization of excitatory and inhibitory synapses by cryo-electron tomography and correlative microscopy</article-title>. <source/>J Neurosci. <year>2018</year>;<volume>38</volume>:<fpage>1493</fpage>-<lpage>1510</lpage>.<pub-id pub-id-type="pmid">29311144</pub-id></mixed-citation>
</ref>
<ref id="bibr16-1177271920950319">
<label>16.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cooke</surname><given-names>SF</given-names></name><name><surname>Bliss</surname><given-names>TV.</given-names></name></person-group>
<article-title>Plasticity in the human central nervous system</article-title>. <source/>Brain. <year>2006</year>;<volume>129</volume>:<fpage>1659</fpage>-<lpage>1673</lpage>.<pub-id pub-id-type="pmid">16672292</pub-id></mixed-citation>
</ref>
<ref id="bibr17-1177271920950319">
<label>17.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bosch</surname><given-names>M</given-names></name><name><surname>Castro</surname><given-names>J</given-names></name><name><surname>Saneyoshi</surname><given-names>T</given-names></name><name><surname>Matsuno</surname><given-names>H</given-names></name><name><surname>Sur</surname><given-names>M</given-names></name><name><surname>Hayashi</surname><given-names>Y.</given-names></name></person-group>
<article-title>Structural and molecular remodeling of dendritic spine substructures during long-term potentiation</article-title>. <source/>Neuron. <year>2014</year>;<volume>82</volume>:<fpage>444</fpage>-<lpage>459</lpage>.<pub-id pub-id-type="pmid">24742465</pub-id></mixed-citation>
</ref>
<ref id="bibr18-1177271920950319">
<label>18.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Piochon</surname><given-names>C</given-names></name><name><surname>Kano</surname><given-names>M</given-names></name><name><surname>Hansel</surname><given-names>C.</given-names></name></person-group>
<article-title>LTD-like molecular pathways in developmental synaptic pruning</article-title>. <source/>Nat Neurosci. <year>2016</year>;<volume>19</volume>:<fpage>1299</fpage>-<lpage>1310</lpage>.<pub-id pub-id-type="pmid">27669991</pub-id></mixed-citation>
</ref>
<ref id="bibr19-1177271920950319">
<label>19.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vitureira</surname><given-names>N</given-names></name><name><surname>Letellier</surname><given-names>M</given-names></name><name><surname>Goda</surname><given-names>Y.</given-names></name></person-group>
<article-title>Homeostatic synaptic plasticity: from single synapses to neural circuits</article-title>. <source/>Curr Opin Neurobiol. <year>2012</year>;<volume>22</volume>:<fpage>516</fpage>-<lpage>521</lpage>.<pub-id pub-id-type="pmid">21983330</pub-id></mixed-citation>
</ref>
<ref id="bibr20-1177271920950319">
<label>20.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cardozo</surname><given-names>PL</given-names></name><name><surname>de Lima</surname><given-names>IBQ</given-names></name><name><surname>Maciel</surname><given-names>EMA</given-names></name><name><surname>Silva</surname><given-names>NC</given-names></name><name><surname>Dobransky</surname><given-names>T</given-names></name><name><surname>Ribeiro</surname><given-names>FM.</given-names></name></person-group>
<article-title>Synaptic elimination in neurological disorders</article-title>. <source/>Curr Neuropharmacol. <year>2019</year>;<volume>17</volume>:<fpage>1071</fpage>-<lpage>1095</lpage>.<pub-id pub-id-type="pmid">31161981</pub-id></mixed-citation>
</ref>
<ref id="bibr21-1177271920950319">
<label>21.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maiti</surname><given-names>P</given-names></name><name><surname>Manna</surname><given-names>J</given-names></name><name><surname>Ilavazhagan</surname><given-names>G</given-names></name><name><surname>Rossignol</surname><given-names>J</given-names></name><name><surname>Dunbar</surname><given-names>GL.</given-names></name></person-group>
<article-title>Molecular regulation of dendritic spine dynamics and their potential impact on synaptic plasticity and neurological diseases</article-title>. <source/>Neurosci Biobehav Rev. <year>2015</year>;<volume>59</volume>:<fpage>208</fpage>-<lpage>237</lpage>.<pub-id pub-id-type="pmid">26562682</pub-id></mixed-citation>
</ref>
<ref id="bibr22-1177271920950319">
<label>22.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kauer</surname><given-names>JA</given-names></name><name><surname>Malenka</surname><given-names>RC.</given-names></name></person-group>
<article-title>Synaptic plasticity and addiction</article-title>. <source/>Nat Rev Neurosci. <year>2007</year>;<volume>8</volume>:<fpage>844</fpage>-<lpage>858</lpage>.<pub-id pub-id-type="pmid">17948030</pub-id></mixed-citation>
</ref>
<ref id="bibr23-1177271920950319">
<label>23.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guilherme</surname><given-names>N</given-names></name><name><surname>Cooke</surname><given-names>SF</given-names></name><name><surname>Bliss</surname><given-names>TVP</given-names></name></person-group>
<article-title>Synaptic plasticity, memory and the hippocampus</article-title>. <source/>Nat Rev Neurosci. <year>2008</year>;<volume>9</volume>:<fpage>65</fpage>-<lpage>75</lpage>.<pub-id pub-id-type="pmid">18094707</pub-id></mixed-citation>
</ref>
<ref id="bibr24-1177271920950319">
<label>24.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boksa</surname><given-names>P.</given-names></name></person-group>
<article-title>Abnormal synaptic pruning in schizophrenia: urban myth or reality?</article-title>
<source/>J Psychiatry Neurosci. <year>2012</year>;<volume>37</volume>:<fpage>75</fpage>-<lpage>77</lpage>.<pub-id pub-id-type="pmid">22339991</pub-id></mixed-citation>
</ref>
<ref id="bibr25-1177271920950319">
<label>25.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Racki</surname><given-names>V</given-names></name><name><surname>Petric</surname><given-names>D</given-names></name><name><surname>Kucic</surname><given-names>N</given-names></name><name><surname>Grzeta</surname><given-names>N</given-names></name><name><surname>Jurdana</surname><given-names>K</given-names></name><name><surname>Roncevic-Grzeta</surname><given-names>I.</given-names></name></person-group>
<article-title>Cortical gray matter loss in schizophrenia: could microglia be the culprit</article-title>. <source/>Med Hypotheses. <year>2016</year>;<volume>88</volume>:<fpage>18</fpage>-<lpage>21</lpage>.<pub-id pub-id-type="pmid">26880628</pub-id></mixed-citation>
</ref>
<ref id="bibr26-1177271920950319">
<label>26.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Osimo</surname><given-names>EF</given-names></name><name><surname>Beck</surname><given-names>K</given-names></name><name><surname>Reis Marques</surname><given-names>T</given-names></name><name><surname>Howes</surname><given-names>OD.</given-names></name></person-group>
<article-title>Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures</article-title>. <source/>Mol Psychiatry. <year>2018</year>;<volume>24</volume>:<fpage>549</fpage>-<lpage>561</lpage>.<pub-id pub-id-type="pmid">29511299</pub-id></mixed-citation>
</ref>
<ref id="bibr27-1177271920950319">
<label>27.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bloom</surname><given-names>GS.</given-names></name></person-group>
<article-title>Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis</article-title>. <source/>JAMA Neurol. <year>2014</year>;<volume>71</volume>:<fpage>505</fpage>-<lpage>508</lpage>.<pub-id pub-id-type="pmid">24493463</pub-id></mixed-citation>
</ref>
<ref id="bibr28-1177271920950319">
<label>28.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>
<article-title>NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease</article-title>. <source/>Alzheimers Dement. <year>2018</year>;<volume>14</volume>:<fpage>535</fpage>-<lpage>562</lpage>.<pub-id pub-id-type="pmid">29653606</pub-id></mixed-citation>
</ref>
<ref id="bibr29-1177271920950319">
<label>29.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yoshiyama</surname><given-names>Y</given-names></name><name><surname>Higuchi</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name></person-group>, <etal>et al</etal>
<article-title>Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model</article-title>. <source/>Neuron. <year>2007</year>;<volume>53</volume>:<fpage>337</fpage>-<lpage>351</lpage>.<pub-id pub-id-type="pmid">17270732</pub-id></mixed-citation>
</ref>
<ref id="bibr30-1177271920950319">
<label>30.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hamelin</surname><given-names>L</given-names></name><name><surname>Lagarde</surname><given-names>J</given-names></name><name><surname>Dorothee</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>
<article-title>Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer’s disease</article-title>. <source/>Brain. <year>2018</year>;<volume>141</volume>:<fpage>1855</fpage>-<lpage>1870</lpage>.<pub-id pub-id-type="pmid">29608645</pub-id></mixed-citation>
</ref>
<ref id="bibr31-1177271920950319">
<label>31.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dani</surname><given-names>M</given-names></name><name><surname>Wood</surname><given-names>M</given-names></name><name><surname>Mizoguchi</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>
<article-title>Microglial activation correlates in vivo with both tau and amyloid in Alzheimer’s disease</article-title>. <source/>Brain. <year>2018</year>;<volume>141</volume>:<fpage>2740</fpage>-<lpage>2754</lpage>.<pub-id pub-id-type="pmid">30052812</pub-id></mixed-citation>
</ref>
<ref id="bibr32-1177271920950319">
<label>32.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liesz</surname><given-names>A.</given-names></name></person-group>
<article-title>The vascular side of Alzheimer’s disease</article-title>. <source/>Science. <year>2019</year>;<volume>365</volume>:<fpage>223</fpage>-<lpage>224</lpage>.<pub-id pub-id-type="pmid">31320524</pub-id></mixed-citation>
</ref>
<ref id="bibr33-1177271920950319">
<label>33.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jurcau</surname><given-names>A</given-names></name><name><surname>Simion</surname><given-names>A.</given-names></name></person-group>
<article-title>Oxidative stress in the pathogenesis of Alzheimer’s disease and cerebrovascular disease with therapeutic implications</article-title>. <source/>CNS Neurol Disord Drug Targets. <year>2020</year>;<volume>19</volume>:<fpage>94</fpage>-<lpage>108</lpage>.<pub-id pub-id-type="pmid">32124703</pub-id></mixed-citation>
</ref>
<ref id="bibr34-1177271920950319">
<label>34.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Terry</surname><given-names>RD</given-names></name><name><surname>Masliiah</surname><given-names>E</given-names></name><name><surname>Salmon</surname><given-names>DP</given-names></name></person-group>, <etal>et al</etal>
<article-title>Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment</article-title>. <source/>Ann Neurol. <year>1991</year>;<volume>30</volume>:<fpage>572</fpage>-<lpage>580</lpage>.<pub-id pub-id-type="pmid">1789684</pub-id></mixed-citation>
</ref>
<ref id="bibr35-1177271920950319">
<label>35.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>B.</given-names></name></person-group>
<article-title>Synapses and dendritic spines as pathogenic targets in Alzheimer’s disease</article-title>. <source/>Neural Plast. <year>2012</year>;<volume>2012</volume>:<fpage>247150</fpage>.<pub-id pub-id-type="pmid">22474602</pub-id></mixed-citation>
</ref>
<ref id="bibr36-1177271920950319">
<label>36.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Bogdanovic</surname><given-names>N</given-names></name><name><surname>Alafuzoff</surname><given-names>I</given-names></name><name><surname>Ekman</surname><given-names>R</given-names></name><name><surname>Davidsson</surname><given-names>P.</given-names></name></person-group>
<article-title>Synaptic pathology in Alzheimer’s disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele</article-title>. <source/>J Neural Transm (Vienna). <year>1996</year>;<volume>103</volume>:<fpage>603</fpage>-<lpage>618</lpage>.<pub-id pub-id-type="pmid">8811505</pub-id></mixed-citation>
</ref>
<ref id="bibr37-1177271920950319">
<label>37.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Selkoe</surname><given-names>DJ.</given-names></name></person-group>
<article-title>Alzheimer’s disease is a synaptic failure</article-title>. <source/>Science. <year>2002</year>;<volume>298</volume>:<fpage>789</fpage>-<lpage>791</lpage>.<pub-id pub-id-type="pmid">12399581</pub-id></mixed-citation>
</ref>
<ref id="bibr38-1177271920950319">
<label>38.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Mallory</surname><given-names>M</given-names></name><name><surname>Alford</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease</article-title>. <source/>Neurology. <year>2001</year>;<volume>56</volume>:<fpage>127</fpage>-<lpage>129</lpage>.<pub-id pub-id-type="pmid">11148253</pub-id></mixed-citation>
</ref>
<ref id="bibr39-1177271920950319">
<label>39.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bertoni-Freddari</surname><given-names>C</given-names></name><name><surname>Fattoretti</surname><given-names>P</given-names></name><name><surname>Casoli</surname><given-names>T</given-names></name><name><surname>Meier-Ruge</surname><given-names>W</given-names></name><name><surname>Ulrich</surname><given-names>J.</given-names></name></person-group>
<article-title>Morphological adaptive response of the synaptic junctional zones in the human dentate gyrus during aging and Alzheimer’s disease</article-title>. <source/>Brain Res. <year>1990</year>;<volume>517</volume>:<fpage>69</fpage>-<lpage>75</lpage>.<pub-id pub-id-type="pmid">2376007</pub-id></mixed-citation>
</ref>
<ref id="bibr40-1177271920950319">
<label>40.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scheff</surname><given-names>SW</given-names></name><name><surname>Price</surname><given-names>DA.</given-names></name></person-group>
<article-title>Synapse loss in the temporal lobe in Alzheimer’s disease</article-title>. <source/>Ann Neurol. <year>1993</year>;<volume>33</volume>:<fpage>190</fpage>-<lpage>199</lpage>.<pub-id pub-id-type="pmid">8434881</pub-id></mixed-citation>
</ref>
<ref id="bibr41-1177271920950319">
<label>41.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reddy</surname><given-names>PH</given-names></name><name><surname>Mani</surname><given-names>G</given-names></name><name><surname>Park</surname><given-names>BS</given-names></name></person-group>, <etal>et al</etal>
<article-title>Differential loss of synaptic proteins in Alzheimer’s disease: implications for synaptic dysfunction</article-title>. <source/>J Alzheimers Dis. <year>2005</year>;<volume>7</volume>:<fpage>103</fpage>-<lpage>117</lpage>; discussion 173.<pub-id pub-id-type="pmid">15851848</pub-id></mixed-citation>
</ref>
<ref id="bibr42-1177271920950319">
<label>42.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clare</surname><given-names>R</given-names></name><name><surname>King</surname><given-names>VG</given-names></name><name><surname>Wirenfeldt</surname><given-names>M</given-names></name><name><surname>Vinters</surname><given-names>HV.</given-names></name></person-group>
<article-title>Synapse loss in dementias</article-title>. <source/>J Neurosci Res. <year>2010</year>;<volume>88</volume>:<fpage>2083</fpage>-<lpage>2090</lpage>.<pub-id pub-id-type="pmid">20533377</pub-id></mixed-citation>
</ref>
<ref id="bibr43-1177271920950319">
<label>43.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scheff</surname><given-names>SW</given-names></name><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>Schmitt</surname><given-names>FA</given-names></name><name><surname>Mufson</surname><given-names>EJ.</given-names></name></person-group>
<article-title>Hippocampal synaptic loss in early Alzheimer’s disease and mild cognitive impairment</article-title>. <source/>Neurobiol Aging. <year>2006</year>;<volume>27</volume>:<fpage>1372</fpage>-<lpage>1384</lpage>.<pub-id pub-id-type="pmid">16289476</pub-id></mixed-citation>
</ref>
<ref id="bibr44-1177271920950319">
<label>44.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scheff</surname><given-names>SW</given-names></name><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>Schmitt</surname><given-names>FA</given-names></name><name><surname>DeKosky</surname><given-names>ST</given-names></name><name><surname>Mufson</surname><given-names>EJ.</given-names></name></person-group>
<article-title>Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment</article-title>. <source/>Neurology. <year>2007</year>;<volume>68</volume>:<fpage>1501</fpage>-<lpage>1508</lpage>.<pub-id pub-id-type="pmid">17470753</pub-id></mixed-citation>
</ref>
<ref id="bibr45-1177271920950319">
<label>45.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Jackson</surname><given-names>RJ</given-names></name><name><surname>Hong</surname><given-names>W</given-names></name></person-group>, <etal>et al</etal>
<article-title>Human brain-derived Aβ oligomers bind to synapses and disrupt synaptic activity in a manner that requires APP</article-title>. <source/>J Neurosci. <year>2017</year>;<volume>37</volume>:<fpage>11947</fpage>-<lpage>11966</lpage>.<pub-id pub-id-type="pmid">29101243</pub-id></mixed-citation>
</ref>
<ref id="bibr46-1177271920950319">
<label>46.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Klyubin</surname><given-names>I</given-names></name><name><surname>Fadeeva</surname><given-names>JV</given-names></name></person-group>, <etal>et al</etal>
<article-title>Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo</article-title>. <source/>Nature. <year>2002</year>;<volume>416</volume>:<fpage>535</fpage>-<lpage>539</lpage>.<pub-id pub-id-type="pmid">11932745</pub-id></mixed-citation>
</ref>
<ref id="bibr47-1177271920950319">
<label>47.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tu</surname><given-names>S</given-names></name><name><surname>Okamoto</surname><given-names>S</given-names></name><name><surname>Lipton</surname><given-names>SA</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name></person-group>
<article-title>Oligomeric Abeta-induced synaptic dysfunction in Alzheimer’s disease</article-title>. <source/>Mol Neurodegener. <year>2014</year>;<volume>9</volume>:<fpage>48</fpage>.<pub-id pub-id-type="pmid">25394486</pub-id></mixed-citation>
</ref>
<ref id="bibr48-1177271920950319">
<label>48.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guerrero-Muñoz</surname><given-names>MJ</given-names></name><name><surname>Gerson</surname><given-names>J</given-names></name><name><surname>Castillo-Carranza</surname><given-names>DL.</given-names></name></person-group>
<article-title>Tau oligomers: the toxic player at synapses in Alzheimer’s disease</article-title>. <source/>Front Cell Neurosci. <year>2015</year>;<volume>9</volume>:<fpage>464</fpage>.<pub-id pub-id-type="pmid">26696824</pub-id></mixed-citation>
</ref>
<ref id="bibr49-1177271920950319">
<label>49.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Colom-Cadena</surname><given-names>M</given-names></name><name><surname>Spires-Jones</surname><given-names>T</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>
<article-title>The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease</article-title>. <source/>Alzheimers Res Ther. <year>2020</year>;<volume>12</volume>:<fpage>21</fpage>.<pub-id pub-id-type="pmid">32122400</pub-id></mixed-citation>
</ref>
<ref id="bibr50-1177271920950319">
<label>50.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>HW</given-names></name><name><surname>Pasternak</surname><given-names>JF</given-names></name><name><surname>Kuo</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>
<article-title>Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus</article-title>. <source/>Brain Res. <year>2002</year>;<volume>924</volume>:<fpage>133</fpage>-<lpage>140</lpage>.<pub-id pub-id-type="pmid">11750898</pub-id></mixed-citation>
</ref>
<ref id="bibr51-1177271920950319">
<label>51.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lambert</surname><given-names>MP</given-names></name><name><surname>Barlow</surname><given-names>AK</given-names></name><name><surname>Chromy</surname><given-names>BA</given-names></name></person-group>, <etal>et al</etal>
<article-title>Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins</article-title>. <source/>Proc Natl Acad Sci U S A. <year>1998</year>;<volume>95</volume>:<fpage>6448</fpage>-<lpage>6453</lpage>.<pub-id pub-id-type="pmid">9600986</pub-id></mixed-citation>
</ref>
<ref id="bibr52-1177271920950319">
<label>52.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shankar</surname><given-names>GM</given-names></name><name><surname>Bloodgood</surname><given-names>BL</given-names></name><name><surname>Townsend</surname><given-names>M</given-names></name><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><name><surname>Sabatini</surname><given-names>BL.</given-names></name></person-group>
<article-title>Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway</article-title>. <source/>J Neurosci. <year>2007</year>;<volume>27</volume>:<fpage>2866</fpage>-<lpage>2875</lpage>.<pub-id pub-id-type="pmid">17360908</pub-id></mixed-citation>
</ref>
<ref id="bibr53-1177271920950319">
<label>53.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cline</surname><given-names>EN</given-names></name><name><surname>Bicca</surname><given-names>MA</given-names></name><name><surname>Viola</surname><given-names>KL</given-names></name><name><surname>Klein</surname><given-names>WL.</given-names></name></person-group>
<article-title>The amyloid-beta oligomer hypothesis: beginning of the third decade</article-title>. <source/>J Alzheimers Dis. <year>2018</year>;<volume>64</volume>:<fpage>S567</fpage>-<lpage>S610</lpage>.<pub-id pub-id-type="pmid">29843241</pub-id></mixed-citation>
</ref>
<ref id="bibr54-1177271920950319">
<label>54.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fein</surname><given-names>JA</given-names></name><name><surname>Sokolow</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>CA</given-names></name></person-group>, <etal>et al</etal>
<article-title>Co-localization of amyloid beta and tau pathology in Alzheimer’s disease synaptosomes</article-title>. <source/>Am J Pathol. <year>2008</year>;<volume>172</volume>:<fpage>1683</fpage>-<lpage>1692</lpage>.<pub-id pub-id-type="pmid">18467692</pub-id></mixed-citation>
</ref>
<ref id="bibr55-1177271920950319">
<label>55.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>RH</given-names></name><name><surname>Capetillo-Zarate</surname><given-names>E</given-names></name><name><surname>Lin</surname><given-names>MT</given-names></name><name><surname>Milner</surname><given-names>TA</given-names></name><name><surname>Gouras</surname><given-names>GK.</given-names></name></person-group>
<article-title>Co-occurrence of Alzheimer’s disease ss-amyloid and tau pathologies at synapses</article-title>. <source/>Neurobiol Aging. <year>2010</year>;<volume>31</volume>:<fpage>1145</fpage>-<lpage>1152</lpage>.<pub-id pub-id-type="pmid">18771816</pub-id></mixed-citation>
</ref>
<ref id="bibr56-1177271920950319">
<label>56.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>LM</given-names></name><name><surname>Strittmatter</surname><given-names>SM.</given-names></name></person-group>
<article-title>Binding sites for amyloid-β oligomers and synaptic toxicity</article-title>. <source/>Cold Spring Harb Perspect Med. <year>2017</year>;<volume>7</volume>:<fpage>a024075</fpage>.<pub-id pub-id-type="pmid">27940601</pub-id></mixed-citation>
</ref>
<ref id="bibr57-1177271920950319">
<label>57.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Younan</surname><given-names>ND</given-names></name><name><surname>Sarell</surname><given-names>CJ</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>DR</given-names></name><name><surname>Viles</surname><given-names>JH.</given-names></name></person-group>
<article-title>The cellular prion protein traps Alzheimer’s Abeta in an oligomeric form and disassembles amyloid fibers</article-title>. <source/>FASEB J. <year>2013</year>;<volume>27</volume>:<fpage>1847</fpage>-<lpage>1858</lpage>.<pub-id pub-id-type="pmid">23335053</pub-id></mixed-citation>
</ref>
<ref id="bibr58-1177271920950319">
<label>58.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brito-Moreira</surname><given-names>J</given-names></name><name><surname>Lourenco</surname><given-names>MV</given-names></name><name><surname>Oliveira</surname><given-names>MM</given-names></name></person-group>, <etal>et al</etal>
<article-title>Interaction of amyloid-beta (Abeta) oligomers with neurexin 2alpha and neuroligin 1 mediates synapse damage and memory loss in mice</article-title>. <source/>J Biol Chem. <year>2017</year>;<volume>292</volume>:<fpage>7327</fpage>-<lpage>7337</lpage>.<pub-id pub-id-type="pmid">28283575</pub-id></mixed-citation>
</ref>
<ref id="bibr59-1177271920950319">
<label>59.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cissé</surname><given-names>M</given-names></name><name><surname>Halabisky</surname><given-names>B</given-names></name><name><surname>Harris</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Reversing EphB2 depletion rescues cognitive functions in Alzheimer model</article-title>. <source/>Nature. <year>2011</year>;<volume>469</volume>:<fpage>47</fpage>-<lpage>52</lpage>.<pub-id pub-id-type="pmid">21113149</pub-id></mixed-citation>
</ref>
<ref id="bibr60-1177271920950319">
<label>60.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal>
<article-title>Amyloid beta oligomers target to extracellular and intracellular neuronal synaptic proteins in Alzheimer’s disease</article-title>. <source/>Front Neurol. <year>2019</year>;<volume>10</volume>:<year>1140</year>.</mixed-citation>
</ref>
<ref id="bibr61-1177271920950319">
<label>61.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Nguyen</surname><given-names>LN</given-names></name><name><surname>Kessels</surname><given-names>HW</given-names></name><name><surname>Hagiwara</surname><given-names>H</given-names></name><name><surname>Sisodia</surname><given-names>S</given-names></name><name><surname>Malinow</surname><given-names>R.</given-names></name></person-group>
<article-title>Amyloid beta from axons and dendrites reduces local spine number and plasticity</article-title>. <source/>Nat Neurosci. <year>2010</year>;<volume>13</volume>:<fpage>190</fpage>-<lpage>196</lpage>.<pub-id pub-id-type="pmid">20037574</pub-id></mixed-citation>
</ref>
<ref id="bibr62-1177271920950319">
<label>62.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Puzzo</surname><given-names>D</given-names></name><name><surname>Piacentini</surname><given-names>R</given-names></name><name><surname>Fa</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>LTP and memory impairment caused by extracellular Abeta and Tau oligomers is APP-dependent</article-title>. <source/>eLife. <year>2017</year>;<volume>6</volume>:<fpage>e26991</fpage>.<pub-id pub-id-type="pmid">28696204</pub-id></mixed-citation>
</ref>
<ref id="bibr63-1177271920950319">
<label>63.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jadhav</surname><given-names>S</given-names></name><name><surname>Cubinkova</surname><given-names>V</given-names></name><name><surname>Zimova</surname><given-names>I</given-names></name></person-group>, <etal>et al</etal>
<article-title>Tau-mediated synaptic damage in Alzheimer’s disease</article-title>. <source/>Transl Neurosci. <year>2015</year>;<volume>6</volume>:<fpage>214</fpage>-<lpage>226</lpage>.<pub-id pub-id-type="pmid">28123806</pub-id></mixed-citation>
</ref>
<ref id="bibr64-1177271920950319">
<label>64.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guo</surname><given-names>JL</given-names></name><name><surname>Lee</surname><given-names>VM.</given-names></name></person-group>
<article-title>Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases</article-title>. <source/>Nat Med. <year>2014</year>;<volume>20</volume>:<fpage>130</fpage>-<lpage>138</lpage>.<pub-id pub-id-type="pmid">24504409</pub-id></mixed-citation>
</ref>
<ref id="bibr65-1177271920950319">
<label>65.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nath</surname><given-names>S</given-names></name><name><surname>Agholme</surname><given-names>L</given-names></name><name><surname>Kurudenkandy</surname><given-names>FR</given-names></name><name><surname>Granseth</surname><given-names>B</given-names></name><name><surname>Marcusson</surname><given-names>J</given-names></name><name><surname>Hallbeck</surname><given-names>M.</given-names></name></person-group>
<article-title>Spreading of neurodegenerative pathology via neuron-to-neuron transmission of beta-amyloid</article-title>. <source/>J Neurosci. <year>2012</year>;<volume>32</volume>:<fpage>8767</fpage>-<lpage>8777</lpage>.<pub-id pub-id-type="pmid">22745479</pub-id></mixed-citation>
</ref>
<ref id="bibr66-1177271920950319">
<label>66.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Del Tredici</surname><given-names>K.</given-names></name></person-group>
<article-title>Alzheimer’s pathogenesis: is there neuron-to-neuron propagation</article-title>. <source/>Acta Neuropathol. <year>2011</year>;<volume>121</volume>:<fpage>589</fpage>-<lpage>595</lpage>.<pub-id pub-id-type="pmid">21516512</pub-id></mixed-citation>
</ref>
<ref id="bibr67-1177271920950319">
<label>67.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Selkoe</surname><given-names>DJ.</given-names></name></person-group>
<article-title>A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration</article-title>. <source/>Nat Rev Neurosci. <year>2016</year>;<volume>17</volume>:<fpage>251</fpage>-<lpage>260</lpage>.<pub-id pub-id-type="pmid">26988744</pub-id></mixed-citation>
</ref>
<ref id="bibr68-1177271920950319">
<label>68.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Calignon</surname><given-names>A</given-names></name><name><surname>Polydoro</surname><given-names>M</given-names></name><name><surname>Suárez-Calvet</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Propagation of tau pathology in a model of early Alzheimer’s disease</article-title>. <source/>Neuron. <year>2012</year>;<volume>73</volume>:<fpage>685</fpage>-<lpage>697</lpage>.<pub-id pub-id-type="pmid">22365544</pub-id></mixed-citation>
</ref>
<ref id="bibr69-1177271920950319">
<label>69.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clavaguera</surname><given-names>F</given-names></name><name><surname>Akatsu</surname><given-names>H</given-names></name><name><surname>Fraser</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>
<article-title>Brain homogenates from human tauopathies induce tau inclusions in mouse brain</article-title>. <source/>Proc Natl Acad Sci U S A. <year>2013</year>;<volume>110</volume>:<fpage>9535</fpage>-<lpage>9540</lpage>.<pub-id pub-id-type="pmid">23690619</pub-id></mixed-citation>
</ref>
<ref id="bibr70-1177271920950319">
<label>70.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Orr</surname><given-names>ME</given-names></name><name><surname>Sullivan</surname><given-names>AC</given-names></name><name><surname>Frost</surname><given-names>B.</given-names></name></person-group>
<article-title>A brief overview of tauopathy: causes, consequences, and therapeutic strategies</article-title>. <source/>Trends Pharmacol Sci. <year>2017</year>;<volume>38</volume>:<fpage>637</fpage>-<lpage>648</lpage>.<pub-id pub-id-type="pmid">28455089</pub-id></mixed-citation>
</ref>
<ref id="bibr71-1177271920950319">
<label>71.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kovacs</surname><given-names>GG.</given-names></name></person-group>
<article-title>Molecular pathological classification of neurodegenerative diseases: turning towards precision medicine</article-title>. <source/>Int J Mol Sci. <year>2016</year>;<volume>17</volume>:<fpage>189</fpage>.</mixed-citation>
</ref>
<ref id="bibr72-1177271920950319">
<label>72.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vogels</surname><given-names>T</given-names></name><name><surname>Murgoci</surname><given-names>AN</given-names></name><name><surname>Hromadka</surname><given-names>T.</given-names></name></person-group>
<article-title>Intersection of pathological tau and microglia at the synapse</article-title>. <source/>Acta Neuropathol Commun. <year>2019</year>;<volume>7</volume>:<fpage>109</fpage>.<pub-id pub-id-type="pmid">31277708</pub-id></mixed-citation>
</ref>
<ref id="bibr73-1177271920950319">
<label>73.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dejanovic</surname><given-names>B</given-names></name><name><surname>Huntley</surname><given-names>MA</given-names></name><name><surname>De Maziere</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies</article-title>. <source/>Neuron. <year>2018</year>;<volume>100</volume>:<fpage>1322</fpage>-<lpage>1336</lpage>.e7.<pub-id pub-id-type="pmid">30392797</pub-id></mixed-citation>
</ref>
<ref id="bibr74-1177271920950319">
<label>74.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jackson</surname><given-names>JS</given-names></name><name><surname>Witton</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>JD</given-names></name></person-group>, <etal>et al</etal>
<article-title>Altered synapse stability in the early stages of tauopathy</article-title>. <source/>Cell Rep. <year>2017</year>;<volume>18</volume>:<fpage>3063</fpage>-<lpage>3068</lpage>.<pub-id pub-id-type="pmid">28355559</pub-id></mixed-citation>
</ref>
<ref id="bibr75-1177271920950319">
<label>75.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goedert</surname><given-names>M</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name><name><surname>Spillantini</surname><given-names>MG.</given-names></name></person-group>
<article-title>The synucleinopathies: twenty years on</article-title>. <source/>J Parkinsons Dis. <year>2017</year>;<volume>7</volume>:<fpage>S51</fpage>-<lpage>S69</lpage>.<pub-id pub-id-type="pmid">28282814</pub-id></mixed-citation>
</ref>
<ref id="bibr76-1177271920950319">
<label>76.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baba</surname><given-names>M</given-names></name><name><surname>Nakajo</surname><given-names>S</given-names></name><name><surname>Tu</surname><given-names>PH</given-names></name></person-group>, <etal>et al</etal>
<article-title>Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies</article-title>. <source/>Am J Pathol. <year>1998</year>;<volume>152</volume>:<fpage>879</fpage>-<lpage>884</lpage>.<pub-id pub-id-type="pmid">9546347</pub-id></mixed-citation>
</ref>
<ref id="bibr77-1177271920950319">
<label>77.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>BrÃ¡s</surname><given-names>IC</given-names></name><name><surname>Dominguez-Meijide</surname><given-names>A</given-names></name><name><surname>Gerhardt</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>
<article-title>Synucleinopathies: where we are and where we need to go</article-title>. <source/>J Neurochem. <year>2020</year>;<volume>153</volume>:<fpage>433</fpage>-<lpage>454</lpage>.<pub-id pub-id-type="pmid">31957016</pub-id></mixed-citation>
</ref>
<ref id="bibr78-1177271920950319">
<label>78.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sanderson</surname><given-names>JB</given-names></name><name><surname>De</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>
<article-title>Analysis of alpha-synuclein species enriched from cerebral cortex of humans with sporadic dementia with Lewy bodies</article-title>. <source/>Brain Commun. <year>2020</year>;<volume>2</volume>:<fpage>fcaa010</fpage>.<pub-id pub-id-type="pmid">32280944</pub-id></mixed-citation>
</ref>
<ref id="bibr79-1177271920950319">
<label>79.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Beyer</surname><given-names>MK</given-names></name><name><surname>Kurz</surname><given-names>MW.</given-names></name></person-group>
<article-title>Dementia in Parkinson’s disease</article-title>. <source/>Curr Opin Neurol. <year>2008</year>;<volume>21</volume>:<fpage>676</fpage>-<lpage>682</lpage>.<pub-id pub-id-type="pmid">18989112</pub-id></mixed-citation>
</ref>
<ref id="bibr80-1177271920950319">
<label>80.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murphy</surname><given-names>DD</given-names></name><name><surname>Rueter</surname><given-names>SM</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VM.</given-names></name></person-group>
<article-title>Synucleins are developmentally expressed, and a-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons</article-title>. <source/>J Neurosci. <year>2000</year>;<volume>20</volume>:<fpage>3214</fpage>-<lpage>3220</lpage>.<pub-id pub-id-type="pmid">10777786</pub-id></mixed-citation>
</ref>
<ref id="bibr81-1177271920950319">
<label>81.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chandra</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Rizo</surname><given-names>J</given-names></name><name><surname>Jahn</surname><given-names>R</given-names></name><name><surname>Sudhof</surname><given-names>TC.</given-names></name></person-group>
<article-title>A broken alpha -helix in folded alpha -Synuclein</article-title>. <source/>J Biol Chem. <year>2003</year>;<volume>278</volume>:<fpage>15313</fpage>-<lpage>15318</lpage>.<pub-id pub-id-type="pmid">12586824</pub-id></mixed-citation>
</ref>
<ref id="bibr82-1177271920950319">
<label>82.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hawk</surname><given-names>BJD</given-names></name><name><surname>Khounlo</surname><given-names>R</given-names></name><name><surname>Shin</surname><given-names>YK</given-names></name></person-group>
<article-title>Alpha-synuclein continues to enhance SNARE-dependent vesicle docking at exorbitant concentrations</article-title>. <source/>Front Neurosci. <year>2019</year>;<volume>13</volume>:<fpage>216</fpage>.<pub-id pub-id-type="pmid">30949020</pub-id></mixed-citation>
</ref>
<ref id="bibr83-1177271920950319">
<label>83.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burre</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Tsetsenis</surname><given-names>T</given-names></name><name><surname>Buchman</surname><given-names>V</given-names></name><name><surname>Etherton</surname><given-names>MR</given-names></name><name><surname>Sudhof</surname><given-names>TC.</given-names></name></person-group>
<article-title>Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro</article-title>. <source/>Science. <year>2010</year>;<volume>329</volume>:<fpage>1663</fpage>-<lpage>1667</lpage>.<pub-id pub-id-type="pmid">20798282</pub-id></mixed-citation>
</ref>
<ref id="bibr84-1177271920950319">
<label>84.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pozo Devoto</surname><given-names>VM</given-names></name><name><surname>Falzone</surname><given-names>TL.</given-names></name></person-group>
<article-title>Mitochondrial dynamics in Parkinson’s disease: a role for alpha-synuclein?</article-title>
<source/>Dis Model Mech. <year>2017</year>;<volume>10</volume>:<fpage>1075</fpage>-<lpage>1087</lpage>.<pub-id pub-id-type="pmid">28883016</pub-id></mixed-citation>
</ref>
<ref id="bibr85-1177271920950319">
<label>85.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cooper</surname><given-names>AA</given-names></name><name><surname>Gitler</surname><given-names>AD</given-names></name><name><surname>Cashikar</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson’s models</article-title>. <source/>Science. <year>2006</year>;<volume>313</volume>:<fpage>324</fpage>-<lpage>328</lpage>.<pub-id pub-id-type="pmid">16794039</pub-id></mixed-citation>
</ref>
<ref id="bibr86-1177271920950319">
<label>86.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Becker</surname><given-names>K</given-names></name><name><surname>Levine</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal>
<article-title>Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration</article-title>. <source/>Acta Neuropathol Commun. <year>2019</year>;<volume>7</volume>:<fpage>41</fpage>.<pub-id pub-id-type="pmid">30871620</pub-id></mixed-citation>
</ref>
<ref id="bibr87-1177271920950319">
<label>87.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bernal-Conde</surname><given-names>LD</given-names></name><name><surname>Ramos-Acevedo</surname><given-names>R</given-names></name><name><surname>Reyes-Hernandez</surname><given-names>MA</given-names></name></person-group>, <etal>et al</etal>
<article-title>Alpha-synuclein physiology and pathology: a perspective on cellular structures and organelles</article-title>. <source/>Front Neurosci. <year>2020</year>;<volume>13</volume>:<fpage>1399</fpage>.<pub-id pub-id-type="pmid">32038126</pub-id></mixed-citation>
</ref>
<ref id="bibr88-1177271920950319">
<label>88.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Loov</surname><given-names>C</given-names></name><name><surname>Scherzer</surname><given-names>CR</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Breakefield</surname><given-names>XO</given-names></name><name><surname>Ingelsson</surname><given-names>M.</given-names></name></person-group>
<article-title>alpha-synuclein in extracellular vesicles: functional implications and diagnostic opportunities</article-title>. <source/>Cell Mol Neurobiol. <year>2016</year>;<volume>36</volume>:<fpage>437</fpage>-<lpage>448</lpage>.<pub-id pub-id-type="pmid">26993503</pub-id></mixed-citation>
</ref>
<ref id="bibr89-1177271920950319">
<label>89.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Forloni</surname><given-names>G</given-names></name><name><surname>Artuso</surname><given-names>V</given-names></name><name><surname>La Vitola</surname><given-names>P</given-names></name><name><surname>Balducci</surname><given-names>C.</given-names></name></person-group>
<article-title>Oligomeropathies and pathogenesis of Alzheimer and Parkinson’s diseases</article-title>. <source/>Mov Disord. <year>2016</year>;<volume>31</volume>:<fpage>771</fpage>-<lpage>781</lpage>.<pub-id pub-id-type="pmid">27030592</pub-id></mixed-citation>
</ref>
<ref id="bibr90-1177271920950319">
<label>90.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prots</surname><given-names>I</given-names></name><name><surname>Grosch</surname><given-names>J</given-names></name><name><surname>Brazdis</surname><given-names>RM</given-names></name></person-group>, <etal>et al</etal>
<article-title>alpha-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies</article-title>. <source/>Proc Natl Acad Sci U S A. <year>2018</year>;<volume>115</volume>:<fpage>7813</fpage>-<lpage>7818</lpage>.<pub-id pub-id-type="pmid">29991596</pub-id></mixed-citation>
</ref>
<ref id="bibr91-1177271920950319">
<label>91.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tarutani</surname><given-names>A</given-names></name><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Murayama</surname><given-names>S</given-names></name><name><surname>Hisanaga</surname><given-names>SI</given-names></name><name><surname>Hasegawa</surname><given-names>M.</given-names></name></person-group>
<article-title>Potent prion-like behaviors of pathogenic alpha-synuclein and evaluation of inactivation methods</article-title>. <source/>Acta Neuropathol Commun. <year>2018</year>;<volume>6</volume>:<fpage>29</fpage>.<pub-id pub-id-type="pmid">29669601</pub-id></mixed-citation>
</ref>
<ref id="bibr92-1177271920950319">
<label>92.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>A.</given-names></name></person-group>
<article-title>Prion-like mechanisms in Parkinson’s disease</article-title>. <source/>Front Neurosci. <year>2019</year>;<volume>13</volume>:<fpage>552</fpage>.<pub-id pub-id-type="pmid">31275093</pub-id></mixed-citation>
</ref>
<ref id="bibr93-1177271920950319">
<label>93.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jellinger</surname><given-names>KA</given-names></name><name><surname>Lantos</surname><given-names>PL.</given-names></name></person-group>
<article-title>Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update</article-title>. <source/>Acta Neuropathol. <year>2010</year>;<volume>119</volume>:<fpage>657</fpage>-<lpage>667</lpage>.<pub-id pub-id-type="pmid">20309568</pub-id></mixed-citation>
</ref>
<ref id="bibr94-1177271920950319">
<label>94.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Gathagan</surname><given-names>RJ</given-names></name><name><surname>Covell</surname><given-names>DJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Cellular milieu imparts distinct pathological alpha-synuclein strains in alpha-synucleinopathies</article-title>. <source/>Nature. <year>2018</year>;<volume>557</volume>:<fpage>558</fpage>-<lpage>563</lpage>.<pub-id pub-id-type="pmid">29743672</pub-id></mixed-citation>
</ref>
<ref id="bibr95-1177271920950319">
<label>95.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Savica</surname><given-names>R</given-names></name><name><surname>Grossardt</surname><given-names>BR</given-names></name><name><surname>Bower</surname><given-names>JH</given-names></name></person-group>, <etal>et al</etal>
<article-title>Survival and causes of death among people with clinically diagnosed synucleinopathies with parkinsonism: a population-based study</article-title>. <source/>JAMA Neurol. <year>2017</year>;<volume>74</volume>:<fpage>839</fpage>-<lpage>846</lpage>.<pub-id pub-id-type="pmid">28505261</pub-id></mixed-citation>
</ref>
<ref id="bibr96-1177271920950319">
<label>96.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sekiya</surname><given-names>H</given-names></name><name><surname>Kowa</surname><given-names>H</given-names></name><name><surname>Koga</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>
<article-title>Wide distribution of alpha-synuclein oligomers in multiple system atrophy brain detected by proximity ligation</article-title>. <source/>Acta Neuropathol. <year>2019</year>;<volume>137</volume>:<fpage>455</fpage>-<lpage>466</lpage>.<pub-id pub-id-type="pmid">30721406</pub-id></mixed-citation>
</ref>
<ref id="bibr97-1177271920950319">
<label>97.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schweighauser</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Tarutani</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Structures of α-synuclein filaments from multiple system atrophy</article-title> [published online ahead of print <month>5</month>
<day>27</day>, <year>2020</year>]. <source/>Nature. doi:<pub-id pub-id-type="doi">10.1038/s41586-020-2317-6.</pub-id></mixed-citation>
</ref>
<ref id="bibr98-1177271920950319">
<label>98.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zaccai</surname><given-names>J</given-names></name><name><surname>McCracken</surname><given-names>C</given-names></name><name><surname>Brayne</surname><given-names>C.</given-names></name></person-group>
<article-title>A systematic review of prevalence and incidence studies of dementia with Lewy bodies</article-title>. <source/>Age Ageing. <year>2005</year>;<volume>34</volume>:<fpage>561</fpage>-<lpage>566</lpage>.<pub-id pub-id-type="pmid">16267179</pub-id></mixed-citation>
</ref>
<ref id="bibr99-1177271920950319">
<label>99.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bellucci</surname><given-names>A</given-names></name><name><surname>Mercuri</surname><given-names>NB</given-names></name><name><surname>Venneri</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Review: Parkinson’s disease: from synaptic loss to connectome dysfunction</article-title>. <source/>Neuropathol Appl Neurobiol. <year>2016</year>;<volume>42</volume>:<fpage>77</fpage>-<lpage>94</lpage>.<pub-id pub-id-type="pmid">26613567</pub-id></mixed-citation>
</ref>
<ref id="bibr100-1177271920950319">
<label>100.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Uéda</surname><given-names>K</given-names></name><name><surname>Fukushima</surname><given-names>H</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>
<article-title>Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease</article-title>. <source/>Proc Natl Acad Sci U S A. <year>1993</year>;<volume>90</volume>:<fpage>11282</fpage>-<lpage>11286</lpage>.<pub-id pub-id-type="pmid">8248242</pub-id></mixed-citation>
</ref>
<ref id="bibr101-1177271920950319">
<label>101.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>RL.</given-names></name></person-group>
<article-title>Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry</article-title>. <source/>Brain Pathol. <year>2000</year>;<volume>10</volume>:<fpage>378</fpage>-<lpage>384</lpage>.<pub-id pub-id-type="pmid">10885656</pub-id></mixed-citation>
</ref>
<ref id="bibr102-1177271920950319">
<label>102.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kovacs</surname><given-names>GG</given-names></name><name><surname>Milenkovic</surname><given-names>I</given-names></name><name><surname>Wöhrer</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series</article-title>. <source/>Acta Neuropathol. <year>2013</year>;<volume>126</volume>:<fpage>365</fpage>-<lpage>384</lpage>.<pub-id pub-id-type="pmid">23900711</pub-id></mixed-citation>
</ref>
<ref id="bibr103-1177271920950319">
<label>103.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Monsell</surname><given-names>SE</given-names></name><name><surname>Phillips</surname><given-names>LE</given-names></name><name><surname>Kukull</surname><given-names>W.</given-names></name></person-group>
<article-title>Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010</article-title>. <source/>J Neuropathol Exp Neurol. <year>2012</year>;<volume>71</volume>:<fpage>266</fpage>-<lpage>273</lpage>.<pub-id pub-id-type="pmid">22437338</pub-id></mixed-citation>
</ref>
<ref id="bibr104-1177271920950319">
<label>104.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moussaud</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>DR</given-names></name><name><surname>Moussaud-Lamodière</surname><given-names>EL</given-names></name><name><surname>Delenclos</surname><given-names>M</given-names></name><name><surname>Ross</surname><given-names>OA</given-names></name><name><surname>McLean</surname><given-names>PJ.</given-names></name></person-group>
<article-title>Alpha-synuclein and tau: teammates in neurodegeneration?</article-title>
<source/>Mol Neurodegener. <year>2014</year>;<volume>9</volume>:<fpage>43</fpage>.<pub-id pub-id-type="pmid">25352339</pub-id></mixed-citation>
</ref>
<ref id="bibr105-1177271920950319">
<label>105.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wenning</surname><given-names>GK</given-names></name><name><surname>Krismer</surname><given-names>F</given-names></name><name><surname>Poewe</surname><given-names>W.</given-names></name></person-group>
<article-title>New insights into atypical parkinsonism</article-title>. <source/>Curr Opin Neurol. <year>2011</year>;<volume>24</volume>:<fpage>331</fpage>-<lpage>338</lpage>.<pub-id pub-id-type="pmid">21577106</pub-id></mixed-citation>
</ref>
<ref id="bibr106-1177271920950319">
<label>106.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Olsson</surname><given-names>B</given-names></name><name><surname>Lautner</surname><given-names>R</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name></person-group>, <etal>et al</etal>
<article-title>CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis</article-title>. <source/>Lancet Neurol. <year>2016</year>;<volume>15</volume>:<fpage>673</fpage>-<lpage>684</lpage>.<pub-id pub-id-type="pmid">27068280</pub-id></mixed-citation>
</ref>
<ref id="bibr107-1177271920950319">
<label>107.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Feldman</surname><given-names>HH</given-names></name><name><surname>Jacova</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>
<article-title>Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria</article-title>. <source/>Lancet Neurol. <year>2014</year>;<volume>13</volume>:<fpage>614</fpage>-<lpage>629</lpage>.<pub-id pub-id-type="pmid">24849862</pub-id></mixed-citation>
</ref>
<ref id="bibr108-1177271920950319">
<label>108.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oeckl</surname><given-names>P</given-names></name><name><surname>Steinacker</surname><given-names>P</given-names></name><name><surname>Feneberg</surname><given-names>E</given-names></name><name><surname>Otto</surname><given-names>M.</given-names></name></person-group>
<article-title>Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update</article-title>. <source/>J Neurochem. <year>2016</year>;<volume>138</volume>:<fpage>184</fpage>-<lpage>192</lpage>.<pub-id pub-id-type="pmid">27186717</pub-id></mixed-citation>
</ref>
<ref id="bibr109-1177271920950319">
<label>109.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sjogren</surname><given-names>M</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Davidsson</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal>
<article-title>CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging</article-title>. <source/>J Neural Transm (Vienna). <year>2000</year>;<volume>107</volume>:<fpage>563</fpage>-<lpage>579</lpage>.<pub-id pub-id-type="pmid">11072752</pub-id></mixed-citation>
</ref>
<ref id="bibr110-1177271920950319">
<label>110.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Riemenschneider</surname><given-names>M</given-names></name><name><surname>Wagenpfeil</surname><given-names>S</given-names></name><name><surname>Vanderstichele</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>
<article-title>Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias</article-title>. <source/>Mol Psychiatry. <year>2003</year>;<volume>8</volume>:<fpage>343</fpage>-<lpage>347</lpage>.<pub-id pub-id-type="pmid">12660807</pub-id></mixed-citation>
</ref>
<ref id="bibr111-1177271920950319">
<label>111.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Otto</surname><given-names>M</given-names></name><name><surname>Wiltfang</surname><given-names>J</given-names></name><name><surname>Tumania</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>
<article-title>Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease</article-title>. <source/>Neurosci Lett. <year>1997</year>;<volume>225</volume>:<fpage>210</fpage>-<lpage>212</lpage>.<pub-id pub-id-type="pmid">9147407</pub-id></mixed-citation>
</ref>
<ref id="bibr112-1177271920950319">
<label>112.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frisoni</surname><given-names>GB</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Thompson</surname><given-names>PM.</given-names></name></person-group>
<article-title>The clinical use of structural MRI in Alzheimer disease</article-title>. <source/>Nat Rev Neurol. <year>2010</year>;<volume>6</volume>:<fpage>67</fpage>-<lpage>77</lpage>.<pub-id pub-id-type="pmid">20139996</pub-id></mixed-citation>
</ref>
<ref id="bibr113-1177271920950319">
<label>113.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barthel</surname><given-names>H</given-names></name><name><surname>Sabri</surname><given-names>O.</given-names></name></person-group>
<article-title>Clinical use and utility of amyloid imaging</article-title>. <source/>J Nucl Med. <year>2017</year>;<volume>58</volume>:<fpage>1711</fpage>-<lpage>1717</lpage>.<pub-id pub-id-type="pmid">28818990</pub-id></mixed-citation>
</ref>
<ref id="bibr114-1177271920950319">
<label>114.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Filippi</surname><given-names>L</given-names></name><name><surname>Chiaravalloti</surname><given-names>A</given-names></name><name><surname>Bagni</surname><given-names>O</given-names></name><name><surname>Schillaci</surname><given-names>O.</given-names></name></person-group>
<article-title>(18)F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer’s disease</article-title>. <source/>Am J Nucl Med Mol Imaging. <year>2018</year>;<volume>8</volume>:<fpage>268</fpage>-<lpage>281</lpage>.<pub-id pub-id-type="pmid">30245918</pub-id></mixed-citation>
</ref>
<ref id="bibr115-1177271920950319">
<label>115.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schöll</surname><given-names>M</given-names></name><name><surname>Maass</surname><given-names>A</given-names></name><name><surname>Mattsson</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal>
<article-title>Biomarkers for tau pathology</article-title>. <source/>Mol Cell Neurosci. <year>2019</year>;<volume>97</volume>:<fpage>18</fpage>-<lpage>33</lpage>.<pub-id pub-id-type="pmid">30529601</pub-id></mixed-citation>
</ref>
<ref id="bibr116-1177271920950319">
<label>116.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Choo</surname><given-names>IH</given-names></name><name><surname>Ni</surname><given-names>R</given-names></name><name><surname>Schöll</surname><given-names>M</given-names></name><name><surname>Wall</surname><given-names>A</given-names></name><name><surname>Almkvist</surname><given-names>O</given-names></name><name><surname>Nordberg</surname><given-names>A.</given-names></name></person-group>
<article-title>Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer’s disease in mild cognitive impairment patients</article-title>. <source/>J Alzheimers Dis. <year>2013</year>;<volume>33</volume>:<fpage>929</fpage>-<lpage>939</lpage>.<pub-id pub-id-type="pmid">23047371</pub-id></mixed-citation>
</ref>
<ref id="bibr117-1177271920950319">
<label>117.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schöll</surname><given-names>M</given-names></name><name><surname>Damián</surname><given-names>A</given-names></name><name><surname>Engler</surname><given-names>H.</given-names></name></person-group>
<article-title>Fluorodeoxyglucose PET in neurology and psychiatry</article-title>. <source/>PET Clin. <year>2014</year>;<volume>9</volume>:<fpage>371</fpage>-<lpage>390</lpage>.<pub-id pub-id-type="pmid">26050943</pub-id></mixed-citation>
</ref>
<ref id="bibr118-1177271920950319">
<label>118.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mecca</surname><given-names>AP</given-names></name><name><surname>Chen</surname><given-names>MK</given-names></name><name><surname>O’Dell</surname><given-names>RS</given-names></name></person-group>, <etal>et al</etal>
<article-title>In vivo measurement of widespread synaptic loss in Alzheimer’s disease with SV2A PET</article-title>. <source/>Alzheimers Dement. <year>2020</year>;<volume>16</volume>:<fpage>974</fpage>-<lpage>982</lpage>.<pub-id pub-id-type="pmid">32400950</pub-id></mixed-citation>
</ref>
<ref id="bibr119-1177271920950319">
<label>119.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jack</surname><given-names>CR</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>
<article-title>A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers</article-title>. <source/>Neurology. <year>2016</year>;<volume>87</volume>:<fpage>539</fpage>-<lpage>547</lpage>.<pub-id pub-id-type="pmid">27371494</pub-id></mixed-citation>
</ref>
<ref id="bibr120-1177271920950319">
<label>120.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ashton</surname><given-names>NJ</given-names></name><name><surname>Nevado-Holgado</surname><given-names>AJ</given-names></name><name><surname>Barber</surname><given-names>IS</given-names></name></person-group>, <etal>et al</etal>
<article-title>A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease</article-title>. <source/>Sci Adv. <year>2019</year>;<volume>5</volume>:<fpage>eaau7220</fpage>.<pub-id pub-id-type="pmid">30775436</pub-id></mixed-citation>
</ref>
<ref id="bibr121-1177271920950319">
<label>121.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kvartsberg</surname><given-names>H</given-names></name><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name></person-group>, <etal>et al</etal>
<article-title>Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls</article-title>. <source/>Alzheimers Res Ther. <year>2015</year>;<volume>7</volume>:<fpage>40</fpage>.<pub-id pub-id-type="pmid">26136856</pub-id></mixed-citation>
</ref>
<ref id="bibr122-1177271920950319">
<label>122.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>A</given-names></name><name><surname>Kaneko</surname><given-names>N</given-names></name><name><surname>Villemagne</surname><given-names>VL</given-names></name></person-group>, <etal>et al</etal>
<article-title>High performance plasma amyloid-beta biomarkers for Alzheimer’s disease</article-title>. <source/>Nature. <year>2018</year>;<volume>554</volume>:<fpage>249</fpage>-<lpage>254</lpage>.<pub-id pub-id-type="pmid">29420472</pub-id></mixed-citation>
</ref>
<ref id="bibr123-1177271920950319">
<label>123.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schindler</surname><given-names>SE</given-names></name><name><surname>Bollinger</surname><given-names>JG</given-names></name><name><surname>Ovod</surname><given-names>V</given-names></name></person-group>, <etal>et al</etal>
<article-title>High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis</article-title>. <source/>Neurology. <year>2019</year>;<volume>93</volume>:<fpage>e1647</fpage>-<lpage>e1659</lpage>.<pub-id pub-id-type="pmid">31371569</pub-id></mixed-citation>
</ref>
<ref id="bibr124-1177271920950319">
<label>124.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Janelidze</surname><given-names>S</given-names></name><name><surname>Stomrud</surname><given-names>E</given-names></name><name><surname>Palmqvist</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Plasma β-amyloid in Alzheimer’s disease and vascular disease</article-title>. <source/>Sci Rep. <year>2016</year>;<volume>6</volume>:<fpage>1</fpage>-<lpage>11</lpage>.<pub-id pub-id-type="pmid">28442746</pub-id></mixed-citation>
</ref>
<ref id="bibr125-1177271920950319">
<label>125.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Palmqvist</surname><given-names>S</given-names></name><name><surname>Janelidze</surname><given-names>S</given-names></name><name><surname>Stomrud</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>
<article-title>Performance of fully automated plasma assays as screening tests for Alzheimer disease–related β-amyloid status</article-title>. <source/>JAMA Neurol. <year>2019</year>;<volume>76</volume>:<fpage>1060</fpage>-<lpage>1069</lpage>.</mixed-citation>
</ref>
<ref id="bibr126-1177271920950319">
<label>126.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mielke</surname><given-names>MM</given-names></name><name><surname>Hagen</surname><given-names>CE</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau-and amyloid-positron emission tomography</article-title>. <source/>Alzheimers Dement. <year>2018</year>;<volume>14</volume>:<fpage>989</fpage>-<lpage>997</lpage>.<pub-id pub-id-type="pmid">29626426</pub-id></mixed-citation>
</ref>
<ref id="bibr127-1177271920950319">
<label>127.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Janelidze</surname><given-names>S</given-names></name><name><surname>Mattsson</surname><given-names>N</given-names></name><name><surname>Palmqvist</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia</article-title>. <source/>Nat Med. <year>2020</year>;<volume>26</volume>:<fpage>379</fpage>-<lpage>386</lpage>.<pub-id pub-id-type="pmid">32123385</pub-id></mixed-citation>
</ref>
<ref id="bibr128-1177271920950319">
<label>128.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thijssen</surname><given-names>EH</given-names></name><name><surname>La Joie</surname><given-names>R</given-names></name><name><surname>Wolf</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration</article-title>. <source/>Nat Med. <year>2020</year>;<volume>26</volume>:<fpage>387</fpage>-<lpage>397</lpage>.<pub-id pub-id-type="pmid">32123386</pub-id></mixed-citation>
</ref>
<ref id="bibr129-1177271920950319">
<label>129.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Karikari</surname><given-names>TK</given-names></name><name><surname>Pascoal</surname><given-names>TA</given-names></name><name><surname>Ashton</surname><given-names>NJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts</article-title>. <source/>Lancet Neurol. <year>2020</year>;<volume>19</volume>:<fpage>422</fpage>-<lpage>433</lpage>.<pub-id pub-id-type="pmid">32333900</pub-id></mixed-citation>
</ref>
<ref id="bibr130-1177271920950319">
<label>130.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mattsson</surname><given-names>N</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Janelidze</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Plasma tau in Alzheimer disease</article-title>. <source/>Neurology. <year>2016</year>;<volume>87</volume>:<fpage>1827</fpage>-<lpage>1835</lpage>.<pub-id pub-id-type="pmid">27694257</pub-id></mixed-citation>
</ref>
<ref id="bibr131-1177271920950319">
<label>131.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khalil</surname><given-names>M</given-names></name><name><surname>Teunissen</surname><given-names>CE</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Neurofilaments as biomarkers in neurological disorders</article-title>. <source/>Nat Rev Neurol. <year>2018</year>;<volume>14</volume>:<fpage>577</fpage>-<lpage>589</lpage>.<pub-id pub-id-type="pmid">30171200</pub-id></mixed-citation>
</ref>
<ref id="bibr132-1177271920950319">
<label>132.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Janelidze</surname><given-names>S</given-names></name><name><surname>Hall</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder</article-title>. <source/>Neurology. <year>2017</year>;<volume>88</volume>:<fpage>930</fpage>-<lpage>937</lpage>.<pub-id pub-id-type="pmid">28179466</pub-id></mixed-citation>
</ref>
<ref id="bibr133-1177271920950319">
<label>133.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mattsson</surname><given-names>N</given-names></name><name><surname>Cullen</surname><given-names>NC</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Blennow</surname><given-names>K.</given-names></name></person-group>
<article-title>Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease</article-title>. <source/>JAMA Neurol. <year>2019</year>;<volume>76</volume>:<fpage>791</fpage>-<lpage>799</lpage>.<pub-id pub-id-type="pmid">31009028</pub-id></mixed-citation>
</ref>
<ref id="bibr134-1177271920950319">
<label>134.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ashton</surname><given-names>NJ</given-names></name><name><surname>Leuzy</surname><given-names>A</given-names></name><name><surname>Lim</surname><given-names>YM</given-names></name></person-group>, <etal>et al</etal>
<article-title>Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration</article-title>. <source/>Acta Neuropathol Commun. <year>2019</year>;<volume>7</volume>:<fpage>1</fpage>-<lpage>11</lpage>.<pub-id pub-id-type="pmid">30606247</pub-id></mixed-citation>
</ref>
<ref id="bibr135-1177271920950319">
<label>135.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mattsson</surname><given-names>N</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Blennow</surname><given-names>K.</given-names></name></person-group>
<article-title>Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease</article-title>. <source/>JAMA Neurol. <year>2017</year>;<volume>74</volume>:<fpage>557</fpage>-<lpage>566</lpage>.<pub-id pub-id-type="pmid">28346578</pub-id></mixed-citation>
</ref>
<ref id="bibr136-1177271920950319">
<label>136.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Skillbäck</surname><given-names>T</given-names></name><name><surname>Mattsson</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal>
<article-title>Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression</article-title>. <source/>JAMA Neurol. <year>2016</year>;<volume>73</volume>:<fpage>60</fpage>-<lpage>67</lpage>.<pub-id pub-id-type="pmid">26524180</pub-id></mixed-citation>
</ref>
<ref id="bibr137-1177271920950319">
<label>137.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Benedet</surname><given-names>Al</given-names></name><name><surname>Ashton</surname><given-names>NJ</given-names></name><name><surname>Pascoal</surname><given-names>TA</given-names></name></person-group>, <etal>et al</etal>
<article-title>Plasma neurofilament light associates with Alzheimer’s disease metabolic decline in amyloid-positive individuals</article-title>. <source/>Alzheimers Dement (Amst). <year>2019</year>;<volume>11</volume>:<fpage>679</fpage>-<lpage>689</lpage>.<pub-id pub-id-type="pmid">31673598</pub-id></mixed-citation>
</ref>
<ref id="bibr138-1177271920950319">
<label>138.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davidsson</surname><given-names>P</given-names></name><name><surname>Jahn</surname><given-names>R</given-names></name><name><surname>Bergquist</surname><given-names>J</given-names></name><name><surname>Ekman</surname><given-names>R</given-names></name><name><surname>Blennow</surname><given-names>K.</given-names></name></person-group>
<article-title>Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid</article-title>. <source/>Mol Chem Neuropathol. <year>1996</year>;<volume>27</volume>:<fpage>195</fpage>-<lpage>210</lpage>.<pub-id pub-id-type="pmid">8962603</pub-id></mixed-citation>
</ref>
<ref id="bibr139-1177271920950319">
<label>139.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davidsson</surname><given-names>P</given-names></name><name><surname>Puchades</surname><given-names>M</given-names></name><name><surname>Blennow</surname><given-names>K.</given-names></name></person-group>
<article-title>Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing</article-title>. <source/>Electrophoresis. <year>1999</year>;<volume>20</volume>:<fpage>431</fpage>-<lpage>437</lpage>.<pub-id pub-id-type="pmid">10217148</pub-id></mixed-citation>
</ref>
<ref id="bibr140-1177271920950319">
<label>140.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Benowitz</surname><given-names>LI</given-names></name><name><surname>Routtenberg</surname><given-names>A.</given-names></name></person-group>
<article-title>GAP-43: an intrinsic determinant of neuronal development and plasticity</article-title>. <source/>Trends Neurosci. <year>1997</year>;<volume>20</volume>:<fpage>84</fpage>-<lpage>91</lpage>.<pub-id pub-id-type="pmid">9023877</pub-id></mixed-citation>
</ref>
<ref id="bibr141-1177271920950319">
<label>141.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Holahan</surname><given-names>MR.</given-names></name></person-group>
<article-title>A shift from a pivotal to supporting role for the growth-associated protein (GAP-43) in the coordination of axonal structural and functional plasticity</article-title>. <source/>Front Cell Neurosci. <year>2017</year>;<volume>11</volume>:<fpage>266</fpage>.<pub-id pub-id-type="pmid">28912688</pub-id></mixed-citation>
</ref>
<ref id="bibr142-1177271920950319">
<label>142.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sjögren</surname><given-names>M</given-names></name><name><surname>Davidsson</surname><given-names>P</given-names></name><name><surname>Gottfries</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer’s disease, reflecting a common pathophysiological process</article-title>. <source/>Dement Geriatr Cogn Disord. <year>2001</year>;<volume>12</volume>:<fpage>257</fpage>-<lpage>264</lpage>.<pub-id pub-id-type="pmid">11351137</pub-id></mixed-citation>
</ref>
<ref id="bibr143-1177271920950319">
<label>143.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sandelius</surname><given-names>Å</given-names></name><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Källén</surname><given-names>Å</given-names></name></person-group>, <etal>et al</etal>
<article-title>Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology</article-title>. <source/>Alzheimers Dement. <year>2019</year>;<volume>15</volume>:<fpage>55</fpage>-<lpage>64</lpage>.<pub-id pub-id-type="pmid">30321501</pub-id></mixed-citation>
</ref>
<ref id="bibr144-1177271920950319">
<label>144.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Remnestal</surname><given-names>J</given-names></name><name><surname>Just</surname><given-names>D</given-names></name><name><surname>Mitsios</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal>
<article-title>CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer’s disease</article-title>. <source/>Proteomics Clin Appl. <year>2016</year>;<volume>10</volume>:<fpage>1242</fpage>-<lpage>1253</lpage>.<pub-id pub-id-type="pmid">27604409</pub-id></mixed-citation>
</ref>
<ref id="bibr145-1177271920950319">
<label>145.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haggmark</surname><given-names>A</given-names></name><name><surname>Bystrom</surname><given-names>S</given-names></name><name><surname>Ayoglu</surname><given-names>B</given-names></name></person-group>, <etal>et al</etal>
<article-title>Antibody-based profiling of cerebrospinal fluid within multiple sclerosis</article-title>. <source/>Proteomics. <year>2013</year>;<volume>13</volume>:<fpage>2256</fpage>-<lpage>2267</lpage>.<pub-id pub-id-type="pmid">23696371</pub-id></mixed-citation>
</ref>
<ref id="bibr146-1177271920950319">
<label>146.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rot</surname><given-names>U</given-names></name><name><surname>Sandelius</surname><given-names>A</given-names></name><name><surname>Emersic</surname><given-names>A</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Blennow</surname><given-names>K.</given-names></name></person-group>
<article-title>Cerebrospinal fluid GAP-43 in early multiple sclerosis</article-title>. <source/>Mult Scler J Exp Transl Clin. <year>2018</year>;<volume>4</volume>:<fpage>2055217318792931</fpage>.<pub-id pub-id-type="pmid">30094057</pub-id></mixed-citation>
</ref>
<ref id="bibr147-1177271920950319">
<label>147.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sandelius</surname><given-names>A</given-names></name><name><surname>Cullen</surname><given-names>NC</given-names></name><name><surname>Kallen</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Transient increase in CSF GAP-43 concentration after ischemic stroke</article-title>. <source/>BMC Neurol. <year>2018</year>;<volume>18</volume>:<fpage>202</fpage>.<pub-id pub-id-type="pmid">30526557</pub-id></mixed-citation>
</ref>
<ref id="bibr148-1177271920950319">
<label>148.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Südhof</surname><given-names>TC.</given-names></name></person-group>
<article-title>The synaptic vesicle cycle</article-title>. <source/>Annu Rev Neurosci. <year>2004</year>;<volume>27</volume>:<fpage>509</fpage>-<lpage>547</lpage>.<pub-id pub-id-type="pmid">15217342</pub-id></mixed-citation>
</ref>
<ref id="bibr149-1177271920950319">
<label>149.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Antonucci</surname><given-names>F</given-names></name><name><surname>Corradini</surname><given-names>I</given-names></name><name><surname>Fossati</surname><given-names>G</given-names></name><name><surname>Tomasoni</surname><given-names>R</given-names></name><name><surname>Menna</surname><given-names>E</given-names></name><name><surname>Matteoli</surname><given-names>M.</given-names></name></person-group>
<article-title>SNAP-25, a known presynaptic protein with emerging postsynaptic functions</article-title>. <source/>Front Synaptic Neurosci. <year>2016</year>;<volume>8</volume>:<fpage>7</fpage>.<pub-id pub-id-type="pmid">27047369</pub-id></mixed-citation>
</ref>
<ref id="bibr150-1177271920950319">
<label>150.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Xiao</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>
<article-title>Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer’s disease</article-title>. <source/>Alzheimers Dement (N Y). <year>2019</year>;<volume>5</volume>:<fpage>871</fpage>-<lpage>882</lpage>.<pub-id pub-id-type="pmid">31853477</pub-id></mixed-citation>
</ref>
<ref id="bibr151-1177271920950319">
<label>151.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Pan</surname><given-names>T</given-names></name></person-group>; <collab>for Alzheimer’s Disease Neuroimaging Initiative</collab>. <article-title>APOE epsilon4 is associated with higher levels of CSF SNAP-25 in prodromal Alzheimer’s disease</article-title>. <source/>Neurosci Lett. <year>2018</year>;<volume>685</volume>:<fpage>109</fpage>-<lpage>113</lpage>.<pub-id pub-id-type="pmid">30144541</pub-id></mixed-citation>
</ref>
<ref id="bibr152-1177271920950319">
<label>152.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Therriault</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>MS</given-names></name></person-group>, <etal>et al</etal>
<article-title>Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer’s disease</article-title>. <source/>Alzheimers Res Ther. <year>2018</year>;<volume>10</volume>:<fpage>80</fpage>.<pub-id pub-id-type="pmid">30115118</pub-id></mixed-citation>
</ref>
<ref id="bibr153-1177271920950319">
<label>153.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bereczki</surname><given-names>E</given-names></name><name><surname>Bogstedt</surname><given-names>A</given-names></name><name><surname>Höglund</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>
<article-title>Synaptic proteins in CSF relate to Parkinson’s disease stage markers</article-title>. <source/>NPJ Parkinsons Dis. <year>2017</year>;<volume>3</volume>:<fpage>7</fpage>.<pub-id pub-id-type="pmid">28649607</pub-id></mixed-citation>
</ref>
<ref id="bibr154-1177271920950319">
<label>154.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Shah</surname><given-names>SZA</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name></person-group>
<article-title>Proteome analysis of potential synaptic vesicle cycle biomarkers in the cerebrospinal fluid of patients with sporadic Creutzfeldt–Jakob disease</article-title>. <source/>Mol Neurobiol. <year>2017</year>;<volume>54</volume>:<fpage>5177</fpage>-<lpage>5191</lpage>.<pub-id pub-id-type="pmid">27562179</pub-id></mixed-citation>
</ref>
<ref id="bibr155-1177271920950319">
<label>155.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barakauskas</surname><given-names>VE</given-names></name><name><surname>Moradian</surname><given-names>A</given-names></name><name><surname>Barr</surname><given-names>AM</given-names></name></person-group>, <etal>et al</etal>
<article-title>Quantitative mass spectrometry reveals changes in SNAP-25 isoforms in schizophrenia</article-title>. <source/>Schizophr Res. <year>2016</year>;<volume>177</volume>:<fpage>44</fpage>-<lpage>51</lpage>.<pub-id pub-id-type="pmid">26971072</pub-id></mixed-citation>
</ref>
<ref id="bibr156-1177271920950319">
<label>156.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Courtney</surname><given-names>NA</given-names></name><name><surname>Bao</surname><given-names>H</given-names></name><name><surname>Briguglio</surname><given-names>JS</given-names></name><name><surname>Chapman</surname><given-names>ER</given-names></name></person-group>
<article-title>Synaptotagmin 1 clamps synaptic vesicle fusion in mammalian neurons independent of complexin</article-title>. <source/>Nat Commun. <year>2019</year>;<volume>10</volume>:<fpage>4076</fpage>.<pub-id pub-id-type="pmid">31501440</pub-id></mixed-citation>
</ref>
<ref id="bibr157-1177271920950319">
<label>157.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Ryu</surname><given-names>JK.</given-names></name></person-group>
<article-title>Models of synaptotagmin-1 to trigger Ca(2+) -dependent vesicle fusion</article-title>. <source/>FEBS Lett. <year>2018</year>;<volume>592</volume>:<fpage>3480</fpage>-<lpage>3492</lpage>.<pub-id pub-id-type="pmid">30004579</pub-id></mixed-citation>
</ref>
<ref id="bibr158-1177271920950319">
<label>158.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Öhrfelt</surname><given-names>A</given-names></name><name><surname>Brinkmalm</surname><given-names>A</given-names></name><name><surname>Dumurgier</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease</article-title>. <source/>Alzheimers Res Ther. <year>2016</year>;<volume>8</volume>:<fpage>41</fpage>.<pub-id pub-id-type="pmid">27716408</pub-id></mixed-citation>
</ref>
<ref id="bibr159-1177271920950319">
<label>159.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tible</surname><given-names>M</given-names></name><name><surname>Sandelius Höglund</surname><given-names>ÅK</given-names></name></person-group>, <etal>et al</etal>
<article-title>Dissection of synaptic pathways through the analysis of cerebrospinal fluid biomarkers: a combined tool for predicting Alzheimer’s disease</article-title> [published online ahead of print <month>6</month>
<day>25</day>, <year>2020</year>]. <source/>Neurology. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000010131.</pub-id></mixed-citation>
</ref>
<ref id="bibr160-1177271920950319">
<label>160.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ohrfelt</surname><given-names>A</given-names></name><name><surname>Brinkmalm</surname><given-names>A</given-names></name><name><surname>Dumurgier</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>A novel ELISA for the measurement of cerebrospinal fluid SNAP-25 in patients with Alzheimer’s disease</article-title>. <source/>Neuroscience. <year>2019</year>;<volume>420</volume>:<fpage>136</fpage>-<lpage>144</lpage>.<pub-id pub-id-type="pmid">30528858</pub-id></mixed-citation>
</ref>
<ref id="bibr161-1177271920950319">
<label>161.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clarke</surname><given-names>MTM</given-names></name><name><surname>Brinkmalm</surname><given-names>A</given-names></name><name><surname>Foiani</surname><given-names>MS</given-names></name></person-group>, <etal>et al</etal>
<article-title>CSF synaptic protein concentrations are raised in those with atypical Alzheimer’s disease but not frontotemporal dementia</article-title>. <source/>Alzheimers Res Ther. <year>2019</year>;<volume>11</volume>:<fpage>105</fpage>.<pub-id pub-id-type="pmid">31847891</pub-id></mixed-citation>
</ref>
<ref id="bibr162-1177271920950319">
<label>162.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lavedan</surname><given-names>C.</given-names></name></person-group>
<article-title>The synuclein family</article-title>. <source/>Genome Res. <year>2020</year>;<volume>8</volume>:<fpage>871</fpage>-<lpage>880</lpage>.</mixed-citation>
</ref>
<ref id="bibr163-1177271920950319">
<label>163.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Locascio</surname><given-names>JJ</given-names></name><name><surname>Schulz-Schaeffer</surname><given-names>W</given-names></name><name><surname>Sixel-Döring</surname><given-names>F</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Schlossmacher</surname><given-names>MG.</given-names></name></person-group>
<article-title>α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study</article-title>. <source/>Lancet Neurol. <year>2011</year>;<volume>10</volume>:<fpage>230</fpage>-<lpage>240</lpage>.<pub-id pub-id-type="pmid">21317042</pub-id></mixed-citation>
</ref>
<ref id="bibr164-1177271920950319">
<label>164.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tokuda</surname><given-names>T</given-names></name><name><surname>Salem</surname><given-names>SA</given-names></name><name><surname>Allsop</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>
<article-title>Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease</article-title>. <source/>Biochem Bioph Res Co. <year>2006</year>;<volume>349</volume>:<fpage>162</fpage>-<lpage>166</lpage>.</mixed-citation>
</ref>
<ref id="bibr165-1177271920950319">
<label>165.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mondello</surname><given-names>S</given-names></name><name><surname>Constantinescu</surname><given-names>R</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Holmberg</surname><given-names>B</given-names></name><name><surname>Jeromin</surname><given-names>A.</given-names></name></person-group>
<article-title>CSF α-synuclein and UCH-L1 levels in Parkinson’s disease and atypical parkinsonian disorders</article-title>. <source/>Parkinsonism Relat Disord. <year>2014</year>;<volume>20</volume>:<fpage>382</fpage>-<lpage>387</lpage>.<pub-id pub-id-type="pmid">24507721</pub-id></mixed-citation>
</ref>
<ref id="bibr166-1177271920950319">
<label>166.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Öhrfelt</surname><given-names>A</given-names></name><name><surname>Grognet</surname><given-names>P</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal>
<article-title>Cerebrospinal fluid α-synuclein in neurodegenerative disorders—a marker of synapse loss?</article-title>
<source/>Neurosci Lett. <year>2009</year>;<volume>450</volume>:<fpage>332</fpage>-<lpage>335</lpage>.<pub-id pub-id-type="pmid">19022350</pub-id></mixed-citation>
</ref>
<ref id="bibr167-1177271920950319">
<label>167.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oeckl</surname><given-names>P</given-names></name><name><surname>Metzger</surname><given-names>F</given-names></name><name><surname>Nagl</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Alpha-, Beta-, and Gamma-synuclein quantification in cerebrospinal fluid by multiple reaction monitoring reveals increased concentrations in Alzheimer’s and Creutzfeldt-Jakob disease but no alteration in synucleinopathies</article-title>. <source/>Mol Cell Proteomics. <year>2016</year>;<volume>15</volume>:<fpage>3126</fpage>-<lpage>3138</lpage>.<pub-id pub-id-type="pmid">27507836</pub-id></mixed-citation>
</ref>
<ref id="bibr168-1177271920950319">
<label>168.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Nie</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>
<article-title>Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson’s disease diagnosis: a systematic review and meta-analysis</article-title>. <source/>Int J Neurosci. <year>2015</year>;<volume>125</volume>:<fpage>645</fpage>-<lpage>654</lpage>.<pub-id pub-id-type="pmid">25202803</pub-id></mixed-citation>
</ref>
<ref id="bibr169-1177271920950319">
<label>169.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eusebi</surname><given-names>P</given-names></name><name><surname>Giannandrea</surname><given-names>D</given-names></name><name><surname>Biscetti</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>
<article-title>Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson’s disease: a systematic review and meta-analysis</article-title>. <source/>Mov Disord. <year>2017</year>;<volume>32</volume>:<fpage>1389</fpage>-<lpage>1400</lpage>.<pub-id pub-id-type="pmid">28880418</pub-id></mixed-citation>
</ref>
<ref id="bibr170-1177271920950319">
<label>170.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Wen</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>W-F</given-names></name><name><surname>Zhang</surname><given-names>C-L</given-names></name><name><surname>Jiao</surname><given-names>L.</given-names></name></person-group>
<article-title>The diagnostic and differential diagnosis utility of cerebrospinal fluid α-synuclein levels in Parkinson’s disease: a meta-analysis</article-title>. <source/>Parkinsons Dis. <year>2015</year>;<volume>2015</volume>;<fpage>567386</fpage>.<pub-id pub-id-type="pmid">26336612</pub-id></mixed-citation>
</ref>
<ref id="bibr171-1177271920950319">
<label>171.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hall</surname><given-names>S</given-names></name><name><surname>Öhrfelt</surname><given-names>A</given-names></name><name><surname>Constantinescu</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>
<article-title>Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders</article-title>. <source/>Arch Neurol. <year>2012</year>;<volume>69</volume>:<fpage>1445</fpage>-<lpage>1452</lpage>.<pub-id pub-id-type="pmid">22925882</pub-id></mixed-citation>
</ref>
<ref id="bibr172-1177271920950319">
<label>172.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tateno</surname><given-names>F</given-names></name><name><surname>Sakakibara</surname><given-names>R</given-names></name><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Kishi</surname><given-names>M</given-names></name><name><surname>Murano</surname><given-names>T.</given-names></name></person-group>
<article-title>Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease</article-title>. <source/>Alzheimer Dis Assoc Disord. <year>2012</year>;<volume>26</volume>:<fpage>213</fpage>-<lpage>216</lpage>.<pub-id pub-id-type="pmid">22037599</pub-id></mixed-citation>
</ref>
<ref id="bibr173-1177271920950319">
<label>173.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wennström</surname><given-names>M</given-names></name><name><surname>Surova</surname><given-names>Y</given-names></name><name><surname>Hall</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy</article-title>. <source/>PLoS ONE. <year>2013</year>;<volume>8</volume>:<fpage>e53250</fpage>.<pub-id pub-id-type="pmid">23308173</pub-id></mixed-citation>
</ref>
<ref id="bibr174-1177271920950319">
<label>174.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Majbour</surname><given-names>NK</given-names></name><name><surname>Chiasserini</surname><given-names>D</given-names></name><name><surname>Vaikath</surname><given-names>NN</given-names></name></person-group>, <etal>et al</etal>
<article-title>Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease</article-title>. <source/>Sci Rep. <year>2017</year>;<volume>7</volume>:<fpage>1</fpage>-<lpage>8</lpage>.<pub-id pub-id-type="pmid">28127051</pub-id></mixed-citation>
</ref>
<ref id="bibr175-1177271920950319">
<label>175.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z-Y</given-names></name><name><surname>Han</surname><given-names>Z-M</given-names></name><name><surname>Liu</surname><given-names>Q-F</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Ye</surname><given-names>K</given-names></name><name><surname>Yao</surname><given-names>Y-Y.</given-names></name></person-group>
<article-title>Use of CSF α-synuclein in the differential diagnosis between Alzheimer’s disease and other neurodegenerative disorders</article-title>. <source/>Int Psychogeriatr. <year>2015</year>;<volume>27</volume>:<fpage>1429</fpage>-<lpage>1438</lpage>.<pub-id pub-id-type="pmid">25851548</pub-id></mixed-citation>
</ref>
<ref id="bibr176-1177271920950319">
<label>176.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berge</surname><given-names>G</given-names></name><name><surname>Sando</surname><given-names>SB</given-names></name><name><surname>Albrektsen</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>
<article-title>Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer’s disease, mild cognitive impairment, or healthy controls: a two year follow-up study</article-title>. <source/>BMC Neurol. <year>2016</year>;<volume>16</volume>:<fpage>180</fpage>.<pub-id pub-id-type="pmid">27653987</pub-id></mixed-citation>
</ref>
<ref id="bibr177-1177271920950319">
<label>177.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kapaki</surname><given-names>E</given-names></name><name><surname>Paraskevas</surname><given-names>GP</given-names></name><name><surname>Emmanouilidou</surname><given-names>E</given-names></name><name><surname>Vekrellis</surname><given-names>K.</given-names></name></person-group>
<article-title>The diagnostic value of CSF α-synuclein in the differential diagnosis of dementia with Lewy bodies vs</article-title>. <source/>PLoS ONE. <year>2013</year>;<volume>8</volume>:<fpage>e81654</fpage>.<pub-id pub-id-type="pmid">24282614</pub-id></mixed-citation>
</ref>
<ref id="bibr178-1177271920950319">
<label>178.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Llorens</surname><given-names>F</given-names></name><name><surname>Kruse</surname><given-names>N</given-names></name><name><surname>Schmitz</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Evaluation of α-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases</article-title>. <source/>Alzheimers Dement. <year>2017</year>;<volume>13</volume>:<fpage>710</fpage>-<lpage>719</lpage>.<pub-id pub-id-type="pmid">27870938</pub-id></mixed-citation>
</ref>
<ref id="bibr179-1177271920950319">
<label>179.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Stewart</surname><given-names>T</given-names></name><name><surname>Toledo</surname><given-names>JB</given-names></name></person-group>, <etal>et al</etal>
<article-title>A longitudinal study of Total and phosphorylated α-Synuclein with other biomarkers in cerebrospinal fluid of Alzheimer’s disease and mild cognitive impairment</article-title>. <source/>J Alzheimers Dis. <year>2018</year>;<volume>61</volume>:<fpage>1541</fpage>-<lpage>1553</lpage>.<pub-id pub-id-type="pmid">29376878</pub-id></mixed-citation>
</ref>
<ref id="bibr180-1177271920950319">
<label>180.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Llorens</surname><given-names>F</given-names></name><name><surname>Kruse</surname><given-names>N</given-names></name><name><surname>Karch</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Validation of α-synuclein as a CSF biomarker for sporadic Creutzfeldt-Jakob disease</article-title>. <source/>Mol Neurobiol. <year>2018</year>;<volume>55</volume>:<fpage>2249</fpage>-<lpage>2257</lpage>.<pub-id pub-id-type="pmid">28321768</pub-id></mixed-citation>
</ref>
<ref id="bibr181-1177271920950319">
<label>181.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmitz</surname><given-names>M</given-names></name><name><surname>Villar-Piqué</surname><given-names>A</given-names></name><name><surname>Llorens</surname><given-names>F</given-names></name></person-group>, <etal>et al</etal>
<article-title>Cerebrospinal fluid total and phosphorylated α-synuclein in patients with Creutzfeldt–Jakob disease and synucleinopathy</article-title>. <source/>Mol Neurobiol. <year>2019</year>;<volume>56</volume>:<fpage>3476</fpage>-<lpage>3483</lpage>.<pub-id pub-id-type="pmid">30136097</pub-id></mixed-citation>
</ref>
<ref id="bibr182-1177271920950319">
<label>182.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Bowman</surname><given-names>FD</given-names></name><name><surname>Drake</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>
<article-title>Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid–method comparison and round robin study</article-title>. <source/>J Neurochem. <year>2019</year>;<volume>149</volume>:<fpage>126</fpage>-<lpage>138</lpage>.<pub-id pub-id-type="pmid">30125936</pub-id></mixed-citation>
</ref>
<ref id="bibr183-1177271920950319">
<label>183.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barbour</surname><given-names>R</given-names></name><name><surname>Kling</surname><given-names>K</given-names></name><name><surname>Anderson</surname><given-names>JP</given-names></name></person-group>, <etal>et al</etal>
<article-title>Red blood cells are the major source of alpha-synuclein in blood</article-title>. <source/>Neurodegener Dis. <year>2008</year>;<volume>5</volume>:<fpage>55</fpage>-<lpage>59</lpage>.<pub-id pub-id-type="pmid">18182779</pub-id></mixed-citation>
</ref>
<ref id="bibr184-1177271920950319">
<label>184.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barkovits</surname><given-names>K</given-names></name><name><surname>Kruse</surname><given-names>N</given-names></name><name><surname>Linden</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Blood contamination in CSF and its impact on quantitative analysis of alpha-synuclein</article-title>. <source/>Cells. <year>2020</year>;<volume>9</volume>:<fpage>370</fpage>.</mixed-citation>
</ref>
<ref id="bibr185-1177271920950319">
<label>185.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Foulds</surname><given-names>PG</given-names></name><name><surname>Diggle</surname><given-names>P</given-names></name><name><surname>Mitchell</surname><given-names>JD</given-names></name></person-group>, <etal>et al</etal>
<article-title>A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson’s disease</article-title>. <source/>Sci Rep. <year>2013</year>;<volume>3</volume>:<year>2540</year>.</mixed-citation>
</ref>
<ref id="bibr186-1177271920950319">
<label>186.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ishii</surname><given-names>R</given-names></name><name><surname>Tokuda</surname><given-names>T</given-names></name><name><surname>Tatebe</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>
<article-title>Decrease in plasma levels of α-synuclein is evident in patients with Parkinson’s disease after elimination of heterophilic antibody interference</article-title>. <source/>PLoS ONE. <year>2015</year>;<volume>10</volume>:<fpage>e0123162</fpage>.<pub-id pub-id-type="pmid">25849645</pub-id></mixed-citation>
</ref>
<ref id="bibr187-1177271920950319">
<label>187.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Malec-Litwinowicz</surname><given-names>M</given-names></name><name><surname>Plewka</surname><given-names>A</given-names></name><name><surname>Plewka</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>
<article-title>The relation between plasma α-synuclein level and clinical symptoms or signs of Parkinson’s disease</article-title>. <source/>Neurol I Neurochir Pol. <year>2018</year>;<volume>52</volume>:<fpage>243</fpage>-<lpage>251</lpage>.</mixed-citation>
</ref>
<ref id="bibr188-1177271920950319">
<label>188.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fan</surname><given-names>Z</given-names></name><name><surname>Pan</surname><given-names>Y-T</given-names></name><name><surname>Zhang</surname><given-names>Z-Y</given-names></name></person-group>, <etal>et al</etal>
<article-title>Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson’s disease</article-title>. <source/>J Neuroinflammation. <year>2020</year>;<volume>17</volume>:<fpage>11</fpage>.<pub-id pub-id-type="pmid">31915018</pub-id></mixed-citation>
</ref>
<ref id="bibr189-1177271920950319">
<label>189.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bougea</surname><given-names>A</given-names></name><name><surname>Stefanis</surname><given-names>L</given-names></name><name><surname>Paraskevas</surname><given-names>GP</given-names></name><name><surname>Emmanouilidou</surname><given-names>E</given-names></name><name><surname>Vekrelis</surname><given-names>K</given-names></name><name><surname>Kapaki</surname><given-names>E.</given-names></name></person-group>
<article-title>Plasma alpha-synuclein levels in patients with Parkinson’s disease: a systematic review and meta-analysis</article-title>. <source/>Neurol Sci. <year>2019</year>;<volume>40</volume>:<fpage>929</fpage>-<lpage>938</lpage>.<pub-id pub-id-type="pmid">30715632</pub-id></mixed-citation>
</ref>
<ref id="bibr190-1177271920950319">
<label>190.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Laske</surname><given-names>C</given-names></name><name><surname>Fallgatter</surname><given-names>AJ</given-names></name><name><surname>Stransky</surname><given-names>E</given-names></name><name><surname>Hagen</surname><given-names>K</given-names></name><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Maetzler</surname><given-names>W.</given-names></name></person-group>
<article-title>Decreased α-synuclein serum levels in patients with Lewy body dementia compared to Alzheimer’s disease patients and control subjects</article-title>. <source/>Dement Geriatr Cogn Disord. <year>2011</year>;<volume>31</volume>:<fpage>413</fpage>-<lpage>416</lpage>.<pub-id pub-id-type="pmid">21757905</pub-id></mixed-citation>
</ref>
<ref id="bibr191-1177271920950319">
<label>191.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abd-Elhadi</surname><given-names>S</given-names></name><name><surname>Honig</surname><given-names>A</given-names></name><name><surname>Simhi-Haham</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>
<article-title>Total and proteinase K-resistant α-synuclein levels in erythrocytes, determined by their ability to bind phospholipids, associate with Parkinson’s disease</article-title>. <source/>Sci Rep. <year>2015</year>;<volume>5</volume>:<fpage>11120</fpage>.<pub-id pub-id-type="pmid">26068055</pub-id></mixed-citation>
</ref>
<ref id="bibr192-1177271920950319">
<label>192.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baldacci</surname><given-names>F</given-names></name><name><surname>Daniele</surname><given-names>S</given-names></name><name><surname>Piccarducci</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>
<article-title>Potential diagnostic value of red blood cells α-synuclein heteroaggregates in Alzheimer’s disease</article-title>. <source/>Mol Neurobiol. <year>2019</year>;<volume>56</volume>:<fpage>6451</fpage>-<lpage>6459</lpage>.<pub-id pub-id-type="pmid">30826968</pub-id></mixed-citation>
</ref>
<ref id="bibr193-1177271920950319">
<label>193.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Daniele</surname><given-names>S</given-names></name><name><surname>Frosini</surname><given-names>D</given-names></name><name><surname>Pietrobono</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>
<article-title>α-synuclein heterocomplexes with β-amyloid are increased in red blood cells of Parkinson’s disease patients and correlate with disease severity</article-title>. <source/>Front Mol Neurosci. <year>2018</year>;<volume>11</volume>:<fpage>53</fpage>.<pub-id pub-id-type="pmid">29520218</pub-id></mixed-citation>
</ref>
<ref id="bibr194-1177271920950319">
<label>194.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kang</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name></person-group>, <etal>et al</etal>
<article-title>Salivary total α-synuclein, oligomeric α-synuclein and SNCA variants in Parkinson’s disease patients</article-title>. <source/>Sci Rep. <year>2016</year>;<volume>6</volume>:<fpage>28143</fpage>.<pub-id pub-id-type="pmid">27335051</pub-id></mixed-citation>
</ref>
<ref id="bibr195-1177271920950319">
<label>195.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Devic</surname><given-names>I</given-names></name><name><surname>Hwang</surname><given-names>H</given-names></name><name><surname>Edgar</surname><given-names>JS</given-names></name></person-group>, <etal>et al</etal>
<article-title>Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson’s disease</article-title>. <source/>Brain. <year>2011</year>;<volume>134</volume>:<fpage>e178</fpage>-<lpage>e178</lpage>.<pub-id pub-id-type="pmid">21349902</pub-id></mixed-citation>
</ref>
<ref id="bibr196-1177271920950319">
<label>196.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vivacqua</surname><given-names>G</given-names></name><name><surname>Suppa</surname><given-names>A</given-names></name><name><surname>Mancinelli</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>
<article-title>Salivary alpha-synuclein in the diagnosis of Parkinson’s disease and progressive supranuclear palsy</article-title>. <source/>Parkinsonism Relat Disord. <year>2019</year>;<volume>63</volume>:<fpage>143</fpage>-<lpage>148</lpage>.<pub-id pub-id-type="pmid">30796010</pub-id></mixed-citation>
</ref>
<ref id="bibr197-1177271920950319">
<label>197.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Hall</surname><given-names>S</given-names></name><name><surname>Ohrfelt</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease</article-title>. <source/>Alzheimers Res Ther. <year>2014</year>;<volume>6</volume>:<fpage>25</fpage>.<pub-id pub-id-type="pmid">24987465</pub-id></mixed-citation>
</ref>
<ref id="bibr198-1177271920950319">
<label>198.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parnetti</surname><given-names>L</given-names></name><name><surname>Chiasserini</surname><given-names>D</given-names></name><name><surname>Persichetti</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>
<article-title>Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson’s disease</article-title>. <source/>Mov Disord. <year>2014</year>;<volume>29</volume>:<fpage>1019</fpage>-<lpage>1027</lpage>.<pub-id pub-id-type="pmid">24436092</pub-id></mixed-citation>
</ref>
<ref id="bibr199-1177271920950319">
<label>199.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>El-Agnaf</surname><given-names>OM</given-names></name><name><surname>Salem</surname><given-names>SA</given-names></name><name><surname>Paleologou</surname><given-names>KE</given-names></name></person-group>, <etal>et al</etal>
<article-title>Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease</article-title>. <source/>FASEB J. <year>2006</year>;<volume>20</volume>:<fpage>419</fpage>-<lpage>425</lpage>.<pub-id pub-id-type="pmid">16507759</pub-id></mixed-citation>
</ref>
<ref id="bibr200-1177271920950319">
<label>200.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Williams</surname><given-names>SM</given-names></name><name><surname>Schulz</surname><given-names>P</given-names></name><name><surname>Sierks</surname><given-names>MR.</given-names></name></person-group>
<article-title>Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson’s and Alzheimer’s diseases</article-title>. <source/>Eur J Neurosci. <year>2016</year>;<volume>43</volume>:<fpage>3</fpage>-<lpage>16</lpage>.<pub-id pub-id-type="pmid">26332448</pub-id></mixed-citation>
</ref>
<ref id="bibr201-1177271920950319">
<label>201.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Feng</surname><given-names>T.</given-names></name></person-group>
<article-title>Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson’s disease</article-title>. <source/>Neurosc Lett. <year>2015</year>;<volume>599</volume>:<fpage>115</fpage>-<lpage>119</lpage>.</mixed-citation>
</ref>
<ref id="bibr202-1177271920950319">
<label>202.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pchelina</surname><given-names>S</given-names></name><name><surname>Emelyanov</surname><given-names>A</given-names></name><name><surname>Baydakova</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>
<article-title>Oligomeric α-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson’s disease</article-title>. <source/>Neurosci Lett. <year>2017</year>;<volume>636</volume>:<fpage>70</fpage>-<lpage>76</lpage>.<pub-id pub-id-type="pmid">27780739</pub-id></mixed-citation>
</ref>
<ref id="bibr203-1177271920950319">
<label>203.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Foulds</surname><given-names>PG</given-names></name><name><surname>Mitchell</surname><given-names>JD</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson’s disease</article-title>. <source/>FASEB J. <year>2011</year>;<volume>25</volume>:<fpage>4127</fpage>-<lpage>4137</lpage>.<pub-id pub-id-type="pmid">21865317</pub-id></mixed-citation>
</ref>
<ref id="bibr204-1177271920950319">
<label>204.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>MJ</given-names></name><name><surname>Cheon</surname><given-names>S-M</given-names></name><name><surname>Bae</surname><given-names>H-R</given-names></name><name><surname>Kim</surname><given-names>S-H</given-names></name><name><surname>Kim</surname><given-names>JW.</given-names></name></person-group>
<article-title>Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson’s disease</article-title>. <source/>J Clin Neurol. <year>2011</year>;<volume>7</volume>:<fpage>215</fpage>-<lpage>222</lpage>.<pub-id pub-id-type="pmid">22259618</pub-id></mixed-citation>
</ref>
<ref id="bibr205-1177271920950319">
<label>205.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vivacqua</surname><given-names>G</given-names></name><name><surname>Latorre</surname><given-names>A</given-names></name><name><surname>Suppa</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Abnormal salivary total and oligomeric alpha-synuclein in Parkinson’s disease</article-title>. <source/>PLoS ONE. <year>2016</year>;<volume>11</volume>:<fpage>e0151156</fpage>.<pub-id pub-id-type="pmid">27011009</pub-id></mixed-citation>
</ref>
<ref id="bibr206-1177271920950319">
<label>206.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fujiwara</surname><given-names>H</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Dohmae</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal>
<article-title>alpha-Synuclein is phosphorylated in synucleinopathy lesions</article-title>. <source/>Nat Cell Biol. <year>2002</year>;<volume>4</volume>:<fpage>160</fpage>-<lpage>164</lpage>.<pub-id pub-id-type="pmid">11813001</pub-id></mixed-citation>
</ref>
<ref id="bibr207-1177271920950319">
<label>207.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Majbour</surname><given-names>NK</given-names></name><name><surname>Vaikath</surname><given-names>NN</given-names></name><name><surname>van Dijk</surname><given-names>KD</given-names></name></person-group>, <etal>et al</etal>
<article-title>Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease</article-title>. <source/>Mol Neurodegener. <year>2016</year>;<volume>11</volume>:<fpage>7</fpage>.<pub-id pub-id-type="pmid">26782965</pub-id></mixed-citation>
</ref>
<ref id="bibr208-1177271920950319">
<label>208.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shahnawaz</surname><given-names>M</given-names></name><name><surname>Tokuda</surname><given-names>T</given-names></name><name><surname>Waragai</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Development of a biochemical diagnosis of Parkinson disease by detection of α-synuclein misfolded aggregates in cerebrospinal fluid</article-title>. <source/>JAMA Neurol. <year>2017</year>;<volume>74</volume>:<fpage>163</fpage>-<lpage>172</lpage>.<pub-id pub-id-type="pmid">27918765</pub-id></mixed-citation>
</ref>
<ref id="bibr209-1177271920950319">
<label>209.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Groveman</surname><given-names>BR</given-names></name><name><surname>Orrù</surname><given-names>CD</given-names></name><name><surname>Hughson</surname><given-names>AG</given-names></name></person-group>, <etal>et al</etal>
<article-title>Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC</article-title>. <source/>Acta Neuropathol Commun. <year>2018</year>;<volume>6</volume>:<fpage>7</fpage>.<pub-id pub-id-type="pmid">29422107</pub-id></mixed-citation>
</ref>
<ref id="bibr210-1177271920950319">
<label>210.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fairfoul</surname><given-names>G</given-names></name><name><surname>McGuire</surname><given-names>LI</given-names></name><name><surname>Pal</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Alpha-synuclein RT-Qu IC in the CSF of patients with alpha-synucleinopathies</article-title>. <source/>Ann Clin Transl Neurol. <year>2016</year>;<volume>3</volume>:<fpage>812</fpage>-<lpage>818</lpage>.<pub-id pub-id-type="pmid">27752516</pub-id></mixed-citation>
</ref>
<ref id="bibr211-1177271920950319">
<label>211.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Represa</surname><given-names>A</given-names></name><name><surname>Deloulme</surname><given-names>JC</given-names></name><name><surname>Sensenbrenner</surname><given-names>M</given-names></name><name><surname>Ben-Ari</surname><given-names>Y</given-names></name><name><surname>Baudier</surname><given-names>J.</given-names></name></person-group>
<article-title>Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate</article-title>. <source/>J Neurosci. <year>1990</year>;<volume>10</volume>:<fpage>3782</fpage>-<lpage>3792</lpage>.<pub-id pub-id-type="pmid">2269883</pub-id></mixed-citation>
</ref>
<ref id="bibr212-1177271920950319">
<label>212.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gerendasy</surname><given-names>DD</given-names></name><name><surname>Sutcliffe</surname><given-names>JG.</given-names></name></person-group>
<article-title>RC3/neurogranin, a postsynaptic calpacitin for setting the response threshold to calcium influxes</article-title>. <source/>Mol Neurobiol. <year>1997</year>;<volume>15</volume>:<fpage>131</fpage>-<lpage>163</lpage>.<pub-id pub-id-type="pmid">9396008</pub-id></mixed-citation>
</ref>
<ref id="bibr213-1177271920950319">
<label>213.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prichard</surname><given-names>L</given-names></name><name><surname>Deloulme</surname><given-names>JC</given-names></name><name><surname>Storm</surname><given-names>DR.</given-names></name></person-group>
<article-title>Interactions between neurogranin and calmodulin in vivo</article-title>. <source/>J Biol Chem. <year>1999</year>;<volume>274</volume>:<fpage>7689</fpage>-<lpage>7694</lpage>.<pub-id pub-id-type="pmid">10075657</pub-id></mixed-citation>
</ref>
<ref id="bibr214-1177271920950319">
<label>214.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Domínguez-González</surname><given-names>I</given-names></name><name><surname>Vázquez-Cuesta</surname><given-names>SN</given-names></name><name><surname>Algaba</surname><given-names>A</given-names></name><name><surname>Díez-Guerra</surname><given-names>FJ.</given-names></name></person-group>
<article-title>Neurogranin binds to phosphatidic acid and associates to cellular membranes</article-title>. <source/>Biochem J. <year>2007</year>;<volume>404</volume>:<fpage>31</fpage>-<lpage>43</lpage>.<pub-id pub-id-type="pmid">17295609</pub-id></mixed-citation>
</ref>
<ref id="bibr215-1177271920950319">
<label>215.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>K-P</given-names></name><name><surname>Huang</surname><given-names>FL</given-names></name><name><surname>Jäger</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Reymann</surname><given-names>KG</given-names></name><name><surname>Balschun</surname><given-names>D.</given-names></name></person-group>
<article-title>Neurogranin/RC3 enhances long-term potentiation and learning by promoting calcium-mediated signaling</article-title>. <source/>J Neurosci. <year>2004</year>;<volume>24</volume>:<fpage>10660</fpage>-<lpage>10669</lpage>.<pub-id pub-id-type="pmid">15564582</pub-id></mixed-citation>
</ref>
<ref id="bibr216-1177271920950319">
<label>216.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thorsell</surname><given-names>A</given-names></name><name><surname>Bjerke</surname><given-names>M</given-names></name><name><surname>Gobom</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer’s disease</article-title>. <source/>Brain Res. <year>2010</year>;<volume>1362</volume>:<fpage>13</fpage>-<lpage>22</lpage>.<pub-id pub-id-type="pmid">20875798</pub-id></mixed-citation>
</ref>
<ref id="bibr217-1177271920950319">
<label>217.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kvartsberg</surname><given-names>H</given-names></name><name><surname>Duits</surname><given-names>FH</given-names></name><name><surname>Ingelsson</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer’s disease</article-title>. <source/>Alzheimers Dement. <year>2014</year>;<volume>11</volume>:<fpage>1180</fpage>-<lpage>1190</lpage>.<pub-id pub-id-type="pmid">25533203</pub-id></mixed-citation>
</ref>
<ref id="bibr218-1177271920950319">
<label>218.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kester</surname><given-names>MI</given-names></name><name><surname>Teunissen</surname><given-names>CE</given-names></name><name><surname>Crimmins</surname><given-names>DL</given-names></name></person-group>, <etal>et al</etal>
<article-title>Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease</article-title>. <source/>JAMA Neurol. <year>2015</year>;<volume>72</volume>:<fpage>1275</fpage>-<lpage>1280</lpage>.<pub-id pub-id-type="pmid">26366630</pub-id></mixed-citation>
</ref>
<ref id="bibr219-1177271920950319">
<label>219.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Skillbäck</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>
<article-title>Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease</article-title>. <source/>Brain. <year>2015</year>;<volume>138</volume>:<fpage>3373</fpage>-<lpage>3385</lpage>.<pub-id pub-id-type="pmid">26373605</pub-id></mixed-citation>
</ref>
<ref id="bibr220-1177271920950319">
<label>220.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Vos</surname><given-names>A</given-names></name><name><surname>Jacobs</surname><given-names>D</given-names></name><name><surname>Struyfs</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>
<article-title>C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer’s disease</article-title>. <source/>Alzheimers Dement. <year>2015</year>;<volume>11</volume>:<fpage>1461</fpage>-<lpage>1469</lpage>.<pub-id pub-id-type="pmid">26092348</pub-id></mixed-citation>
</ref>
<ref id="bibr221-1177271920950319">
<label>221.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tarawneh</surname><given-names>R</given-names></name><name><surname>D’Angelo</surname><given-names>G</given-names></name><name><surname>Crimmins</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>
<article-title>Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease</article-title>. <source/>JAMA Neurol. <year>2016</year>;<volume>73</volume>:<fpage>561</fpage>-<lpage>571</lpage>.<pub-id pub-id-type="pmid">27018940</pub-id></mixed-citation>
</ref>
<ref id="bibr222-1177271920950319">
<label>222.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sanfilippo</surname><given-names>C</given-names></name><name><surname>Forlenza</surname><given-names>O</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Blennow</surname><given-names>K.</given-names></name></person-group>
<article-title>Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer’s disease and in mild cognitive impairment due to AD</article-title>. <source/>J Neural Transm (Vienna). <year>2016</year>;<volume>123</volume>:<fpage>1443</fpage>-<lpage>1447</lpage>.<pub-id pub-id-type="pmid">27531278</pub-id></mixed-citation>
</ref>
<ref id="bibr223-1177271920950319">
<label>223.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lista</surname><given-names>S</given-names></name><name><surname>Toschi</surname><given-names>N</given-names></name><name><surname>Baldacci</surname><given-names>F</given-names></name></person-group>, <etal>et al</etal>
<article-title>Cerebrospinal fluid neurogranin as a biomarker of neurodegenerative diseases: a cross-sectional study</article-title>. <source/>J Alzheimers Dis. <year>2017</year>;<volume>59</volume>:<fpage>1327</fpage>-<lpage>1334</lpage>.<pub-id pub-id-type="pmid">28731449</pub-id></mixed-citation>
</ref>
<ref id="bibr224-1177271920950319">
<label>224.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sutphen</surname><given-names>CL</given-names></name><name><surname>McCue</surname><given-names>L</given-names></name><name><surname>Herries</surname><given-names>EM</given-names></name></person-group>, <etal>et al</etal>
<article-title>Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer’s disease</article-title>. <source/>Alzheimers Dement. <year>2018</year>;<volume>14</volume>:<fpage>869</fpage>-<lpage>879</lpage>.<pub-id pub-id-type="pmid">29580670</pub-id></mixed-citation>
</ref>
<ref id="bibr225-1177271920950319">
<label>225.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Diaz-Lucena</surname><given-names>D</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>
<article-title>CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD</article-title>. <source/>J Neurol Neurosurg Psychiatry. <year>2019</year>;<volume>90</volume>:<fpage>846</fpage>-<lpage>853</lpage>.<pub-id pub-id-type="pmid">31097472</pub-id></mixed-citation>
</ref>
<ref id="bibr226-1177271920950319">
<label>226.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wellington</surname><given-names>H</given-names></name><name><surname>Paterson</surname><given-names>RW</given-names></name><name><surname>Portelius</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>
<article-title>Increased CSF neurogranin concentration is specific to Alzheimer disease</article-title>. <source/>Neurology. <year>2016</year>;<volume>86</volume>:<fpage>829</fpage>-<lpage>835</lpage>.<pub-id pub-id-type="pmid">26826204</pub-id></mixed-citation>
</ref>
<ref id="bibr227-1177271920950319">
<label>227.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Olsson</surname><given-names>B</given-names></name><name><surname>Höglund</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>
<article-title>Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology</article-title>. <source/>Acta Neuropathol. <year>2018</year>;<volume>136</volume>:<fpage>363</fpage>-<lpage>376</lpage>.<pub-id pub-id-type="pmid">29700597</pub-id></mixed-citation>
</ref>
<ref id="bibr228-1177271920950319">
<label>228.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Becker</surname><given-names>B</given-names></name><name><surname>Nazir</surname><given-names>FH</given-names></name><name><surname>Brinkmalm</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>
<article-title>Alzheimer-associated cerebrospinal fluid fragments of neurogranin are generated by Calpain-1 and prolyl endopeptidase</article-title>. <source/>Molecular Neurodegeneration. <year>2018</year>;<volume>13</volume>:<fpage>1</fpage>-<lpage>12</lpage>.<pub-id pub-id-type="pmid">29310663</pub-id></mixed-citation>
</ref>
<ref id="bibr229-1177271920950319">
<label>229.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Willemse</surname><given-names>EAJ</given-names></name><name><surname>De Vos</surname><given-names>A</given-names></name><name><surname>Herries</surname><given-names>EM</given-names></name></person-group>, <etal>et al</etal>
<article-title>Neurogranin as cerebrospinal fluid biomarker for Alzheimer disease: an assay comparison study</article-title>. <source/>Clin Chem. <year>2018</year>;<volume>64</volume>:<fpage>927</fpage>-<lpage>937</lpage>.<pub-id pub-id-type="pmid">29523639</pub-id></mixed-citation>
</ref>
<ref id="bibr230-1177271920950319">
<label>230.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wesenhagen</surname><given-names>KEJ</given-names></name><name><surname>Teunissen</surname><given-names>CE</given-names></name><name><surname>Visser</surname><given-names>PJ</given-names></name><name><surname>Tijms</surname><given-names>BM</given-names></name></person-group>
<article-title>Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer’s disease: a literature review</article-title>. <source/>Crit Rev Clin Lab Sci. <year>2020</year>;<volume>57</volume>:<fpage>86</fpage>-<lpage>98</lpage>.<pub-id pub-id-type="pmid">31694431</pub-id></mixed-citation>
</ref>
<ref id="bibr231-1177271920950319">
<label>231.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brinkmalm</surname><given-names>G</given-names></name><name><surname>Sjodin</surname><given-names>S</given-names></name><name><surname>Simonsen</surname><given-names>AH</given-names></name></person-group>, <etal>et al</etal>
<article-title>A parallel reaction monitoring mass spectrometric method for analysis of potential CSF biomarkers for Alzheimer’s disease</article-title>. <source/>Proteomics Clin Appl. <year>2018</year>;<volume>12</volume>. doi:<pub-id pub-id-type="doi">10.1002/prca.201700131.</pub-id></mixed-citation>
</ref>
<ref id="bibr232-1177271920950319">
<label>232.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lleó</surname><given-names>A</given-names></name><name><surname>Núñez-Llaves</surname><given-names>R</given-names></name><name><surname>Alcolea</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>
<article-title>Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer’s disease cerebrospinal fluid</article-title>. <source/>Mol Cell Proteomics. <year>2019</year>;<volume>18</volume>:<fpage>546</fpage>-<lpage>560</lpage>.<pub-id pub-id-type="pmid">30606734</pub-id></mixed-citation>
</ref>
<ref id="bibr233-1177271920950319">
<label>233.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Hopf</surname><given-names>C</given-names></name><name><surname>Reddy</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>
<article-title>Narp and NP1 form heterocomplexes that function in developmental and activity-dependent synaptic plasticity</article-title>. <source/>Neuron. <year>2003</year>;<volume>39</volume>:<fpage>513</fpage>-<lpage>528</lpage>.<pub-id pub-id-type="pmid">12895424</pub-id></mixed-citation>
</ref>
<ref id="bibr234-1177271920950319">
<label>234.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>S-J</given-names></name><name><surname>Wei</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>
<article-title>Presynaptic neuronal pentraxin receptor organizes excitatory and inhibitory synapses</article-title>. <source/>J Neurosci. <year>2017</year>;<volume>37</volume>:<fpage>1062</fpage>-<lpage>1080</lpage>.<pub-id pub-id-type="pmid">27986928</pub-id></mixed-citation>
</ref>
<ref id="bibr235-1177271920950319">
<label>235.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soldan</surname><given-names>A</given-names></name><name><surname>Moghekar</surname><given-names>A</given-names></name><name><surname>Walker</surname><given-names>KA</given-names></name></person-group>, <etal>et al</etal>
<article-title>Resting-state functional connectivity is associated with cerebrospinal fluid levels of the synaptic protein NPTX2 in non-demented older adults</article-title>. <source/>Front Aging Neurosci. <year>2019</year>;<volume>11</volume>:<fpage>132</fpage>.<pub-id pub-id-type="pmid">31231205</pub-id></mixed-citation>
</ref>
<ref id="bibr236-1177271920950319">
<label>236.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spellman</surname><given-names>DS</given-names></name><name><surname>Wildsmith</surname><given-names>KR</given-names></name><name><surname>Honigberg</surname><given-names>LA</given-names></name></person-group>, <etal>et al</etal>
<article-title>Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer’s Disease Neuroimaging Initiative (ADNI) CSF</article-title>. <source/>Proteomics Clin Appl. <year>2015</year>;<volume>9</volume>:<fpage>715</fpage>-<lpage>731</lpage>.<pub-id pub-id-type="pmid">25676562</pub-id></mixed-citation>
</ref>
<ref id="bibr237-1177271920950319">
<label>237.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Begcevic</surname><given-names>I</given-names></name><name><surname>Tsolaki</surname><given-names>M</given-names></name><name><surname>Brinc</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>
<article-title>Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer’s disease progression</article-title>. <source/>F1000Res. <year>2018</year>;<volume>7</volume>:<year>1012</year>.</mixed-citation>
</ref>
<ref id="bibr238-1177271920950319">
<label>238.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wildsmith</surname><given-names>KR</given-names></name><name><surname>Schauer</surname><given-names>SP</given-names></name><name><surname>Smith</surname><given-names>AM</given-names></name></person-group>, <etal>et al</etal>
<article-title>Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics</article-title>. <source/>Mol Neurodegener. <year>2014</year>;<volume>9</volume>:<fpage>22</fpage>.<pub-id pub-id-type="pmid">24902845</pub-id></mixed-citation>
</ref>
<ref id="bibr239-1177271920950319">
<label>239.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Llano</surname><given-names>DA</given-names></name><name><surname>Bundela</surname><given-names>S</given-names></name><name><surname>Mudar</surname><given-names>RA</given-names></name><name><surname>Devanarayan</surname><given-names>V</given-names></name></person-group>, <collab>Alzheimer’s Disease Neuroimaging Initiative (ADNI)</collab>. <article-title>A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer’s disease state classification and for predicting future disease progression</article-title>. <source/>PLoS ONE. <year>2017</year>;<volume>12</volume>:<fpage>e0182098</fpage>.<pub-id pub-id-type="pmid">28771542</pub-id></mixed-citation>
</ref>
<ref id="bibr240-1177271920950319">
<label>240.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lim</surname><given-names>B</given-names></name><name><surname>Tsolaki</surname><given-names>M</given-names></name><name><surname>Soosaipillai</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer’s disease</article-title>. <source/>Clin Chem Lab Med. <year>2019</year>;<volume>57</volume>:<fpage>1875</fpage>-<lpage>1881</lpage>.<pub-id pub-id-type="pmid">31415236</pub-id></mixed-citation>
</ref>
<ref id="bibr241-1177271920950319">
<label>241.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lim</surname><given-names>B</given-names></name><name><surname>Sando</surname><given-names>SB</given-names></name><name><surname>Grøntvedt</surname><given-names>GR</given-names></name><name><surname>Bråthen</surname><given-names>G</given-names></name><name><surname>Diamandis</surname><given-names>EP.</given-names></name></person-group>
<article-title>Cerebrospinal fluid neuronal pentraxin receptor as a biomarker of long-term progression of Alzheimer’s disease: a 24-month follow-up study</article-title>. <source/>Neurobiol Aging. <year>2020</year>;<volume>93</volume>:97.e1-<volume>97</volume><fpage>e7</fpage>.</mixed-citation>
</ref>
<ref id="bibr242-1177271920950319">
<label>242.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xiao</surname><given-names>MF</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Craig</surname><given-names>MT</given-names></name></person-group>, <etal>et al</etal>
<article-title>NPTX2 and cognitive dysfunction in Alzheimer’s disease</article-title>. <source/>eLife. <year>2017</year>;<volume>6</volume>:<fpage>e23798</fpage>.<pub-id pub-id-type="pmid">28440221</pub-id></mixed-citation>
</ref>
<ref id="bibr243-1177271920950319">
<label>243.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Swanson</surname><given-names>A</given-names></name><name><surname>Willette</surname><given-names>AA</given-names></name></person-group>, <collab>Alzheimer’s Disease Neuroimaging Initiative</collab>. <article-title>Neuronal Pentraxin 2 predicts medial temporal atrophy and memory decline across the Alzheimer’s disease spectrum</article-title>. <source/>Brain Behav Immun. <year>2016</year>;<volume>58</volume>:<fpage>201</fpage>-<lpage>208</lpage>.<pub-id pub-id-type="pmid">27444967</pub-id></mixed-citation>
</ref>
<ref id="bibr244-1177271920950319">
<label>244.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kroksveen</surname><given-names>A</given-names></name><name><surname>Guldbrandsen</surname><given-names>A</given-names></name><name><surname>Vedeler</surname><given-names>C</given-names></name><name><surname>Myhr</surname><given-names>K</given-names></name><name><surname>Opsahl</surname><given-names>J</given-names></name><name><surname>Berven</surname><given-names>F.</given-names></name></person-group>
<article-title>Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls</article-title>. <source/>Acta Neurol Scand Suppl. <year>2012</year>;<volume>195</volume>:<fpage>90</fpage>-<lpage>96</lpage>.</mixed-citation>
</ref>
<ref id="bibr245-1177271920950319">
<label>245.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van der Ende</surname><given-names>EL</given-names></name><name><surname>Meeter</surname><given-names>LH</given-names></name><name><surname>Stingl</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>
<article-title>Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics</article-title>. <source/>Ann Clin Transl Neurol. <year>2019</year>;<volume>6</volume>:<fpage>698</fpage>-<lpage>707</lpage>.<pub-id pub-id-type="pmid">31019994</pub-id></mixed-citation>
</ref>
<ref id="bibr246-1177271920950319">
<label>246.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Magdalinou</surname><given-names>N</given-names></name><name><surname>Noyce</surname><given-names>A</given-names></name><name><surname>Pinto</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>
<article-title>Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics</article-title>. <source/>Parkinsonism Relat Disord. <year>2017</year>;<volume>37</volume>:<fpage>65</fpage>-<lpage>71</lpage>.<pub-id pub-id-type="pmid">28214264</pub-id></mixed-citation>
</ref>
<ref id="bibr247-1177271920950319">
<label>247.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Finnema</surname><given-names>SJ</given-names></name><name><surname>Nabulsi</surname><given-names>NB</given-names></name><name><surname>Eid</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>
<article-title>Imaging synaptic density in the living human brain</article-title>. <source/>Sci Transl Med. <year>2016</year>;<volume>8</volume>:<fpage>348ra96</fpage>.</mixed-citation>
</ref>
<ref id="bibr248-1177271920950319">
<label>248.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bartholome</surname><given-names>O</given-names></name><name><surname>Van den Ackerveken</surname><given-names>P</given-names></name><name><surname>SÃ¡nchez Gil</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Puzzling out synaptic vesicle 2 family members functions</article-title>. <source/>Front Mol Neurosci. <year>2017</year>;<volume>10</volume>:<fpage>148</fpage>.<pub-id pub-id-type="pmid">28588450</pub-id></mixed-citation>
</ref>
<ref id="bibr249-1177271920950319">
<label>249.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>D’Alessandro</surname><given-names>R</given-names></name><name><surname>Meldolesi</surname><given-names>J.</given-names></name></person-group>
<article-title>Expression and function of the dense-core vesicle membranes are governed by the transcription repressor REST</article-title>. <source/>FEBS Lett. <year>2013</year>;<volume>587</volume>:<fpage>1915</fpage>-<lpage>1922</lpage>.<pub-id pub-id-type="pmid">23651552</pub-id></mixed-citation>
</ref>
<ref id="bibr250-1177271920950319">
<label>250.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tanner</surname><given-names>VA</given-names></name><name><surname>Ploug</surname><given-names>T</given-names></name><name><surname>Tao-Cheng</surname><given-names>JH.</given-names></name></person-group>
<article-title>Subcellular localization of SV2 and other secretory vesicle components in PC12 cells by an efficient method of preembedding EM immunocytochemistry for cell cultures</article-title>. <source/>J Histochem Cytochem. <year>1996</year>;<volume>44</volume>:<fpage>1481</fpage>-<lpage>1488</lpage>.<pub-id pub-id-type="pmid">8985140</pub-id></mixed-citation>
</ref>
<ref id="bibr251-1177271920950319">
<label>251.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bajjalieh</surname><given-names>SM</given-names></name><name><surname>Frantz</surname><given-names>GD</given-names></name><name><surname>Weimann</surname><given-names>JM</given-names></name><name><surname>Mcconnell</surname><given-names>SK</given-names></name><name><surname>Scheller</surname><given-names>RH.</given-names></name></person-group>
<article-title>Differential expression of synaptic vesicle protein 2 (SV2) isoforms</article-title>. <source/>J Neuro. <year>1994</year>;<volume>14</volume>:<fpage>5223</fpage>-<lpage>5235</lpage>.</mixed-citation>
</ref>
<ref id="bibr252-1177271920950319">
<label>252.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Crowder</surname><given-names>KM</given-names></name><name><surname>Gunther</surname><given-names>JM</given-names></name><name><surname>Jones</surname><given-names>TA</given-names></name></person-group>, <etal>et al</etal>
<article-title>Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)</article-title>. <source/>Proc Natl Acad U S A. <year>1999</year>;<volume>96</volume>:<fpage>15268</fpage>-<lpage>15273</lpage>.</mixed-citation>
</ref>
<ref id="bibr253-1177271920950319">
<label>253.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nowack</surname><given-names>A</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Custer</surname><given-names>KL</given-names></name><name><surname>Bajjalieh</surname><given-names>SM.</given-names></name></person-group>
<article-title>SV2 regulates neurotransmitter release via multiple mechanisms</article-title>. <source/>Am J Physiol Cell Physiol. <year>2010</year>;<volume>299</volume>:<fpage>C960</fpage>-<lpage>C967</lpage>.<pub-id pub-id-type="pmid">20702688</pub-id></mixed-citation>
</ref>
<ref id="bibr254-1177271920950319">
<label>254.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Nowack</surname><given-names>A</given-names></name><name><surname>Kensel-Hammes</surname><given-names>P</given-names></name><name><surname>Gardner</surname><given-names>RG</given-names></name><name><surname>Bajjalieh</surname><given-names>SM.</given-names></name></person-group>
<article-title>Cotrafficking of SV2 and synaptotagmin at the synapse</article-title>. <source/>J Neurosci. <year>2010</year>;<volume>30</volume>:<fpage>5569</fpage>-<lpage>5578</lpage>.<pub-id pub-id-type="pmid">20410110</pub-id></mixed-citation>
</ref>
<ref id="bibr255-1177271920950319">
<label>255.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>M-K</given-names></name><name><surname>Mecca</surname><given-names>AP</given-names></name><name><surname>Naganawa</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging</article-title>. <source/>JAMA Neurol. <year>2018</year>;<volume>75</volume>:<fpage>1215</fpage>-<lpage>1224</lpage>.<pub-id pub-id-type="pmid">30014145</pub-id></mixed-citation>
</ref>
<ref id="bibr256-1177271920950319">
<label>256.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Robinson</surname><given-names>JL</given-names></name><name><surname>Molina-Porcel</surname><given-names>L</given-names></name><name><surname>Corrada</surname><given-names>MM</given-names></name></person-group>, <etal>et al</etal>
<article-title>Perforant path synaptic loss correlates with cognitive impairment and Alzheimer’s disease in the oldest-old</article-title>. <source/>Brain. <year>2014</year>;<volume>137</volume>:<fpage>2578</fpage>-<lpage>2587</lpage>.<pub-id pub-id-type="pmid">25012223</pub-id></mixed-citation>
</ref>
<ref id="bibr257-1177271920950319">
<label>257.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matuskey</surname><given-names>D</given-names></name><name><surname>Tinaz</surname><given-names>S</given-names></name><name><surname>Wilcox</surname><given-names>KC</given-names></name></person-group>, <etal>et al</etal>
<article-title>Synaptic changes in Parkinson disease assessed with in vivo imaging</article-title>. <source/>Ann Neurol. <year>2020</year>;<volume>87</volume>:<fpage>329</fpage>-<lpage>338</lpage>.<pub-id pub-id-type="pmid">31953875</pub-id></mixed-citation>
</ref>
<ref id="bibr258-1177271920950319">
<label>258.</label>
<mixed-citation publication-type="web">
<person-group person-group-type="author"><name><surname>Holland</surname><given-names>N</given-names></name><name><surname>Jones</surname><given-names>PS</given-names></name><name><surname>Savulich</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>
<article-title>Reduced synaptic density in progressive supranuclear palsy and corticobasal syndrome, revealed by [11C] UCB-J PET</article-title>. <source/>medrxiv. <year>2020</year>
<ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2020.01.24.20018697v2">https://www.medrxiv.org/content/10.1101/2020.01.24.20018697v2</ext-link>.</mixed-citation>
</ref>
<ref id="bibr259-1177271920950319">
<label>259.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ashton</surname><given-names>NJ</given-names></name><name><surname>Höglund</surname><given-names>K</given-names></name><name><surname>Leuzy</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Cerebrospinal fluid synaptic vesicle glycoprotein 2A in Alzheimer's disease</article-title>. <source/>Alzheimers Dement. <year>2019</year>;<volume>15</volume>:<fpage>P545</fpage>.</mixed-citation>
</ref>
<ref id="bibr260-1177271920950319">
<label>260.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cho</surname><given-names>RW</given-names></name><name><surname>Park</surname><given-names>JM</given-names></name><name><surname>Wolff</surname><given-names>SB</given-names></name></person-group>, <etal>et al</etal>
<article-title>mGluR1/5-dependent long-term depression requires the regulated ectodomain cleavage of neuronal pentraxin NPR by TACE</article-title>. <source/>Neuron. <year>2008</year>;<volume>57</volume>:<fpage>858</fpage>-<lpage>871</lpage>.<pub-id pub-id-type="pmid">18367087</pub-id></mixed-citation>
</ref>
<ref id="bibr261-1177271920950319">
<label>261.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kadavath</surname><given-names>H</given-names></name><name><surname>Hofele</surname><given-names>RV</given-names></name><name><surname>Biernat</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Tau stabilizes microtubules by binding at the interface between tubulin heterodimers</article-title>. <source/>Proc Natl Acad Sci U S A. <year>2015</year>;<volume>112</volume>:<fpage>7501</fpage>-<lpage>7506</lpage>.<pub-id pub-id-type="pmid">26034266</pub-id></mixed-citation>
</ref>
<ref id="bibr262-1177271920950319">
<label>262.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Veleri</surname><given-names>S</given-names></name><name><surname>Punnakkal</surname><given-names>P</given-names></name><name><surname>Dunbar</surname><given-names>GL</given-names></name><name><surname>Maiti</surname><given-names>P.</given-names></name></person-group>
<article-title>Molecular insights into the roles of rab proteins in intracellular dynamics and neurodegenerative diseases</article-title>. <source/>Neuromolecular Med. <year>2018</year>;<volume>20</volume>:<fpage>18</fpage>-<lpage>36</lpage>.<pub-id pub-id-type="pmid">29423895</pub-id></mixed-citation>
</ref>
<ref id="bibr263-1177271920950319">
<label>263.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Laguerre</surname><given-names>F</given-names></name><name><surname>Anouar</surname><given-names>Y</given-names></name><name><surname>Montero-Hadjadje</surname><given-names>M.</given-names></name></person-group>
<article-title>Chromogranin A in the early steps of the neurosecretory pathway</article-title>. <source/>IUBMB Life. <year>2020</year>;<volume>72</volume>:<fpage>524</fpage>-<lpage>532</lpage>.<pub-id pub-id-type="pmid">31891241</pub-id></mixed-citation>
</ref>
<ref id="bibr264-1177271920950319">
<label>264.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Davidsson</surname><given-names>P</given-names></name><name><surname>Wallin</surname><given-names>A</given-names></name><name><surname>Ekman</surname><given-names>R.</given-names></name></person-group>
<article-title>Chromogranin A in cerebrospinal fluid: a biochemical marker for synaptic degeneration in Alzheimer’s disease</article-title>. <source/>Dementia. <year>1995</year>;<volume>6</volume>:<fpage>306</fpage>-<lpage>311</lpage>.<pub-id pub-id-type="pmid">8563783</pub-id></mixed-citation>
</ref>
<ref id="bibr265-1177271920950319">
<label>265.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>M</given-names></name><name><surname>Del Campo</surname><given-names>M</given-names></name><name><surname>Morrema</surname><given-names>THJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer’s disease</article-title>. <source/>Alzheimers Res Ther. <year>2018</year>;<volume>10</volume>:<fpage>52</fpage>.<pub-id pub-id-type="pmid">29859129</pub-id></mixed-citation>
</ref>
<ref id="bibr266-1177271920950319">
<label>266.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Galvin</surname><given-names>JE</given-names></name><name><surname>Uryu</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>VM-Y</given-names></name><name><surname>Trojanowski</surname><given-names>JQ.</given-names></name></person-group>
<article-title>Axon pathology in Parkinson’s disease and Lewy body dementia hippocampus contains α-, β-, and γ-synuclein</article-title>. <source/>Proc Natl Acad Sci U S A. <year>1999</year>;<volume>96</volume>:<fpage>13450</fpage>-<lpage>13455</lpage>.<pub-id pub-id-type="pmid">10557341</pub-id></mixed-citation>
</ref>
<ref id="bibr267-1177271920950319">
<label>267.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oeckl</surname><given-names>P</given-names></name><name><surname>Halbgebauer</surname><given-names>S</given-names></name><name><surname>Anderl-Straub</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Targeted mass spectrometry suggests beta-synuclein as synaptic blood marker in Alzheimer’s disease</article-title>. <source/>J Proteome Research. <year>2020</year>;<volume>19</volume>:<fpage>1310</fpage>-<lpage>1318</lpage>.<pub-id pub-id-type="pmid">32101007</pub-id></mixed-citation>
</ref>
<ref id="bibr268-1177271920950319">
<label>268.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name></person-group>
<article-title>14-3-3 proteins in glutamatergic synapses</article-title>. <source/>Neural Plast. <year>2018</year>;<volume>2018</volume>:<fpage>8407609</fpage>.<pub-id pub-id-type="pmid">29849571</pub-id></mixed-citation>
</ref>
<ref id="bibr269-1177271920950319">
<label>269.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Foote</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name></person-group>
<article-title>14-3-3 proteins in neurological disorders</article-title>. <source/>Int J Biochem Mol Biol. <year>2012</year>;<volume>3</volume>:<fpage>152</fpage>-<lpage>164</lpage>.<pub-id pub-id-type="pmid">22773956</pub-id></mixed-citation>
</ref>
<ref id="bibr270-1177271920950319">
<label>270.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Antonell</surname><given-names>A</given-names></name><name><surname>Tort-Merino</surname><given-names>A</given-names></name><name><surname>RÃ-os</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias</article-title>. <source/>Alzheimers Dement. <year>2020</year>;<volume>16</volume>:<fpage>262</fpage>-<lpage>272</lpage>.<pub-id pub-id-type="pmid">31668967</pub-id></mixed-citation>
</ref>
<ref id="bibr271-1177271920950319">
<label>271.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sze</surname><given-names>C-I</given-names></name><name><surname>Troncoso</surname><given-names>JC</given-names></name><name><surname>Kawas</surname><given-names>C</given-names></name><name><surname>Mouton</surname><given-names>P</given-names></name><name><surname>Price</surname><given-names>DL</given-names></name><name><surname>Martin</surname><given-names>LJ.</given-names></name></person-group>
<article-title>Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease</article-title>. <source/>J Neuropathol Exp Neurol. <year>1997</year>;<volume>56</volume>:<fpage>933</fpage>-<lpage>944</lpage>.<pub-id pub-id-type="pmid">9258263</pub-id></mixed-citation>
</ref>
<ref id="bibr272-1177271920950319">
<label>272.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davidsson</surname><given-names>P</given-names></name><name><surname>Blennow</surname><given-names>K.</given-names></name></person-group>
<article-title>Neurochemical dissection of synaptic pathology in Alzheimer’s disease</article-title>. <source/>Int Psychogeriatr. <year>1998</year>;<volume>10</volume>:<fpage>11</fpage>-<lpage>23</lpage>.<pub-id pub-id-type="pmid">9629521</pub-id></mixed-citation>
</ref>
<ref id="bibr273-1177271920950319">
<label>273.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schlaf</surname><given-names>G</given-names></name><name><surname>Salje</surname><given-names>C</given-names></name><name><surname>Wetter</surname><given-names>A</given-names></name><name><surname>Stuertz</surname><given-names>K</given-names></name><name><surname>Felgenhauer</surname><given-names>K</given-names></name><name><surname>Mäder</surname><given-names>M.</given-names></name></person-group>
<article-title>Determination of synapsin I and synaptophysin in body fluids by two- site enzyme-linked immunosorbent assays</article-title>. <source/>J Immunol Methods. <year>1998</year>;<volume>213</volume>:<fpage>191</fpage>-<lpage>199</lpage>.<pub-id pub-id-type="pmid">9692851</pub-id></mixed-citation>
</ref>
<ref id="bibr274-1177271920950319">
<label>274.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goetzl</surname><given-names>EJ</given-names></name><name><surname>Kapogiannis</surname><given-names>D</given-names></name><name><surname>Schwartz</surname><given-names>JB</given-names></name></person-group>, <etal>et al</etal>
<article-title>Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer’s disease</article-title>. <source/>FASEB J. <year>2016</year>;<volume>30</volume>:<fpage>4141</fpage>-<lpage>4148</lpage>.<pub-id pub-id-type="pmid">27601437</pub-id></mixed-citation>
</ref>
<ref id="bibr275-1177271920950319">
<label>275.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Manek</surname><given-names>R</given-names></name><name><surname>Moghieb</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name></person-group>, <etal>et al</etal>
<article-title>Protein biomarkers and neuroproteomics characterization of microvesicles/exosomes from human cerebrospinal fluid following traumatic brain injury</article-title>. <source/>Mol Neurobiol. <year>2018</year>;<volume>55</volume>:<fpage>6112</fpage>-<lpage>6128</lpage>.<pub-id pub-id-type="pmid">29188495</pub-id></mixed-citation>
</ref>
<ref id="bibr276-1177271920950319">
<label>276.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chiasserini</surname><given-names>D</given-names></name><name><surname>van Weering</surname><given-names>JR</given-names></name><name><surname>Piersma</surname><given-names>SR</given-names></name></person-group>, <etal>et al</etal>
<article-title>Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset</article-title>. <source/>Journal of Proteomics. <year>2014</year>;<volume>106</volume>:<fpage>191</fpage>-<lpage>204</lpage>.<pub-id pub-id-type="pmid">24769233</pub-id></mixed-citation>
</ref>
<ref id="bibr277-1177271920950319">
<label>277.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goetzl</surname><given-names>EJ</given-names></name><name><surname>Abner</surname><given-names>EL</given-names></name><name><surname>Jicha</surname><given-names>GA</given-names></name><name><surname>Kapogiannis</surname><given-names>D</given-names></name><name><surname>Schwartz</surname><given-names>JB.</given-names></name></person-group>
<article-title>Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer’s disease</article-title>. <source/>FASEB J. <year>2018</year>;<volume>32</volume>:<fpage>888</fpage>-<lpage>893</lpage>.<pub-id pub-id-type="pmid">29025866</pub-id></mixed-citation>
</ref>
<ref id="bibr278-1177271920950319">
<label>278.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Cook</surname><given-names>TJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease</article-title>. <source/>Acta Neuropathol. <year>2014</year>;<volume>128</volume>:<fpage>639</fpage>-<lpage>650</lpage>.<pub-id pub-id-type="pmid">24997849</pub-id></mixed-citation>
</ref>
<ref id="bibr279-1177271920950319">
<label>279.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bellingham</surname><given-names>SA</given-names></name><name><surname>Guo</surname><given-names>B</given-names></name><name><surname>Coleman</surname><given-names>B</given-names></name><name><surname>Hill</surname><given-names>AF.</given-names></name></person-group>
<article-title>Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases</article-title>. <source/>Front Physiol. <year>2012</year>;<volume>3</volume>:<fpage>124</fpage>.<pub-id pub-id-type="pmid">22563321</pub-id></mixed-citation>
</ref>
<ref id="bibr280-1177271920950319">
<label>280.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Janas</surname><given-names>AM</given-names></name><name><surname>SapoÅ„</surname><given-names>K</given-names></name><name><surname>Janas</surname><given-names>T</given-names></name><name><surname>Stowell</surname><given-names>MH</given-names></name><name><surname>Janas</surname><given-names>T.</given-names></name></person-group>
<article-title>Exosomes and other extracellular vesicles in neural cells and neurodegenerative diseases</article-title>. <source/>Biochim Biophys Acta. <year>2016</year>;<volume>1858</volume>:<fpage>1139</fpage>-<lpage>1151</lpage>.<pub-id pub-id-type="pmid">26874206</pub-id></mixed-citation>
</ref>
<ref id="bibr281-1177271920950319">
<label>281.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Cullen</surname><given-names>V</given-names></name><name><surname>Kahn</surname><given-names>I</given-names></name></person-group>, <etal>et al</etal>
<article-title>Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration</article-title>. <source/>Exp Neurol. <year>2008</year>;<volume>213</volume>:<fpage>315</fpage>-<lpage>325</lpage>.<pub-id pub-id-type="pmid">18625222</pub-id></mixed-citation>
</ref>
<ref id="bibr282-1177271920950319">
<label>282.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leinonen</surname><given-names>V</given-names></name><name><surname>Menon</surname><given-names>LG</given-names></name><name><surname>Carroll</surname><given-names>RS</given-names></name></person-group>, <etal>et al</etal>
<article-title>Cerebrospinal fluid biomarkers in idiopathic normal pressure hydrocephalus</article-title>. <source/>Int J Alzheimers Dis. <year>2011</year>;<volume>2011</volume>:<fpage>312526</fpage>.<pub-id pub-id-type="pmid">21660204</pub-id></mixed-citation>
</ref>
<ref id="bibr283-1177271920950319">
<label>283.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sjögren</surname><given-names>M</given-names></name><name><surname>Blomberg</surname><given-names>M</given-names></name><name><surname>Jonsson</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Neurofilament protein in cerebrospinal fluid: a marker of white matter changes</article-title>. <source/>J Neurosci Res. <year>2001</year>;<volume>66</volume>:<fpage>510</fpage>-<lpage>516</lpage>.<pub-id pub-id-type="pmid">11746370</pub-id></mixed-citation>
</ref>
<ref id="bibr284-1177271920950319">
<label>284.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sjögren</surname><given-names>M</given-names></name><name><surname>Rosengren</surname><given-names>L</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Davidsson</surname><given-names>P</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Wallin</surname><given-names>A.</given-names></name></person-group>
<article-title>Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD</article-title>. <source/>Neurology. <year>2000</year>;<volume>54</volume>:<fpage>1960</fpage>-<lpage>1964</lpage>.<pub-id pub-id-type="pmid">10822437</pub-id></mixed-citation>
</ref>
<ref id="bibr285-1177271920950319">
<label>285.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kušnierová</surname><given-names>P</given-names></name><name><surname>Zeman</surname><given-names>D</given-names></name><name><surname>Hradílek</surname><given-names>P</given-names></name><name><surname>Čábal</surname><given-names>M</given-names></name><name><surname>Zapletalová</surname><given-names>O.</given-names></name></person-group>
<article-title>Neurofilament levels in patients with neurological diseases: a comparison of neurofilament light and heavy chain levels</article-title>. <source/>J Clin Lab Anal. <year>2019</year>;<volume>33</volume>:<fpage>e22948</fpage>.<pub-id pub-id-type="pmid">31199010</pub-id></mixed-citation>
</ref>
<ref id="bibr286-1177271920950319">
<label>286.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuhle</surname><given-names>J</given-names></name><name><surname>Plattner</surname><given-names>K</given-names></name><name><surname>Bestwick</surname><given-names>JP</given-names></name></person-group>, <etal>et al</etal>
<article-title>A comparative study of CSF neurofilament light and heavy chain protein in MS</article-title>. <source/>Mult Scler. <year>2013</year>;<volume>19</volume>:<fpage>1597</fpage>-<lpage>1603</lpage>.<pub-id pub-id-type="pmid">23529999</pub-id></mixed-citation>
</ref>
<ref id="bibr287-1177271920950319">
<label>287.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weston</surname><given-names>PS</given-names></name><name><surname>Poole</surname><given-names>T</given-names></name><name><surname>Ryan</surname><given-names>NS</given-names></name></person-group>, <etal>et al</etal>
<article-title>Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration</article-title>. <source/>Neurology. <year>2017</year>;<volume>89</volume>:<fpage>2167</fpage>-<lpage>2175</lpage>.<pub-id pub-id-type="pmid">29070659</pub-id></mixed-citation>
</ref>
<ref id="bibr288-1177271920950319">
<label>288.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Preische</surname><given-names>O</given-names></name><name><surname>Schultz</surname><given-names>SA</given-names></name><name><surname>Apel</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease</article-title>. <source/>Nat Med. <year>2019</year>;<volume>25</volume>:<fpage>277</fpage>-<lpage>283</lpage>.<pub-id pub-id-type="pmid">30664784</pub-id></mixed-citation>
</ref>
<ref id="bibr289-1177271920950319">
<label>289.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmitz</surname><given-names>M</given-names></name><name><surname>Ebert</surname><given-names>E</given-names></name><name><surname>Stoeck</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>
<article-title>Validation of 14-3-3 protein as a marker in sporadic Creutzfeldt-Jakob disease diagnostic</article-title>. <source/>Mol Neurobiol. <year>2016</year>;<volume>53</volume>:<fpage>2189</fpage>-<lpage>2199</lpage>.<pub-id pub-id-type="pmid">25947081</pub-id></mixed-citation>
</ref>
<ref id="bibr290-1177271920950319">
<label>290.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lauterborn</surname><given-names>JC</given-names></name><name><surname>Cox</surname><given-names>CD</given-names></name><name><surname>Chan</surname><given-names>SW</given-names></name><name><surname>Vanderklish</surname><given-names>PW</given-names></name><name><surname>Lynch</surname><given-names>G</given-names></name><name><surname>Gall</surname><given-names>CM.</given-names></name></person-group>
<article-title>Synaptic actin stabilization protein loss in Down syndrome and Alzheimer disease</article-title>. <source/>Brain Pathol. <year>2019</year>;<volume>30</volume>:<fpage>319</fpage>-<lpage>331</lpage>.<pub-id pub-id-type="pmid">31410926</pub-id></mixed-citation>
</ref>
<ref id="bibr291-1177271920950319">
<label>291.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Keller</surname><given-names>R</given-names></name><name><surname>Basta</surname><given-names>R</given-names></name><name><surname>Salerno</surname><given-names>L</given-names></name><name><surname>Elia</surname><given-names>M.</given-names></name></person-group>
<article-title>Autism, epilepsy, and synaptopathies: a not rare association</article-title>. <source/>Neurol Sci. <year>2017</year>;<volume>38</volume>:<fpage>1353</fpage>-<lpage>1361</lpage>.<pub-id pub-id-type="pmid">28455770</pub-id></mixed-citation>
</ref>
<ref id="bibr292-1177271920950319">
<label>292.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grant</surname><given-names>SG.</given-names></name></person-group>
<article-title>Synaptopathies: diseases of the synaptome</article-title>. <source/>Curr Opin Neurobiol. <year>2012</year>;<volume>22</volume>:<fpage>522</fpage>-<lpage>529</lpage>.<pub-id pub-id-type="pmid">22409856</pub-id></mixed-citation>
</ref>
<ref id="bibr293-1177271920950319">
<label>293.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scheff</surname><given-names>SW</given-names></name><name><surname>Neltner</surname><given-names>JH</given-names></name><name><surname>Nelson</surname><given-names>PT.</given-names></name></person-group>
<article-title>Is synaptic loss a unique hallmark of Alzheimer’s disease?</article-title>
<source/>Biochemical Pharmacology. <year>2014</year>;<volume>88</volume>:<fpage>517</fpage>-<lpage>528</lpage>.<pub-id pub-id-type="pmid">24412275</pub-id></mixed-citation>
</ref>
<ref id="bibr294-1177271920950319">
<label>294.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Wilde</surname><given-names>MC</given-names></name><name><surname>Overk</surname><given-names>CR</given-names></name><name><surname>Sijben</surname><given-names>JW</given-names></name><name><surname>Masliah</surname><given-names>E.</given-names></name></person-group>
<article-title>Meta-analysis of synaptic pathology in Alzheimer’s disease reveals selective molecular vesicular machinery vulnerability</article-title>. <source/>Alzheimers Dement. <year>2016</year>;<volume>12</volume>:<fpage>633</fpage>-<lpage>644</lpage>.<pub-id pub-id-type="pmid">26776762</pub-id></mixed-citation>
</ref>
<ref id="bibr295-1177271920950319">
<label>295.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Almeida</surname><given-names>CG</given-names></name><name><surname>Tampellini</surname><given-names>D</given-names></name><name><surname>Takahashi</surname><given-names>RH</given-names></name></person-group>, <etal>et al</etal>
<article-title>Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses</article-title>. <source/>Neurobiol Dis. <year>2005</year>;<volume>20</volume>:<fpage>187</fpage>-<lpage>198</lpage>.<pub-id pub-id-type="pmid">16242627</pub-id></mixed-citation>
</ref>
<ref id="bibr296-1177271920950319">
<label>296.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Canas</surname><given-names>PM</given-names></name><name><surname>Simoes</surname><given-names>AP</given-names></name><name><surname>Rodrigues</surname><given-names>RJ</given-names></name><name><surname>Cunha</surname><given-names>RA.</given-names></name></person-group>
<article-title>Predominant loss of glutamatergic terminal markers in a beta-amyloid peptide model of Alzheimer’s disease</article-title>. <source/>Neuropharmacology. <year>2014</year>;<volume>76</volume>:<fpage>51</fpage>-<lpage>56</lpage>.<pub-id pub-id-type="pmid">24029236</pub-id></mixed-citation>
</ref>
<ref id="bibr297-1177271920950319">
<label>297.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roselli</surname><given-names>F</given-names></name><name><surname>Tirard</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses</article-title>. <source/>J Neurosci. <year>2005</year>;<volume>25</volume>:<fpage>11061</fpage>-<lpage>11070</lpage>.<pub-id pub-id-type="pmid">16319306</pub-id></mixed-citation>
</ref>
<ref id="bibr298-1177271920950319">
<label>298.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ekman</surname><given-names>U</given-names></name><name><surname>Ferreira</surname><given-names>D</given-names></name><name><surname>Westman</surname><given-names>E.</given-names></name></person-group>
<article-title>The A/T/N biomarker scheme and patterns of brain atrophy assessed in mild cognitive impairment</article-title>. <source/>Sci Rep. <year>2018</year>;<volume>8</volume>:<fpage>8431</fpage>.<pub-id pub-id-type="pmid">29849029</pub-id></mixed-citation>
</ref>
<ref id="bibr299-1177271920950319">
<label>299.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ashton</surname><given-names>NJ</given-names></name><name><surname>Hye</surname><given-names>A</given-names></name><name><surname>Rajkumar</surname><given-names>AP</given-names></name></person-group>, <etal>et al</etal>
<article-title>An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders</article-title>. <source/>Nat Rev Neurol. <year>2020</year>;<volume>16</volume>:<fpage>265</fpage>-<lpage>284</lpage>.<pub-id pub-id-type="pmid">32322100</pub-id></mixed-citation>
</ref>
<ref id="bibr300-1177271920950319">
<label>300.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferretti</surname><given-names>MT</given-names></name><name><surname>Martinkova</surname><given-names>J</given-names></name><name><surname>Biskup</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>
<article-title>Sex and gender differences in Alzheimer’s disease: current challenges and implications for clinical practice: position paper of the Dementia and Cognitive Disorders Panel of the European Academy of Neurology</article-title>. <source/>Eur J Neurol. <year>2020</year>;<volume>27</volume>:<fpage>928</fpage>-<lpage>943</lpage>.<pub-id pub-id-type="pmid">32056347</pub-id></mixed-citation>
</ref>
<ref id="bibr301-1177271920950319">
<label>301.</label>
<mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>DeFelipe</surname><given-names>J</given-names></name><name><surname>Alonso-Nanclares</surname><given-names>L</given-names></name></person-group>
<article-title>The synapse: differences between men and women</article-title>. In: <person-group person-group-type="editor"><name><surname>Pfaff</surname><given-names>DW</given-names></name><name><surname>Christen</surname><given-names>Y</given-names></name></person-group>, eds. <source/>Multiple Origins of Sex Differences in Brain. Research and Perspectives in Endocrine Interactions. <publisher-loc>Berlin, Heidelberg</publisher-loc>: <publisher-name>Springer</publisher-name>; <volume>2013</volume>:<fpage>43</fpage>-<lpage>57</lpage>.</mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>